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Abstract
A major hurdle hindering the advancement of cell-based cancer vaccines is the
inability to non-invasively track in vivo therapeutic cell migration. Within cancer
immunotherapy, antigen presenting cell-based (APC) immunotherapies can be
dendritic cell-based (DC) and elicit de novo anti-tumor immune responses or
formulated as mixed APC-based immunotherapy generated from peripheral blood
mononuclear cells (PBMC). Mixed APC-based therapies contain monocytes and B
cells as APC and can enhance a pre-existing anti-tumor immune response such that
objective anti-tumor responses are observed. In either APC-based formulation, the
quantity of anti-tumor APC reaching a secondary lymphoid organ post injection is
predictive of the magnitude of the ensuing anti-tumor immune response.
This thesis investigates

19

F cellular MRI in conjunction with a

19

F-perfluorocarbon

(19F-PFC) labeling agent as a non-invasive, quantifiable imaging modality that serves
as a surrogate marker of APC-based cancer immunotherapy effectiveness. Pre-clinical
studies involving murine bone marrow-derived DC (BMDC) and human monocytederived DC (moDC) demonstrated 19F-PFC labeling of a high proportion (>95%) of
DC without affecting viability, phenotype and function. In vivo migration of 19F-PFClabeled DC to the popliteal lymph node was detected and the subsequent induction of
an anti-tumor CD8+ T cell response did not differ compared to control DC. Moreover,
this thesis outlines a tumor-bearing mouse model of melanoma suitable for correlating
19

F-PFC-labeled BMDC migration to the lymph node with objective anti-tumor

response.
Similar to DC, 19F-PFC efficiently labeled human PBMC without altering viability,
phenotype, function and in vivo migration. To progress towards a clinical trial to image
autologous 19F-PFC-labeled PBMC in humans, a protocol to label human PBMC with
19

F-PFC under Good Manufacturing Practice-compliant (GMP) conditions was

designed. Nearly 100% of PBMC incorporated 19F-PFC without affecting viability or
cell lineage composition and were migration competent as demonstrated by in vivo
migration to the popliteal lymph node in a mouse model. Furthermore, mock human
i

injections in a ham shank using clinical MR parameters resulted in the first reported
detection of 19F-PFC-labeled PBMC at a depth of 1.2 cm, demonstrating that clinical
19

F cellular MRI is a suitable non-invasive imaging technique to assess APC-based

immunotherapy effectiveness.

Keywords
Dendritic cell (DC), antigen presenting cell (APC), peripheral blood mononuclear cell
(PBMC), 19Fluorine, cellular MRI, cell tracking, cancer immunotherapy, APC-based
cancer vaccine, Good Manufacturing Practice (GMP)
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Chapter 1

1

Thesis Introduction

1.1 Emerging strategies to combat cancer: cancer
immunotherapy
Worldwide, 14.1 million new cancer cases were reported in 20121. For men, prostate cancer
is the second most common malignancy, accounting for 14% of all male cancers, and is
the cause of the second highest number of deaths related to cancer2. In the clinic, standard
treatments such as the chemotherapeutic agents, docetaxel, mitoxantrone and estramustine,
radiation therapy and surgical resection are first-line treatments that are commonly
employed and have proven effective3, yet 30% of prostate cancer patients progress to
hormone refractory metastatic prostate cancer, for which limited treatment options such as
abiraterone and carbazitaxel are available4, 5, 6. This is in addition to 15% of prostate cancer
patients that present with metastatic disease7. Therefore, there is an urgent need for the
development of novel, effective therapies to combat prostate cancers that are not responsive
to standard therapies8.
In general, cancers develop one or more strategies to evade recognition by the immune
system and thus, each have a different immunogenic potential9, 10. As cancer cells arise
from host cells, the immune system is biased towards not recognizing a tumor as foreign
and thus, not launching an appropriate and robust anti-tumor response in vivo11, 12. Tumor
cells can also present mutated self-proteins or neo-antigens on their cell surface, upregulate surface expression of a specific protein or proteins as well as present germ lineassociated proteins that arise through epigenetic changes that would otherwise not normally
be expressed on a differentiated cell12, 13, 14, 15, 16, 17. The immune system can recognize the
subtle differences between tumor tissue and surrounding, healthy tissue and exploit
differences to initiate an anti-cancer immune response. Manipulation of the immune system
to improve its immune recognition and subsequent destruction of a tumor is a relatively
new research area known as cancer immunotherapy3, 7, 18.

2

To evade the immune system, tumors often down-regulate surface expression of human
leukocyte antigen (HLA), or major histocompatibility complex (MHC) in mice, so as to
limit the amount of tumor-associated antigens (TAA) being presented to CD8+ and CD4+
T cells of the immune system and accordingly, dampen the tumor-specific immune
response19, 20, 21, 22. Even if tumor antigen presentation in the context of surface HLA does
occur to CD8+ T cells, tumors have developed the capacity to secrete immunosuppressive
cytokines into the tumor microenvironment23. A robust immune response is not initiated in
the absence of required signals as observed in an immunosuppressive environment where
co-stimulatory molecules are not up-regulated24. Moreover, even if a proper immune
response to a TAA is launched, there still is the possibility that the tumor microenvironment
can suppress this immune response and in some cases, can even drive infiltrating
lymphocytes towards exhaustion or anergy25, 26, 27.
Depending on the combination of immune evasion properties a cancer possesses, each one
may exhibit a different level of immunogenicity. Poorly immunogenic tumors, such as
high-grade breast, gastric and pancreatic carcinoma28, 29, 30 are not ideal for investigating
the effectiveness of cancer immunotherapy. However, cancers such as prostate cancer,
melanoma, malignant glioma, non-small-cell lung carcinoma (NSCLC) and renal cell
carcinoma are immunogenic and thus, serve as a suitable platform for improving upon
existing cancer immunotherapies and for investigating novel immunotherapeutic
approaches31, 32, 33, 34, 35, 36, 37, 38, 39. Prostate cancer also has well-defined TAA, such as
prostate specific antigen (PSA), prostatic acid phosphatase (PAP) and prostate-specific
membrane antigen (PSMA)40, 41, 42, 43, 44, all of which can be employed as a target for TAAspecific immunotherapy. Furthermore, prostate cancer progresses slowly and the prostate
gland itself is not necessary for maintaining life. Because of these attributes,
immunotherapies have sufficient time to fully exert their anti-tumor function without
concern over an immune response that is too strong and has the potential to destroy nearby
healthy tissue in vital organs45 46, 47.
A broad range of immunotherapeutic options have been investigated for use as novel antitumor strategies, with the type, kinetics and immunogenicity of a tumor being taken into
consideration. TAA-specific immunotherapies can arise from administration of ex vivo-
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cultured TAA-specific antigen presenting cell- (APC)-based vaccines, infusion of ex vivoexpanded tumor-infiltrating lymphocytes (TIL) specific to a tumor or even genetically
engineered chimeric antigen receptor (CAR) T cell designed to recognize a specific surface
TAA48, 49, 50. Non-specific immunotherapies also exist, such as the systemic administration
of cytokines51, 52. Combinatorial approaches have proven effective as well, such as using
checkpoint inhibitors to prolong the activation state of TAA-specific T cell
immunotherapies53 . Both non-specific, TAA-specific and combinations thereof will be
discussed in detail in this thesis.

1.2 Non-specific cancer immunotherapies
Early research on cancer immunotherapy focused on systemically administering proinflammatory cytokines, such as interleukin-2 (IL-2) or IL-1252, 54, 55, 56, 57, to create an in
vivo environment that is capable of either controlling growth and metastasis or destroying
an existing tumor. Without such up-regulation of the body’s immune response, the strong
and sometimes overwhelmingly immunosuppressive effects that can be induced by a tumor
could compromise the body’s immune system from fully recognizing, initiating and
maintaining an immune response against a tumor27, 58, 59, 60. IL-2 administration serves to
activate and expand CD8+ T cells into CD8+ cytotoxic T lymphocytes (CTL) that perform
cell-mediated tumor destruction48,

61

while also indirectly initiating a tumor-specific

humoral response via activation of CD4+ T helper (TH) cells that provide signals to B cells
required for antibody production62. Pro-inflammatory cytokine treatment has shown
beneficial results in the clinic, albeit at a level that is insufficient to promote objective
tumor regression and render the patient tumor-free54,

63, 64

. Furthermore, because such

techniques are non-specific, there is great potential for over-activation of intended cell
lineage targets. Such is the case with T cells and IL-2 treatment or non-specific activation
of a pro-inflammatory microenvironment with IL-12 that results in broad activation of
unintended immune cell lineages54, 65. Systemic administration of toll-like receptor (TLR)
agonists have also been associated with toxicities in vivo66. Collectively, this leads to
significant treatment-associated toxicity known as rapid lethal inflammatory syndrome as
a result of immune system over-activation, contributing to patient morbidity and
diminishing its effectiveness56,

57, 61, 67, 68, 69, 70, 71

. To avoid broad and potentially

4

uncontrolled activation of the immune system, immunotherapies that elicit TAA-specific
immune responses have garnered much research attention7,

72

. This way, the body’s

immune response can be directed specifically to the tumor and in theory, would limit offtarget effects and uncontrolled systemic immune responses that are potentially fatal in
nature.

1.3 TAA-specific cancer immunotherapies
To avoid the detrimental effects of an immunosuppressive tumor environment, immune
cells can be cultured ex vivo to expand existing tumor-specific T cell populations or
rendered tumor-specific through TAA-loading of APC prior to administration back into the
host to elicit new anti-tumor responses72,

73, 74, 75, 76, 77

. With respect to TAA-specific

immunotherapies, a wide variety of both naturally occurring cell lineages as well as
engineered immune cells, can be cultured ex vivo as described below or specifically
targeted in vivo. Regardless of which method is employed, the goal is to provide all the
signals and conditions necessary to activate, expand and render the therapeutic cells of
interest capable of launching a TAA-specific immune response78.
T cells that have become properly activated in vivo in a TAA-specific manner are capable
of tracking to a tumor to exert their function. In the case of CD8+ CTL, after migration,
they have the capacity to specifically recognize tumor cells and initiate tumor cell lysis79,
80, 81

. Collectively, T cells, as well as B cells and NK cells, that track to and invade a tumor

are referred to as TIL. Because only properly activated and functioning T cells are able to
traffic to the tumor82, 83, TIL therapy takes advantage of the natural process of T cell
activation occurring in vivo while improving their anti-tumor potential by ex vivoexpanding these cells with multiple rounds of proliferation to a therapeutically-relevant
number13, 14, 17, 84, 85, 86, 87. Previous research has shown that the presence of CTL infiltrating
melanomas, an immunogenic cancer, correlated with improvements in patient survival.
As mentioned above, activated TAA-specific T cells localize to a tumor and exert their
function. However, in chronic conditions such as cancer, CTL are experiencing chronic
stimulation as well as being surrounded by immunosuppressive cytokines25, 26. In this
situation, T cell exhaustion can occur. This is characterized by a reduction in function, up-
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regulation of inhibitory receptors as well as negative regulation by cytokines in the tumor
microenvironment88. Blocking antibodies such as ipilimumab and nivolumab, bind to
cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1),
respectively89, 90. This prevents ligands from binding to CTLA-4 and PD-1 and transmitting
exhaustion signals to the CTL. Broadly speaking, these blocking antibodies are referred to
as checkpoint inhibitors and extend the lifespan of CTL to permit a greater window of time
to exert cell-mediated anti-tumor immune responses91, 92, 93, 94, 95, 96. Checkpoint inhibitors
have been associated with toxicities as a result of prolonging the activation state of T cells
that are not tumor-specific94,

97, 98, 99

. However, uncontrolled T cell activation can be

combated by ex vivo-targeting inhibitors to bind only TAA-specific CTL100, 101.
More recently, techniques to engineer and expand immune cells that directly recognize a
tumor and initiate its destruction have been developed. The most well-known of these cells
are CAR T cells102, 103. The ability to engineer and ex vivo-expand tumor-specific T cells
permits a large number of tumor-specific therapeutic cells to be generated without the need
for repeated and time consuming apheresis procedures to obtain a large quantity of
therapeutic cells104, 105. One drawback of this technique is that CAR T cells can only be
targeted to surface-expressed TAA106, 107, limiting the repertoire of proteins for which to
engineer a CAR T cell to recognize. Although TAA-specific in nature, toxicities have been
observed in CAR-modified T cells targeting CD19, BCMA and CD22 immunotherapy in
patients that have diffuse large B cell lymphoma, multiple myeloma and refractory acute
lymphoblastic leukemia84, 108, 109, 110, 111. CAR T cell therapy toxicity is mediated through
cytokine-release syndrome112,

113, 114

and can also lead to macrophage activation

syndrome115, 116, 117, which has resulted in lethal toxicity 105. Further research is required
to properly harness the anti-tumor potential of CAR T cells without associated lifethreatening toxicities.
Rather than ex vivo-culturing, expanding and/or engineering tumor-specific T cells,
alternative cell-based cancer immunotherapies involve APC78. Dendritic cells (DC) are the
primary professional APC that form the bridge between the innate and adaptive immune
systems and can initiate novel TAA-specific immune responses118,

119

. Monocytes,

macrophages and B cells can also serve as APC and are capable of stimulating existing T
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cell responses120, 121. APC-based immunotherapies exist either in the form of a mixed cell
population, such as peripheral blood mononuclear cell- (PBMC)-based therapies or as an
enriched cell-specific population, such as DC-based immunotherapy7, 122, 123. In the context
of cancer immunotherapy, both formulations serve as the link between the innate and
adaptive immune systems and function as an adjuvant118, 119. However, depending on the
cell type used as the APC, the vaccine could either help boost a pre-existing immune
response if non-professional APC are used, or initiate the cascade of events required to
activate a naïve T cell and render it TAA-specific if a professional APC, like a DC, was
used as an adjuvant124. In addition to TAA-specific adaptive immune responses, APC can
activate Natural Killer (NK) and Natural Killer T (NKT) cells via release of IL-12 and cell
surface-bound expression of IL-15125,

126, 127, 128, 129

. This results in increased IFNg

production by NK cells as well as activation of NK and NKT cells to exert their cytotoxic
effects on tumor cells in a TAA-independent fashion130, 131, 132, 133. Lastly, APC have been
shown to activate macrophages, both directly through IL-2 release and indirectly through
APC-derived IL-12 stimulating NK cell production of IFNg that in turn, activates and
enhances the cytolytic function of macrophages134, 135, 136, 137, 138.

1.4 Professional APC
DC exist in the periphery in an immature state, and due to their high endocytic capacity,
are constantly sampling the environment and processing antigen such that it can be
presented to the adaptive arm of the immune system139, 140. DC can be either myeloidderived DC (mDC) or CD123+ BDCA2+ or BDCA4+ plasmacytoid-derived DC (pDC)141,
142

. Although both types of DC have been used in cancer immunotherapy142, 143, 144, pDC

are generally more important with respect to anti-viral immune responses due to their
ability to secrete high levels of type I interferon upon virus recognition145, 146, 147. mDC
consist of multiple subsets such as CD1a+ CD207+ Langerhan’s cells148, 149, CD14+ dermal
DC150 and CD11c+, CD1c+, CD141+ mDC151. The DC-related data presented in this thesis
focuses on CD11c+ monocyte-derived DC (moDC), which are the DC subset most often
utilized in clinical trials152. After taking up antigen, APC process protein antigens into
peptides that bind MHC Class I and MHC Class II and this antigen:MHC complex is
presented on the cell surface. This allows for T cell recognition of these antigens through
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the T cell receptor (TCR) recognizing peptide in the context of MHC151, 153, 154. MHC Class
I presents endogenous peptides and initiates CD8+ T cell activation for T cells whose TCR
specifically recognizes the antigenic peptide being displayed155,

156, 157, 158, 159, 160

. In

contrast, exogenous antigen is processed and presented as peptides in the context of MHC
Class II, which leads to the activation of CD4+ TH cells and provides the necessary
downstream signaling for B cells to produce an efficient humoral-mediated immune
response62, 161. APC function further extends to their ability to initiate activation of CD8+
CTL that are responsible for direct cell-mediated killing162, 163. In this manner, APC not
only bridge the innate and adaptive immune system but also activate both arms of the
adaptive immune system, a feature of which much attention has been focused to develop
novel APC-based immunotherapies in a cancer setting.
Professional APC, such as DC, possess the unique ability to prime naïve T cells in
secondary lymphoid organs and initiate a TAA-specific immune response27, 164. Prior to
priming naïve T cells, DC are found in an immature state in the periphery processing and
presenting antigens from their surrounding environment139. It is in this state where TAA
uptake and processing for presentation to the adaptive arm of the immune system takes
place119. If this TAA uptake coincides with pathogen- and damage-associated molecular
patterns (PAMP/DAMP) signaling through the extensive cell surface and internal
expression of pattern recognition receptors (PRR) associated with DC, they begin to
mature163. Maturation includes up-regulation of cell surface molecules important for costimulation, such as CD80, CD83 and CD86139, 165, 166 as well as surface expression of
migration markers like CCR7167, which are required for DC to reach secondary lymphoid
organs by following a gradient established by chemokine ligands such as CCL19 and
CCL21168, 169, 170. CCR7 up-regulation occurs in conjunction with CCR1, CCR2 and CCR5
down-regulation, which are known to promote retention of DC in peripheral tissues167, 171,
172

and thus, DC migration to a lymph node, for example, takes place.

While migrating to secondary lymphoid tissues, DC continue to mature, lose their ability
to take up and process antigen while optimizing antigen presentation and begin to express
cell surface molecules critical to DC activation, such as CD409, 139. Ligation and signaling
through CD40 by CD154 (CD40L) present on CD4+ T cells results in the production of IL-
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123, 173, 174, 175, 176 which skews the subsequent immune response in a TH1 direction177, 178,
179

. It should also be noted that ligation and signaling through CD40 is required for an

effective, and not tolerogenic, TAA-specific immune response to take place180. Through
maturation and activation, these DC are now capable of interacting with T cells in the
paracortex area of the lymph node181, 182 such that a strong, anti-tumor immune response
with appropriate co-stimulatory engagement can be initiated176, 183, 184. Within the lymph
node, mature DC can stimulate naïve CD8+ and CD4+ T cells to become either CD8+ CTL
or CD4+ TH cells and thus, have been widely used in cancer immunotherapy to elicit potent
tumor-specific T cell activation3, 101, 185, 186. Furthermore, mature DC are capable of cross
presentation, which is the processing and subsequent presentation of exogenous antigen in
the context of MHC Class I. This is the mechanism by which mature DC can present
exogenous TAA to CD8+ T cells, which in turn become activated into CTL155, 156, 157, 158,
159

. Through cross presentation, the number of TAA for which a CTL immune response

can be launched against is greatly increased. CD8+ CTL are normally associated with an
adaptive immune response launched against viruses; however, with respect to cancer
immunotherapy, cross presentation of TAA by mature DC can lead to activation of TAAspecific CTL, which can directly recognize and destroy a tumor160, 187. Through cytokine
release from a mature DC, they can dictate the type of tumor-specific immune response
that ensues and activate a broad spectrum of immune cell lineages188, 189. For example,
activated DC can secrete IL-2 and IL-12, which can further promote the differentiation of
naïve T cells into TH1 cells185, 186, 190, 191, as well as the proliferation and increased CTL
cytotoxicity, NK cells, and NKT cells125, 134, 192. IL-2 and IL-12 also serves to promote the
release of IFNg by NK cells, which is a key cytokine mediator of anti-tumor immune
responses, that leads to the activation of macrophages which further aid in skewing a TH1
CD4+ T cell response132, 135, 136, 193, 194. DC can both directly and indirectly activate B cells
to initiate a tumor-specific humoral immune response as well as activation of
macrophages193, 195. This combination of both innate and adaptive immune cell activation,
although complex, forms the basis of APC-based cancer immunotherapy.
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1.5 Shortcomings of current DC-based cancer
immunotherapeutic outcomes
In the context of DC-based cancer immunotherapy, migration from a distal location to
secondary lymphoid organ is critical for proper DC maturation and activation and hence,
therapeutic success196, 197, 198. Previous studies have shown that the number of antigenloaded DC that reach a secondary lymphoid organ is directly proportional to the magnitude
of the ensuing antigen-specific immune response. By increasing the number of DC that
migrate to a lymph node, the probability of DC interacting with and activating T cells in
the lymph node is improved199. Although this study used CD4+ TH cells as a readout of
immune response, it can be extrapolated to CD8+ T cells as well, as activated CD4+ T cells
and the cytokines they secrete dictate the duration and strength of CD8+ CTL-mediated
immune responses185, 186. Moreover, injection of ex vivo-cultured DC at a distal site rather
than directly into a secondary lymphoid organ is preferred as only the properly matured
and activated DC have the capacity to efficiently migrate to a secondary lymphoid organ200.
If immature DC, which are poor producers of pro-inflammatory cytokines, were to arrive
at the lymph node presenting TAA without up-regulation of co-stimulatory molecules,
proper T cell activation would not take place and thus, T cell anergy, deletion and/or
tolerance would occur139, 201, 202. Intranodal injection of matured DC loaded with TAA has
been performed; however, the integrity of the lymph node is lost with direct injection and
this could negatively affect the interaction between DC and T cells198, 203. Also, even with
image-guided injections, the lymph node is only directly injected successfully
approximately 50% of the time64, 196, 204. Lastly, direct injections of DC into the lymph node
bypasses and does not take advantage of the natural maturation and activation process that
DC undergo while migrating to a lymph node33, 205, 206. This explains why more DC are
found in the lymph node after intranodal injection compared to distal injection of DC, but
the associated ensuing TAA-specific immune response is superior after intradermal distal
injection64, 183, 198.
As DC are found at a very low concentration in peripheral blood141, 157, human DC-based
cancer immunotherapies can be generated through isolation of DC-precursor cells, such as
monocytes207, 208, 209, and ex vivo-culturing these cells under strictly controlled conditions
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to yield a high purity of moDC210. Thus, TAA-presenting moDC are generated without the
influence of the tumor-induced immunosuppressive microenvironment75, 77. moDC can
also be matured ex vivo through co-culture with a well-characterized cytokine cocktail
containing tumor necrosis factor (TNF-a), IL-6, IL-1b and prostaglandin E2 (PGE2)207, 211,
212, 213

. This cocktail induces moDC maturation within 24 hours, such that upon

administration into the host, they are capable of launching an efficient tumor-specific T
cell response in vivo. In addition to maturation, IL-2 production by DC in secondary
lymphoid organs binds CD25 of naïve T cells present at the immunological synapse and is
absolutely required for proper T cell priming214.
Currently, the efficacy of professional DC-based cancer vaccines is limited as only 3-5%
of injected cells reach secondary lymphoid organs post injection183,

198, 199, 215, 216, 217

.

Therefore, their interaction with and stimulation of anti-tumor T cell-mediated immune
responses is sub-optimal. Further research is needed to improve the proportion of DC that
reach secondary lymphoid organs post injection53,

218, 219

. Research pertaining to DC

manufacturing can be optimized such that DC release appropriate pro-inflammatory
cytokines and chemokines that result in enhancement of their immunogenic potential220,
221

. One approach to enhancing the immunogenicity of a DC-based immunotherapy is to

formulate new cytokine cocktails or adding ligands that bind PRR, such as TLR agonists7,
222, 223, 224, 225

to ex vivo DC cultures. Agonists for TLR3226, TLR4155, TLR7/8227 and

TLR9228 have all been investigated for use in DC-based immunotherapies. The intent of
this approach is to produce DC with improved migration capacity and to direct the
maturation process to produce a pro-inflammatory (TH1-mediated) rather than tolerogenic
response24, 229, 230 as well as promote the activation of innate immune cells24, 231. This serves
as a means by which to increase the effectiveness of the TAA-specific response that DC
initiate through TAA presentation and migration to secondary lymphoid organs232, 233.
It is also important to note that DC-based cancer vaccines are expensive to manufacture in
an ex vivo setting and are associated with extensive and often time-consuming protocols
before they can be administered back into the host152,

165

. Furthermore, for vaccine

strategies in which monocytes are employed to generate moDC, negative selection of
monocytes is required152, 234. This further increases the cost and time of DC-based cancer
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immunotherapy and impedes introduction of novel DC-based immunotherapies into the
clinic as not all reagents required for ex vivo cultures are manufactured under Good
Manufacturing Practice (GMP)-compliant conditions, which is required if autologous DC
are to be injected back into a patient235,

236

. Therefore, research has also focused on

generating shorter cell culture protocols or on using non-professional APC-based cancer
vaccine immunotherapy alternatives. The goal of these alternatives is to produce a vaccine
that is capable of activating and potentiating anti-tumor responses in vivo to an
immunologically-relevant strength with a decreased financial burden associated with ex
vivo culture costs237.

1.6 Non-professional APC
Other APC, such as B cells, monocytes and macrophages, are prevalent in high numbers
in vivo when compared to the most professional APC, DC238. Additionally, other
leukocytes, such as NK cells, express MHC Class II on their surface but their overall
numbers are small compared to B cells and monocytes131, 238, 239. Granulocyte populations
can also serve as APC but they do not survive in culture long enough to be useful in ex
vivo-prepared

APC

therapeutic

approaches240.

Furthermore,

mixed

APC-based

immunotherapeutic approaches are derived from PBMC that are largely void of
granulocytes following gradient centrifugation. Both professional and non-professional
APC can serve as adjuvants in the context of cancer vaccines through appropriate
presentation of tumor-specific epitopes to CD4+ and CD8+ T cells in conjunction with
necessary co-stimulatory- and supportive cytokine-mediated signaling. However, nonprofessional APC function to increase or expand on a pre-existing adaptive immunity to
the peptide being presented, which in the context of cancer immunotherapy, is a TAA241,
242, 243

.

Mixed or heterogeneous APC-based cancer immunotherapy strategies have proven
effective in increasing overall survival in cancer patients7. However, research into
improving these existing therapies such that the TAA-specific immune response can reach
its full potential is required. Although heterogeneous APC-based cancer immunotherapies
are not as costly as DC-based vaccines, they remain expensive compared to conventional
therapies considering the modest increase in overall survival that they currently provide244,
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. The most well-known APC-based cancer immunotherapy strategy, Sipuleucel-T

(ProvengeÒ), was the first ever approved for use in humans7. Sipuleucel-T significantly
prolonged overall survival by 4.1 months in castrate-resistant prostate cancer patients in a
double-blind, placebo-controlled multi-centre Phase III trial246. This immunotherapy is
derived from autologous human PBMC, which consists of a heterogeneous leukocyte
population. This population consists of a large percentage of APC such as monocytes and
B cells as well as other cell types including T cells and NK cells247, 248 that have integral
roles in establishing and maintaining long-term anti-cancer immunity.
In this immunotherapy, prostate cancer patients receive three autologous leukapheresis
infusions241, 249. PBMC from prostate cancer patients are cultured ex vivo with a fusion
protein that consists of granulocyte-macrophage colony stimulating factor (GM-CSF)
fused to PAP, which is expressed in 95% of prostate cancers42, 248, 250. GM-CSF serves to
properly activate the APC within the PBMC while PAP is a prostate-specific immunogenic
antigen required for increasing and potentiating an already-existing but dampened tumorspecific immune response in vivo7,

249

. Thus, the already primed anti-tumor immune

response can be boosted to reach an immunologically relevant level that provides benefit
to the host. The fusion protein was created such that all APC expressing the receptor for
GM-CSF (CD116)251 that uptake and process this fusion product are rendered activated
and present a prostate-specific TAA. This is especially important given that TAA-specific
APC can lead to tolerance to a tumor antigen, or as described previously, can even be
detrimental to the patient, if not co-expressing activation and co-stimulatory markers with
TAA presentation201. Patients undergo three rounds of leukapheresis to obtain PBMC,
which are then cultured ex vivo with the fusion protein mentioned above for three days and
infused back into the patient intravenously at greater than or equal to 40x106 large cells
expressing CD54241, 246. CD54 is the ligand for integrin complex lymphocyte functionassociated antigen (LFA-1, also known as CD11a252) and is expressed on a variety of
immune cell subsets253, 254. Upon CD54 binding, LFA-1 on CD8+ T cells adopts a high
affinity conformation that stabilizes the immunological synapse and results in a more
robust subsequent immune response. In the absence of this increased immunological
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synapse stability, the cytotoxic activity and IFNg secretion of activated CD8+ T cells is
greatly diminished255, 256.

1.7 Advantages of mixed APC-based cancer
immunotherapies
The process to generate this immunotherapy ranges from 48-72 hours, which is much
shorter than a DC-based vaccine immunotherapy and does not employ the use of expensive
enrichment procedures and costly pro-inflammatory cytokine cocktails required to
properly mature DC246. Although only modest survival benefits have been observed with
this type of cell-based prostate cancer vaccine immunotherapy, Sipuleucel-T set an
important precedent in the field of cancer immunotherapy upon receiving Food and Drug
Administration (FDA) approval78, 257. However, its mechanism of action is still not fully
understood, and the approach requires improvement in order to be more efficacious246, 258.
It is largely unknown where the PBMC that comprise Sipuleucel-T migrate to post injection
and in which specific in vivo locations they expand pre-existing anti-tumor immune
responses and exert their therapeutic effects. It has never been demonstrated that PAPspecific T cells activated by Sipuleucel-T APC actually penetrate the tumor in increased
numbers. It is assumed that they reach secondary lymphoid organs considering that
antibodies to PAP and PAP-specific T cells have been detected in the peripheral blood of
patients following treatment42,

120, 259, 260

. Thus, tracking of the cells post injection,

quantifying them in various anatomical locations and monitoring their persistence in vivo
could serve as a non-invasive surrogate marker of predicting the ensuing tumor-specific
immune response. Furthermore, as it is largely unknown where ex vivo-cultured APC
migrate to post-injection and how long they persist at these locations, non-invasive tracking
and quantification of APC could be advantageous. This would identify other in vivo
locations in which these cells migrate to and what effect (positive or negative) this
migration has on the host in the context of cancer immunotherapy8, 43, 83.
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1.8 Non-invasive imaging modalities to predict cell-based
cancer immunotherapeutic outcomes
Although numerous types of non-invasive imaging modalities exist, care must be exercised
when choosing the appropriate non-invasive imaging modality196, 261, 262, 263. Ultimately,
data compiled from pre-clinical small animal studies and in vitro human studies should be
used as the basis for clinically translating knowledge into human studies. Therefore,
clinically relevant non-invasive imaging modalities can be used in combination with an
established DC-based or APC-based cancer vaccine immunotherapy to predict the
effectiveness of the ensuing immune response. This information can also be used to derive,
as well as gain, insight into unanswered questions regarding the immunological importance
of migration to other in vivo locations109, 264 such as sites of metastases. Moreover, this
imaging modality should not affect the immunogenicity, viability and phenotype of the
cell-based cancer vaccine.
Therapeutic cell tracking has been conducted in vivo using a wide variety of imaging
techniques, such as scintigraphy, single photon emission computed tomography (SPECT),
and positron emission tomography (PET)196, 265, 266, 267, 268. The main limitation of these
techniques is time, as they each employ radioactive tracers with short half-lives and are a
source of radiation themselves269. When considering cell tracking in vivo in the context of
cancer immunotherapy, therapeutic cells can reach secondary lymphoid organs within
hours after injection and persist at a given location for many days77, 270, which is too long
of a window to image with most radioactive tracers. Thus, scintigraphy, SPECT and PET
imaging modalities are not amenable to longitudinal studies265, 266, 269, 271, 272. However,
radionuclides with longer half-lives, such as Zirconium-89 (t1/2 = 3.3 days) in combination
with stable transduction of cells with reporter transgenes that increase and maintain label
uptake highlight the future potential use of PET imaging for longer term in vivo clinical
cell tracking

267

. Currently, radionuclide-based modalities do not provide an anatomical

context to the observed signal, which is absolutely necessary when considering the
immunological effect that a professional or non-professional APC has at a given in vivo
location. These imaging techniques are often combined with computed tomography (CT)
scans to provide two- or three-dimensional anatomical information; however, this
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introduces further radiation exposure to the patient and is not practical when considering
longitudinal imaging studies that includes multiple rounds of imaging of the same patient
who may also have been subjected to significant radiation cancer therapy269, 273.
Optical imaging techniques such as fluorescence and bioluminescence do not involve
radiation exposure, are highly sensitive and have been used to detect DC in mice274. They
are only well-suited for small animal imaging and pre-clinical studies. A FDA-approved
fluorescence agent, indocyanine green (IC-Green) is suitable for use in humans; however,
the limited depth that light can penetrate in vivo still poses an issue and thus, is not widely
used for clinical studies141, 275. Current research into constitutive expression of reporter
genes, such as cell surface receptors or transporters that facilitate increased label uptake,
in targeted cells have broadened the applicability of these pre-clinical imaging techniques.
Furthermore, labeling cells of interest using a reporter transgene expression system
circumvents the limitations surrounding label dilution as a result of labeled cell
proliferation267. However, repeated imaging using this technique may become
compromised if an immune response to the reporter gene takes place in addition to or
instead of an immune response to the TAA276, 277. Unlike the above imaging modalities,
magnetic resonance imaging (MRI) permits exquisite soft tissue contrast, does not involve
ionizing radiation and thus, is conducive to longitudinal imaging studies dealing with
tracking and quantification of cell migration in vivo278.

1.9 Cellular MRI as a suitable non-invasive imaging
platform
Traditionally, MRI is used to generate standard three-dimensional proton images that
provide excellent contrast between soft tissues of varying composition278. Alternatively,
MRI imaging can be exploited to track specified cell populations in vivo using a technique
known as cellular MRI279. Therapeutic cells of interest can either be labeled with a contrast
agent or cell labeling agent that permits their detection and is able to discriminate labeled
cells from surrounding tissue that has not incorporated contrast or cell labeling agents (see
Table 1-1)280, 281, 282. With respect to contrast agents, therapeutic cells can be labeled with
such an agent prior to injection or targeted in vivo using a contrast agent directly injected
into the body. In the latter case, the contrast agent can be taken up directly by
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phagocytic/endocytic cells or targeted to a specific cell type through conjugation to a
receptor ligand protein or to an antibody that specifically recognizes the cell population of
interest, for example, the murine DC marker CD11c283, 284. A standard proton scan prior to
infusion of therapeutics cells needs to take place, followed by the same scan post-infusion
at an identified time point. Upon comparison of the two scans, labeled cells can be
identified either by a loss or gain of contrast at a given location, depending on the contrast
agent used285, 286. Contrast agents that produce a hyperintense signal, such as gadoliniumand manganese-based agents have been used in vivo287, 288, 289, 290. However, difficulties
exist in loading certain therapeutic cell types with manganese, gadolinium and other
lanthanide metals, the sensitivity of detection is low with these agents on the order of 105
cells/voxel and under certain circumstances they may be associated with toxicity287, 288, 289,
290, 291

.

An alternative class of cell labeling agents are iron oxide-based contrast agents, such as
superparamagnetic iron oxides (SPIO) Feridex and Resovist, micron-sized Bangs particles
and ultra-small SPIO (USPIO) nanoparticles such as Feraheme or Sinerem292. Iron oxide
nano- or micron-sized particles generate a hypointense signal293. Feridex and Resovist were
previously approved for human use until they were removed from the market in 2008
primarily due to lack of clinical use. Currently, Resovist is now only available for purchase
in Japan294, 295, 296. Although the sensitivity of detection of iron oxide particles using clinical
1.5-3 Tesla (T) MRI scanners that generate hypointensities is on the order of tens to
hundreds of cells per voxel in vivo, a hypointense signal is difficult to quantify and is semiquantitative at best297, 298. Furthermore, hypointense signals observed in vivo can also result
from the inherent physical and chemical properties of soft tissue and bone and result in the
generation of chemical shift artifacts. Therefore, iron-labeled cells cannot be detected with
100% certainty and in combination with this contrast agent being removed from the market
and not yielding unambiguous detection of injected cells, researchers began to explore
alternative means of cell detection using MRI299, 300, 301.

1.10 19Fluorine (19F-based) cellular MRI
The high endocytic ability of APC and more specifically, DC, can be exploited to label
these therapeutic cells with a large amount of labeling agent that in turn, leads to an
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increased sensitivity of detection using cellular MRI302. A

19

fluorine perfluorocarbon-

(PFC)-based cell labeling agent (CS-1000, Celsense, Inc.) is manufactured from a
hydrocarbon in which all hydrogen atoms are replaced with
19

19

fluorine atoms to create a

F-PFC and formulated into an emulsion to increase the capacity of cells to uptake larger

amounts of the label299. Labeling of these cells occurs via macropinocytosis and results in
label being incorporated into multi-lamellar macropinosomes in the cytoplasm303. A GMPcompliant formulation that obtained FDA conditional approval as a new investigational
drug for use in a DC cancer immunotherapy vaccine clinical trial for the treatment of
colorectal cancer77 exists, which is an important aspect for those interested in translational
research. It should also be noted that this same type of agent has been previously used as a
replacement oxygen carrier in humans without any observed adverse reactions304, 305 as
well as used in contrast-enhanced ultrasound306. By using this cell labeling agent in
conjunction with 19F cellular MRI, labeled therapeutic cells can be directly detected in vivo
because of

19

F incorporation, with anatomical context to this observed signal being

provided upon overlaying a 19F scan with a conventional proton (1H) MRI scan. This is
made possible by using a dual-tuned radiofrequency coil capable of detecting both 19F and
1

H atoms77. This labeling agent has garnered much attention due to its ability to label a

high percentage of APC and has been shown to label primary human DC on the order of
1013

19

F atoms/cell291. Additional cell types such as T cells, both manufactured and

primary, macrophages and mesenchymal stem cells (MSC) have been labeled with this
agent270, 283, 299, 307, 308. Also, the positive signal produced from labeled cells in vivo can be
quantified. For quantification to be ascertained, the in vivo signal intensity must be
compared to a reference tube of known concentration of 19F atoms, followed by conducting
nuclear magnetic resonance (NMR) spectroscopy to determine the average loading of 19F
atoms into cells and thus, permits the quantification of the number of 19F-labeled cells at a
given location in vivo77, 307, 309. Although the sensitivity of detection is lower than ironbased contrast agents and is on the order of 103-104 cells per voxel, 19F-labeled cells can
be unambiguously detected due to the negligible endogenous 19F signal observed anywhere
in the body, including immunologically-relevant locations, such as secondary lymphoid
organs261,

291, 310

. Although fluorinated anesthetics can concentrate in vivo in regions

containing high amounts of lipids, such as the fat pad surrounding lymph nodes, it is
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possible to eliminate this contaminating fluorine signal from true signal produced by 19FPFC-labeled cells311. Moreover, the stable isotope of fluorine is exploited for this imaging
technique, allowing for longitudinal cell tracking of terminally differentiated cells for up
to one week, or even longer provided the labeled cell remains viable77, 270, 307, 308. In the
case of terminally differentiated cells such as DC there will be little to no dilution of signal
due to cell proliferation203. It is unknown if loss of

19

F signal occurs due to release of

exosomes, but it should be noted that DC do actively produce exosomes312. This cell
labeling agent is very stable as no known eukaryotic enzyme capable of degrading or
modifying it exists, it is not cytotoxic at therapeutic levels and is stable at low pH311,
eliminating the worry that acidification of endosomes containing this labeling agent would
reduce signal detection. Finally, the amount of

19

F incorporated in a therapeutic cell

injection is so low that researchers are not concerned from a patient safety perspective77.
The total 19F incorporation amount is multiple orders of magnitude less than the fluorine
content contained within toothpaste and other oral care products such as mouthwash
(personal calculation). Altogether, this agent permits accurate quantification of therapeutic
cells in a defined in vivo location.
Extensive immunological characterization of the cell labeling agent and how it affects the
inherent function of immune cells that it is incorporated into was conducted in this thesis.
Rather than simply focusing on labeling a cell with a cell labeling agent and detecting it,
an immunological approach was investigated, such that upon translation to future clinical
trials, one can be assured that a cell label is simply being used to label a cell without any
negative impact on the normal immunological function of that given cell type.
By using a novel 19F MRI-based imaging technique to track and quantify in vivo migration
of therapeutic cells in both human and murine models of cancer immunotherapy, as well
as using this technique to non-invasively predict immunotherapeutic outcome, the
unanswered questions of where therapeutic cells migrate to post-injection and what the
immunological consequence of such migration is can begin to be answered. Lastly, this
platform can be broadly used to study and improve the effectiveness of cell-based therapies
in alternative contexts such as tracking the fate of transplanted stem cells and investigating

19

the migration and persistence of immune cells in the context of autoimmune diseases270,
313

.

Regardless of whether a cancer immunotherapeutic approach consists of introduction of
tumor-specific peptides in vivo to be taken up and processed by resident APC, infusion of
checkpoint inhibitors, CAR T cell intravenous infusion or an ex vivo-cultured and activated
APC vaccine presenting TAA, knowledge of the location and persistence of therapeutic
cells in vivo still largely remains unknown17, 314. The lack of knowledge of location and
quantification of therapeutic cell or cell products once administered in the host is impeding
the development of novel strategies to increase the effectiveness of previously established
therapies as well as serve as a surrogate marker for comparing the effectiveness of newly
emerging vaccine or cell-based immunotherapy formulations. Furthermore, knowledge of
off-target migration of therapeutic cells can help to modify new therapies such that
associated toxicity issues (eg. CAR T cell off-target effects in non-tumor cell-bearing
tissues105, 114, 315) can be prevented prior to introduction into humans and thus, improve the
safety profiles of immunotherapies without decreasing their effectiveness in vivo. This
thesis serves to establish 19F cellular MRI as a non-invasive imaging modality to track and
quantify APC-based cancer vaccine immunotherapies upon re-injection into the host as
well as compare and contrast the immunological effectiveness and ease of translation of
homogeneous professional APC-based vaccines such as DC-based vaccines and mixed
heterogeneous APC-vaccines derived from PBMC.
Both human and mouse-derived DC are investigated to determine if they can be labeled
with a 19F-PFC compound without affecting their viability, phenotype, function and in vivo
migration. Assessing tumor-specific T cell proliferation launched by a DC-based vaccine
as well as the effect this 19F-PFC has on a tumor-specific immune response is explored.
Finally, pre-clinical translation of APC-based immunotherapies is conducted using a
heterogeneous mixed-APC based vaccine approach. Taken together, the extensive
knowledge learned in pre-clinical small animal models regarding APC-based
immunotherapy, as well as the proof of principle investigation into labeling human primary
cells with this

19

F-PFC-based cell labeling agent under GMP conditions was used to
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assemble a clinical trial application to Health Canada to image autologous 19F-PFC-labeled
cells in humans.
Table 1-1. Properties of MRI-based contrast and cell labeling agents used in vivo.
Class of Agent

Examples

Type of Agent

Sensitivity of Detection
(cells)

Iron Oxide
Nanoparticles

Lumiremâ
Feridex I.V.â
Resovistâ
Ferahemeâ
Sinerem281, 284

Negative
(hypointense)
contrast agent316

10-100/voxel317, 318

Gadolinium
Chelates

ProHance291

Positive
(hyperintense)
contrast agent291

105/voxel291

MnCO3, MnO2

Positive
(hyperintense)
contrast agent290

105/voxel291

Manganese
Oxide/Carbonate
19

Fluorine
Perfluorocarbon
(19F-PFC)

CS-1000282

Direct 19F
detection

103-104/voxel291
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Murine DC-based cancer immunotherapies
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2.2 Introduction and Rationale
As dendritic cells are professional APC, they can activate naïve T cells to launch a potent
TAA-specific immune response27, 164. To function as an adjuvant in the context of APCbased cancer immunotherapy, DC must present TAA in combination with appropriate costimulation and activation molecules and cytokine support to launch an effective nontolerogenic TAA-specific immune response78. Thus far, the overall efficacy of DC serving
as an adjuvant within a cancer immunotherapy has been sub-optimal yet free of toxicity
concerns207, 319.
One possible explanation for the overall ineffectiveness of DC-based immunotherapies is
the lack of standardization in pre-clinical models that persist when translated into human
clinical trials74. As circulating DC account for less than 1% of total PBMC157, culturing
DC from precursor cell populations is widely used to generate a sufficient number of DC207,
208, 209

. Also, variations in delivering TAA to DC and their route of administration have

been described64,

74, 153, 204, 320

. As a result of the often harsh immunosuppressive

environment induced by a tumor in vivo, ex vivo culturing of DC is preferred such that
culture conditions can be strictly controlled to yield properly matured and activated DC
prior to administration back into the host74, 76, 321. Ex vivo culturing conditions have also
been modified in an effort to increase the immunogenicity of TAA-specific DC218, 220, 221.
Therefore, due to the lack of standardization when investigating DC in the context of cancer
immunotherapy, comparing the effectiveness of novel anti-cancer strategies as well as
improving upon the immunogenicity of an established vaccine formulation becomes
difficult.
Irrespective of the methods employed to yield therapeutic DC, injected DC must traffic
from a distal location to a secondary lymphoid organ to properly exert their function196, 197,
198

. Previous research indicates that only approximately 5% of injected DC reach a

secondary lymphoid organ, such as a lymph node, post injection198, 200, 217. This limited
migration is another main contributing factor to sub-optimal effectiveness of DC-based
cancer vaccines218, 219 as the quantification of DC migration to the lymph node is directly
proportional to the outcome of the ensuing immune response199. Currently, the absence of
a non-invasive longitudinal imaging technique to track therapeutic cells after injection

24

hinders the development of more effective immunotherapies109,

264

, as knowledge

pertaining to in vivo anatomical locations and persistence of therapeutic cells in these
locations cannot be ascertained through non-invasive means.
19

F cellular MRI can serve as a suitable non-invasive imaging platform to detect and

quantify migration of DC in vivo 291, 302, 310, which in turn can be used as a surrogate marker
to compare and improve upon the effectiveness of different immunotherapeutic DC vaccine
formulations. To test this non-invasive imaging platform, an investigation to determine if
murine bone marrow-derived DC (BMDC) can be labeled with a

19

F-PFC cell labeling

agent without alterations to viability, phenotype and function was conducted. BMDC were
chosen as the immune cell type for initial studies of

19

F-PFC labeling as BMDC bone

marrow precursors are very similar to blood monocytes, are highly endocytic and upon
maturation and activation, become migration-competent to reach lymph nodes and initiate
an antigen-specific immune response279, 322. Also, BMDC are terminally differentiated and
therefore, 19F-PFC signal dilution as a result of cell proliferation is not a concern203.
Using a wide range of culture conditions that included increasing the concentration of 19FPFC in culture, optimal ex vivo culture conditions for labeling BMDC with

19

F-PFC

without significantly altering viability and phenotype were determined. As previous

19

F

cellular MRI studies have simply reported that 19F-labeled therapeutic cells were migration
competent in vivo77, 302 without comparison to the migration competency of unlabeled cells
from the same source, it cannot be said that 19F cell labeling agents do not hinder in vivo
migration. Therefore, we designed in vivo migration experiments that permit migration
comparisons between control unlabeled and 19F-PFC-labeled BMDC. All previous studies
employing mouse models to examine the feasibility of using 19F-PFC to track cells in vivo
employed high field MRI scanners in the range of 7 T to 11.7 T, far from the normal
magnetic field strength available in the majority of clinical scanners299. Therefore, it was
important to assess whether

19

F-PFC-labeleled BMDC can be labeled with sufficient

amounts of 19F-PFC and reach the lymph node in detectable quantities via 19F cellular MRI
using a 3 T clinical scanner. The sensitivity of detection was further tested to determine if
differences in migration can be ascertained between different in vivo conditions, such as
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pre-treatment of the popliteal lymph node area with an inflammatory cytokine prior to
BMDC administration.
Experiments to measure the antigen-specific immune response induced by BMDC
immunization were conducted to determine if 19F-PFC labeling of BMDC affected their
capacity to present a model tumor antigen to and induce proliferation of cognate CD8+ T
cells when compared to unlabeled BMDC. The model tumor antigen used was ovalbumin,
which has a well-defined immunogenic peptide, SIINFEKL (OVA257-264), that is surfacepresented in the context of MHC Class I and is restricted to the murine b haplotype, H-2Kb
261

. A commercially-available tetramer that detects SIINFEKL-peptide in the context of a

CD8+ T cell TCR was used to measure antigen-specific immune responses. Lastly,
ovalbumin has been used as a model tumor antigen in B16-F10 melanoma261, 323.
The B16-F10 melanoma cell line, originally developed by Fidler324 was generated by 10
successive adoptive transfers of lung metastases following intravenous injection of B16
cells in C57Bl/6 mice323, 325. This cell line326, which usually metastasizes to the lung, is
highly aggressive and proliferative, resulting in the death of most tumor-bearing mice if
left untreated at or before 40 days post subcutaneous or intradermal inoculation327, 328.
BMDC from tumor-bearing mice, in the absence of immunotherapy, are unable to stimulate
a sufficient TAA-specific T cell response due to the harsh immunosuppressive environment
induced by this cell line329,

330, 331, 332

. Therefore, BMDC-based and T cell-based

immunotherapeutic strategies have been investigated to combat this cancer261,

333

.

However, it has yet to be determined if this immunotherapy can be used as a platform to
investigate if 19F cellular MRI can successfully detect and quantify the migration of TAAspecific BMDC in vivo and serve as a surrogate marker of vaccine effectiveness in a tumorbearing mouse model.
For human moDC studies, different maturation cytokine cocktail and TLR ligand
combinations used to induce maturation of ex vivo-cultured 19F-PFC-labeled moDC were
conducted and compared to unlabeled control moDC from same donor. The viability and
phenotype as assessed by antigen presentation and co-stimulation (HLA-DR, CD80,
CD86)139, activation (CD83, CD40, CD54)9 and migration (CCR7)167 cell surface markers
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was measured for both

19

F-PFC-labeled and control unlabeled moDC in each culture

condition. Cytokine secretion profiles were measured for each culture condition and
included both pro-inflammatory (IL-12p70 and IFNg) and anti-inflammatory (IL-10)
cytokines173. Cytokine secretion by ex vivo-maturated moDC is important as it dictates the
type and strength of ensuing immune response, which in the case of cancer immunotherapy,
a TH1-mediated immune response is preferred136, 190, 193. These studies seek to efficiently
label human moDC with

19

F-PFC to permit in vivo detection using

19

F cellular MRI

without altering viability, phenotype and function. The data for this part of the study is
presented in Appendix I.
This chapter outlines the pre-clinical studies conducted using an established therapeutic
BMDC model to investigate whether

19

F cellular MRI is a suitable, non-invasive,

longitudinal imaging technique sensitive enough to permit correlating the strength of an
ensuing immune response with

19

F-PFC-labeled BMDC migration to a secondary

lymphoid organ in a tumor-bearing mouse model.

2.3 Materials
2.3.1

Animals

C57Bl/6 male mice (8-10 weeks old) were purchased from Charles River Laboratories
(Wilmington, USA) and B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J male mice (8-10 weeks)
were originally purchased from Jackson Laboratories (Bar Harbor, USA) but were later
provided as a gift by Dr. Steven Kerfoot (Department of Microbiology and Immunology,
University of Western Ontario). All experiments were pre-approved by the Animal Use
Subcommittee at the University of Western Ontario and conducted in accordance with an
approved protocol from University of Western Ontario’s Council on Animal Care (Protocol
#2015-046). All experiments complied with policies published by the Canadian Council
on Animal Care. Mice were anaesthetized with 2% isoflurane in oxygen.

2.3.2

Reagents

RPMI was purchased from ThermoFisher Scientific (Burlington, Canada) and completed
with 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 mg/mL L-Glutamine, minimal
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essential media non-essential amino acids (MEM NEAA), sodium pyruvate (10 mM),
HEPES and 2-mercaptoethanol (55 µM) (all from ThermoFisher Scientific). Cytokines
used in culture media, GM-CSF, IL-4, IL-6, IL-1b, and TNFa were obtained from
PeproTech (Montreal, Canada), and murine CpG ODN 1826 was purchased from
InvivoGen (San Diego, USA) and PGE2 was purchased from Sigma (Oakville, Canada).
To generate BMDC, Hank’s balanced salt solution (HBSS), phosphate buffered saline
(PBS) and Trypan blue was sourced from ThermoFisher Scientific, while bovine serum
albumin (BSA) and normal goat serum (NGS) were purchased from Calbiotech (Spring
Valley, USA) and Jackson Immunoresearch (West Grove, USA), respectively. Sigma
supplied Histodenz™ non-ionic density gradient medium and SIINFEKL peptide (the
immunogenic protein of chicken ovalbumin, amino acid residues 257-265). Rabbit
complement was obtained from Cedarlane (Burlington, Canada), purified anti-mouse I-Ab
(clone 25-9-17) was ordered from Biolegend (San Diego, USA) and purified rat anti-mouse
B220 (RA3-6B2) was purchased from BD Bioscience (Mississauga, Canada).
For flow cytometry, FITC Annexin V/7-aminoactinomycin D (7-AAD), CD19-PE (6D5),
CD11b-Alexa Fluor 700 (M1/70), CD3e-FITC (145-2C11), CD86-BV421 (GL-1), CCR7PE (4B12), H-2Kb-PerCP/Cy5.5 (AF6-88.5), H-2Kb SIINFEKL-PE/Cy7 (25-D1.16), and
CD11c-APC (N418) were all obtained from Biolegend. CellTrace™ carboxyfluorescein
succinimidyl ester (CFSE) cell proliferation kit, CD8a monoclonal antibody (KT15) and
goat anti-rat IgG (H&L) secondary antibody conjugated to APC were obtained from
ThermoFisher Scientific, while Class I iTAg MHC Tetramer H-2Kb/PE SIINFEKL was
purchased from MBL International Corporation (Woburn, USA).
Ammonium-chloride-potassium (ACK) lysis buffer was purchased from Stemcell
Technologies, Vancouver, Canada). Lastly, 19F-PFC cell labeling agents (CS-1000 ATM
and CS-ATM DM Red, with the latter being the red fluorescent version of CS-1000 ATM)
were purchased from Celsense, Inc. (Pittsburgh, USA).
For experiments related to the transduction and transfection of the B16-F10 mouse
melanoma cell line (B16-F10 (ATCC® CRL-6475™) obtained from Dr. Grant
McFadden334 that stably expresses ovalbumin and luciferase, Geneticin™ (G418 sulfate),
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ampicillin, PureLink™ HiPure plasmid filter midiprep kit, Opti-MEM™, Lipofectamine®
2000, 0.25% trypsin-EDTA, pre-cast NuPAGE® 10% Bis-Tris gel, iBlot® 2 nitrocellulose
(NC) regular stacks, iBlot® 2 system, ovalbumin polyclonal antibody conjugated to
horseradish peroxidase (HRP), 10X loading buffer, and SuperSignal™ West Pico PLUS
chemiluminescent substrate were all purchased from ThermoFisher Scientific (Burlington,
Canada). Plasmid DNA (pcDNA3-TfR-OVA) was shipped as a bacterial stab in agar from
Addgene (Cambridge, USA), purified ovalbumin protein was obtained from Sigma Aldrich
(Oakville, Canada), and a BLUeye pre-stained protein ladder was purchased from
FroggaBio, Inc. (Toronto, Canada). Perkin Elmer (Guelph, Canada) supplied the lentiviral
particle used in transduction, RediFect™ Red-FLuc-green fluorescent protein (RediFect™
Red FLuc-GFP), RediJect D-Luciferin Ultra, hybrid optical/X-ray scanner IVIS Lumina
XRMS in vivo imaging system and LivingImage Software. Lastly, an Odyssey® Fc
Imaging System from LI-COR (Lincoln, USA) was used to image western blots.

2.3.3

BMDC generation and 19F-PFC labeling

BMDC were prepared based on the method of Inaba et al and Dekaban et al298, 335. Briefly,
C57Bl/6 mice were euthanized using isoflurane and both femurs and tibias were collected.
Surrounding soft tissue was cleared from bones which were subsequently disinfected with
70% ethanol for 1 min at room temperature. Following the transfer of disinfected bones to
sterile HBSS+0.1% BSA, epiphyses were cut at both ends and a 10 mL syringe with
HBSS+0.1% BSA and 27G1/2 needle was used to flush bone marrow through a 70 µm
filter to create a single cell suspension. Red blood cells were removed from cell suspension
via a 5 minute room temperature incubation with ACK lysis buffer. After washing with
cold HBSS+0.1% BSA and centrifugation, remaining cells were counted and resuspended
in 2 mL complete RPMI. Anti-B220 and anti-I-Ab antibodies were added at 1 µL per 107
cells and incubated on ice for 30 minutes. After washing in HBSS+0.1% BSA, the bone
marrow cell suspension was incubated with 4 mL rabbit complement at 37°C to lyse B and
T cell precursors. After extensive washing, the remaining cells were resuspended in
complete RPMI at 3x105 cells/mL and GM-CSF and IL-4 were added at final
concentrations of 4 ng/mL and 10 ng/mL, respectively. The cell suspension was then
cultured for 4 days at 37°C/5% CO2 (20 mL cell suspension per T75cm2 flask).
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On day 4 of culture, BMDC were isolated using 13.5% Histodenz™ gradient centrifugation
(25 min, 500xg, 20°C, no brakes). Approximately half of the enriched BMDC were
resuspended in complete RPMI (5x105 cells/mL) containing GM-CSF and IL-4 as
mentioned above (control unlabeled BMDC), while the remaining BMDC were
resuspended in the same media, followed by the addition of 19F-PFC cell labeling agent at
either 2.5, 5.0, and 7.5 mg/mL. For all subsequent studies following the initial labeling
with

19

F-PFC, the concentration of

19

F-PFC used was 5 mg/mL. All BMDC were then

cultured overnight in 6 well plates at 37°C/5% CO2.
A cytokine cocktail consisting of IL-1b (10 ng/mL), IL-6 (25 ng/mL), TNFa (25 ng/mL),
PGE2 (10-6 M) and CpG ODN 1826 (0.2 µM) was added to all wells on day 5 of culture to
induce maturation of BMDC for the final 24h of culture. On day 6 of culture, each BMDC
condition was collected separately and an aliquot of mature BMDC was removed from
each condition for viability and phenotyping analysis. Remaining BMDC were then
formulated into injection doses and NMR spectroscopy cell pellets for in vivo 19F cellular
MRI studies. For some experiments, further processing of BMDC took place immediately
prior to injection and is explained in detail below.

2.3.4

BMDC phenotyping and viability assessment

An aliquot of cells from day 0 (before and after complement depletion), day 4 and from all
culture conditions on day 6 was collected for phenotypic analysis. Cell aliquots were
blocked in 5% NGS (v/v) in HBSS+0.1% BSA for 30 minutes on ice and then stained for
CCR7-PE for 20 minutes at room temperature. Cells were then moved to ice and stained
for an additional 25 minutes with CD11c-APC and CD86-BV421. Cells were washed and
resuspended in HBSS+0.1% BSA, fixed with 4% paraformaldehyde (PFA), and stored at
4°C until acquisition on an LSRII analytical flow cytometer (BD Biosciences).
Trypan blue exclusion was used to determine viability each time an aliquot was removed
for phenotyping. A more stringent viability assessment was also performed using FITCAnnexin V and 7-AAD staining. After phenotype staining was complete, BMDC were
stained with FITC-Annexin V at room temperature for 20 minutes followed by the addition
of 7-AAD immediately prior to acquisition on an LSRII analytical flow cytometer (BD
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Biosciences). Any sample containing 7-AAD was not fixed with 4% PFA and was acquired
immediately.

2.3.5

Adoptive cell transfer

Day 6 mature BMDC labeled with or without

19

F-PFC cell labeling agent were washed

extensively with PBS and formulated into 2.5x106 cell injection doses in 40 µL of PBS.
Footpad injections conducted on isoflurane-anesthetized mice with 2.5x106

19

F-PFC-

labeled BMDC into one hind footpad and 2.5x106 control unlabeled BMDC into the
contralateral hind footpad. In a second group of mice, adoptive cell transfer was performed
the same as above; however, 1x106 BMDC were injected instead of 2.5x106 BMDC.
To compare migration between 19F-PFC-labeled and unlabeled BMDC, 2.5x106 and 1x106
BMDC injections were performed as stated above, but with one modification. Immediately
prior to injection, 19F-PFC-labeled BMDC and control unlabeled BMDC were additionally
labeled with the intracellular fluorescent labeling agent CellTrace™ CFSE to allow for
histological comparison of migration to popliteal lymph nodes post injection between 19FPFC-labeled and unlabeled BMDC. Collected BMDC were resuspended in warm PBS +
0.5% FBS at 1x106 BMDC/mL and combined with 1 µM CFSE for 10 minutes at 37°C.
The reaction was quenched with cold complete media for 5 minutes on ice and formulated
into 19F-PFC+ CFSE+ BMDC and CFSE+ BMDC injection doses. CFSE incorporation for
both BMDC conditions was verified using flow cytometry by comparing to an aliquot of
cells from the same culture condition before CFSE staining took place.
In addition to the aforementioned experiment that used an external fluorescent label into
the cytosol (CFSE), a similar experiment was conducted that relied on a constitutively
expressed fluorophore such that migration between

19

F-PFC-labeled BMDC and control

BMDC could be compared without having to incorporate or consider the effect of an
external label on the adoptively transferred cells. B6.Cg-Tg(CAG-DsRed*MST)1Nagy/J
mouse bone marrow was cultured as previously described above to yield day 6 mature
BMDC that all express a variant of red fluorescent protein (DsRed, 558 nm excitation, 583
nm emission). Then, 2x106 DsRed+ BMDC were injected into the hind footpad of 4 mice,
with 2x106 DsRed+

19

F-PFC+ BMDC injected into the contralateral hind footpad. Thus,
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after 48 hours of migration, popliteal lymph nodes were removed following euthanasia,
and a histological comparison of the migration capacity of

19

F-PFC-labeled BMDC and

control unlabeled BMDC can be compared and quantified using DsRed fluorescence as a
readout. Flow cytometry was used to verify DsRed-expression of 19F-PFC+ DsRed+ and
DsRed+ control BMDC immediately prior to injection.
To determine if pre-conditioning of the popliteal lymph node with murine IL-1b increased
BMDC migration, 3x106 19F-PFC+ BMDC were injected into the footpads of 7 C57Bl/6
mice. Injections were prepared exactly as stated above. However, 3h prior to footpad
injections, 4 C57Bl/6 mice were anesthetized with isoflurane and received injections of
300 ng of murine IL-1b into both popliteal lymph node regions, while the 3 remaining
C57Bl/6 mice did not receive a cytokine pre-injection.
The last adoptive cell transfer that took place was performed to assess model tumor
antigen-specific immune responses. Two hours prior to hind footpad injection, all day 6
19

F-PFC-labeled BMDC and half of unlabeled day 6 BMDC were co-cultured with 0.2

µg/mL of cell suspension of the immunogenic chicken ovalbumin peptide, SIINFEKL.
Injections of 2.5x106 cells were formulated as described above for 3 injection conditions:
unlabeled BMDC not presenting SIINFEKL peptide, unlabeled BMDC presenting
SIINFEKL peptide, and 19F-PFC-labeled BMDC presenting SIINFEKL peptide. Injections
for each condition were performed into both the right and left hind footpad of anesthetized
C57Bl/6 mice (n=5 per group).

2.3.6

MRI of BMDC migration

For studies that required 19F cellular MRI imaging, C57Bl/6 mice were imaged 48 hours
following footpad injection. Mouse imaging was performed with either a 9.4 T Varian
small-animal MRI scanner (Santa Clara, CA, USA) or a 3 T clinical MRI scanner (General
Electric, ON, CA). Three dimensional-balanced steady state free precession (bSSFP)
sequences were used for both proton and 19F MR imaging at 9.4 T and 3 T. Animals were
imaged alongside reference tubes containing a known 19F concentration (3.33x1016 19F/μL
or 7.3x1016 19F/μL) suspended in agarose. Mice were anesthetized with 2% isoflurane, with
breathing rate and temperature monitored throughout the scan. MR images were acquired
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at 9.4 T using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm), tuned
to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively. For proton imaging
the scan parameters were: repetition time (TR) = 5.0 ms, echo time (TE) = 2.5 ms, receiver
bandwidth (rBW) = ±39 kHz, flip angle (FA) = 30°, phase cycles (PC) = 4, averages = 3,
resolution = 200x200x200 μm3. For 19F imaging the parameters were: TR = 4.0 ms, TE =
1.9 ms, rBW = ±12.5 kHz, FA = 70°, PC = 4, averages = 200, resolution = 1x1x1 mm3. To
avoid 19F present in isoflurane confounding the 19F-PFC signal, imaging was performed by
centering on the 19F-PFC Cell Sense-specific frequency as we previously described270. The
total protocol time for both proton and 19F imaging was under 90 minutes for both 9.4 T
and 3 T. MR images were acquired at 3 T using a 4.3x4.3 cm dual-tuned surface coil
(Clinical MR Solutions, WI, USA). For proton imaging the scan parameters were TR =
12.8 ms, TE = 6.4 ms, rBW = ±31.25 kHz, FA = 20°, PC = 6, NEX = 1 and 200x200x200
µm3 resolution. For 19F imaging the parameters were, TR = 5.8 ms, TE = 6.4 ms, rBW =
±10 kHz, FA = 20°, NEX = 200 and 1x1x1 mm3 resolution.

2.3.7

19

F-PFC loading efficiency and signal quantification

The mean intracellular 19F content of BMDC was determined by NMR spectroscopy using
a 400 MHz Varian vertical spectrometer. First, a known number of 19F-PFC-labeled cells
was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a
solution containing 100 µL of 5% Triton X-100. After lysing, the cells were transferred to
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA
provides a reference peak for quantifying the number of 19F spins/cell, since NMR signal
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm.
The number of BMDC detected within MR images was determined with Voxel TrackerTM
software (Celsense Inc, Pittsburgh, PA)270, 308. Prior to analysis, a signal correction was
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal
contained within a hand-drawn region of interest (ROI) was compared to the average signal
produced by the reference tube containing a known

19

F concentration. This information
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was used alongside the 19F spins/cell, measured by NMR, to quantify the apparent number
of cells located at the ROI.

2.3.8

Post-MRI histology

Immediately following MR imaging of C57Bl/6 mice that received hind footpad injections
of 2.5x106 or 1x106 19F-PFC+ CFSE+ BMDC or CFSE+ control BMDC, both the left and
right popliteal lymph nodes from each animal were removed and fixed in 4% PFA at room
temperature. Cryoprotection of lymph nodes using sucrose gradients of 10, 20 and 30%
was conducted at 4°C. The popliteal lymph nodes were then cryosectioned into 16 µm
sections, digitally imaged and the CFSE+ fluorescence of

19

F-PFC+ CFSE+ BMDC and

CFSE+ control BMDC were quantified using Image Pro Plus 5.1 software and compared
between BMDC culture conditions and between high (2.5x106) and low (1x106) BMDC
injections. The same methodology for fluorescence microscopy quantification was
conducted 48 hours after footpad injection of 2x106 DsRed+ 19F-PFC-labeled BMDC and
2x106 DsRed+ BMDC, only with endogenous DsRed fluorescence being quantified rather
than externally added CFSE fluorescence.

2.3.9

Quantification of ovalbumin-specific in vivo immune response

To create a model tumor antigen-specific immune response, day 6 matured

19

F-PFC-

labeled BMDC and control BMDC were loaded with the MHC Class I (H-2Kb)
immunogenic peptide of ovalbumin, SIINFEKL, prior to footpad injections (SIINFEKL
loading mentioned in detail previously above). Control BMDC not presenting SIINFEKL
served as the negative control. An aliquot of BMDC from all three injection conditions was
phenotyped as stated previously with the following antibodies: CD11c-APC, CCR7-PE
and CD86-BV421 as well as stained with H-2Kb-PerCP/Cy5.5 and H-2Kb:SIINFEKLPE/Cy7 for 25 minutes on ice to confirm peptide presentation in the context of H-2Kb.
Following BMDC footpad injections, C57Bl/6 mice were left for 7 days to allow for a
CD8+ T cell-specific immune response to be launched against the SIINFEKL peptide. At
this point, both popliteal lymph nodes were removed from each mouse in each injection
condition and were passed through a 70 µm strainer to obtain a single cell suspension. Flow
cytometry staining for CD3e-FITC, CD8a monoclonal antibody and goat anti-rat IgG
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APC-conjugated secondary antibody to identify all CD3+ CD8+ T cells in the lymph node
cell suspension was then performed for each mouse for 25 minutes on ice. Within this
population, a Class I iTAg MHC Tetramer H-2Kb/PE SIINFEKL was used to stain cells
for 20 minutes at room temperature to identify CD8+ T cells that have specific
immunoreactivity to SIINFEKL peptide in the context of H-2Kb as a result of SIINFEKLpresenting BMDC injection. After staining for CD3e, CD8a and tetramer, cells were
washed and resuspended in HBSS+0.1% BSA, followed by immediate acquisition on an
LSRII analytical flow cytometer (BD Biosciences).

2.3.10

Generation of ovalbumin- and luciferase-expressing B16-F10
melanoma cell line

A murine B16-F10 melanoma cell line was grown in RPMI media supplemented with 10%
FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 mg/mL L-Glutamine, HEPES and
2-mercaptoethanol (55 µM). A lentiviral transduction (RediFect™ Red-FLuc-GFP) was
performed in the laboratory of Dr. Paula Foster such that this cell line stably expressed
Luciola italica luciferase and GFP. A FACSAria III flow cytometric cell sorter (BD) was
used to sort and collect the highest 2% of GFP-expressing cells. B16-F10 GFP+ Luc+ cells
were then propagated in culture. Next, a bacterial stab in agar containing a plasmid that
expresses ampicillin and G418 sulfate resistance as well as codes for ovalbumin, pcDNA3TfR-OVA, was quadrant streaked on lysogeny broth (LB) agar containing ampicillin (100
µg/mL) and cultured overnight at 37°C. The next day, a single colony was picked from the
LB agar plate and cultured overnight in 200 mL of LB broth containing ampicillin (100
µg/mL). A PureLink™ HiPure plasmid filter midiprep kit and manufacturer’s instructions
permitted the collection of plasmid DNA. Plasmid DNA (3 µg) and Opti-MEM™ (142.5
µL) were combined and Lipofectamine® 2000 (15 µL) and Opti-MEM™ (142.5 µL) were
combined in a separate Eppendorf tube. Both solutions were then mixed and left to sit at
room temperature for 5 minutes. This 300 µL solution was then added to a well of a 6 well
plate (VWR) which contained adherent B16-F10 Luc+ cells grown at approximately 60%
confluency. A further 500 µL of Opti-MEM™ was added and a transfection then took place
for 48 hours at 37°C/5% CO2.
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After 48 hours, the transfected cells were collected using 0.25% trypsin-EDTA and
resuspended in 50 mL complete RPMI containing Geneticin™ G418 sulfate (3 mg/mL)336
as the selection pressure for ovalbumin expression. After 48-72 hours, 3 individual cell
clusters were picked from the plate with a sterile P200 pipette tip and cultured in a T25cm2
flask (VWR). B16-F10 Luc+ ovalbumin+ cells were then frozen for long-term storage while
a cell pellet from each cell cluster was prepared to verify ovalbumin production via a
Western blot analysis.
A Western blot was conducted on lysates of these cell lines and included appropriate
controls. Briefly, 160 µg of protein from each lysate was loaded into a lane, followed by
160 µg of protein from an untransfected B16-F10 Luc+ cell line as a negative control and
50 ng of purified ovalbumin as the positive control. All samples were combined with 10X
loading buffer and boiled for 5 minutes prior to loading in their appropriate lanes, with
BLUeye pre-stained protein ladder being added to the outside lanes. A pre-cast NuPAGE®
10% Bis-Tris gel was run for 135 minutes at 150 V, followed by a transfer to a NC
membrane (iBlot® 2 NC regular stacks) using the iBlot® 2 system. A 5% milk solution
(w/v) in TBST was added for 1 hour at room temperature as a block step, followed by an
overnight incubation at 4°C with a 1:2500 dilution in TBST of a polyclonal HRPconjugated antibody (ThermoFisher Scientific) to detect ovalbumin. Two 30 minute
washes in TBST were performed and ~2 minutes after addition of a SuperSignal™ West
Pico PLUS chemiluminescent substrate, the blot was read on an Odyssey® Fc Imaging
System (LI-COR).
Alongside the Western blot analysis, B16-F10 Luc+ ovalbumin+ cells were then stained
with an antibody to detect surface expression of H-2Kb to verify that this melanoma cell
line has not down-regulated its surface expression of H-2Kb. To determine if this B16-F10
cell line was transduced appropriately, 1x105 cells were added to an Eppendorf tube and
suspended in 150 µL of RediJect D-luciferin Ultra (30 mg/mL). An Eppendorf tube
containing only D-luciferin substrate served as the negative control. After a 6 minute room
temperature incubation, the cells were centrifuged, supernatant was discarded and the cell
pellet was overlaid with 1% agarose. Both a GFP image and bioluminescent image were
acquired on a hybrid optical/X-ray scanner IVIS Lumina XRMS in vivo Imaging System
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and LivingImage Software. Lastly, to confirm luciferase expression in a more biologicallyrelevant context, a subcutaneous injection of 2x105 transfected and transduced B16-F10
cells in the back of a C57Bl/6 mouse was performed. Once the tumor was established, 150
µL of RediJect D-Luciferin Ultra (30 mg/mL) was administered intraperitoneally and after
6 minutes, a bioluminescent image was acquired as described above.

2.3.11

Correlating 19F-PFC-labeled SIINFEKL-presenting BMDC
migration to the lymph node with the ensuing antigen-specific
immune response to a model tumor antigen ovalbumin (OVA)
in a mouse model of melanoma

To assess the correlation between 19F-PFC-labeled BMDC migration and ensuing tumor
antigen-specific immune response in a mouse model of melanoma, tumors were established
on the back of C57Bl/6 mice as described previously. Two days later, both 19F-PFC-labeled
BMDC and unlabeled BMDC were co-incubated with SIINFEKL peptide and surface
presentation of SIINFEKL in the context of H-2Kb was verified using flow cytometry as
previously stated. Unlabeled BMDC not presenting SIINFEKL served as the negative
control. A 3x106 cell injection for each population was performed into each hind footpad
(n=2 per cell culture condition completed, n=10 in total upon completion). Tumor-bearing
mice that received
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F-PFC-labeled BMDC injections underwent 3 T MRI scans with a

4.3x4.3 cm dual-tuned 1H/19F surface coil (Clinical MR Solutions, Wisconsin, USA). The
parameters were as follows: for 1H imaging, 0.2 mm3 spatial resolution, field of view
(FOV) = 60 x 30 mm, matrix = 300 x 150, slice thickness = 0.2 mm, FA = 20°, rBW = +/31.25 kHz, TR/TE = 12.8/6.4 ms, NEX = 1 and 6 PC with a scan time of 23
minutes. 19F imaging parameters were: 1 mm3 spatial resolution, FOV = 60 x 30 mm,
matrix = 60 x 30, slice thickness = 1 mm, FA = 72°, BW = +/-10 kHz, TR/TE = 5.8/2.9 ms
and NEX = 200, resulting in a scan time of 28 minutes. For mice that received unlabeled
BMDC injections, 1H imaging parameters were: 0.2 mm3 spatial resolution, FOV = 60 x
30 mm, matrix = 300 x 150, slice thickness = 0.2 mm, FA = 20°, BW = +/-31.25 kHz,
TR/TE = 12.8/6.4 ms, NEX = 1 and PC = 4, with a scan time of 13 minutes. Finally, tumorbearing mice underwent bioluminescent imaging every second day until the predetermined experimental endpoint was reached (primary tumor ³ 600 mm3). Tumor
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volumes were calculated using the formula: volume = (width2 x length)/2, with width and
length being perpendicular tumor diameter measurements.

2.3.12

Statistical analysis

All data was presented as the mean with the standard error of the mean. A paired t-test
(Graph Pad Prism, Version 7, La Jolla, USA), one-way ANOVA or two-way ANOVA
were used and was defined when statistics were reported. Multiple comparisons were
conducted for one- and two-way ANOVAs. Differences between means were considered
significant if p ≤ 0.05. When written, the number of independent experiments is denoted
by (N) while the number of replicates per independent experiment is defined by (n).

2.4 Results
2.4.1

The current established BMDC protocol generates high
purity of CD11c+ BMDC and permits efficient loading of 19FPFC without affecting viability or phenotype

On day 4 of the 6 day established protocol for generating BMDC from bone marrow
precursors, immature BMDC are enriched from culture using Histodenz™ gradient
centrifugation, which yields immature dendritic cells that are CD19-CD3-CD11b+CD11c+
with >80% purity (Fig. 2-1A-D). On day 6 of culture, mature CD11c+ BMDC constitute
>80% of total cells (Fig. 2-2A). This established protocol was used to determine the highest
concentration of 19F-PFC that can be added to BMDC culture on day 4 without affecting
viability or phenotype. Concentrations ranging from 2.5 mg/mL to 7.5 mg/mL were added
in culture and the resulting phenotype and viability was assessed. The viability of control
BMDC in which no 19F-PFC was added was also included in this experiment. Irrespective
of the concentration of

19

F-PFC in culture, the phenotype of BMDC did not differ with

respect to CD11c, CCR7 and CD86 cell surface percentage expression (Fig. 2-2A-C/E).
Next, the viability of BMDC for each 19F-PFC concentration (and appropriate control) was
investigated using trypan blue exclusion and more rigorously with FITC-Annexin V/7AAD staining (Fig. 2-2D). Viability was unaffected when increasing the concentration of
19

F-PFC from 2.5 mg/mL to 5 mg/mL (Fig. 2-2F) while also resulting in a 1.7-fold increase

in the amount of

19

F-PFC incorporated on average per cell as ascertained using nuclear
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magnetic spectroscopy (NMR) (Fig. 2-2G). This is in contrast to the decrease in viability
observed with the 7.5 mg/mL

19

F-PFC cell culture condition. Although a significant

increase in 19F-PFC incorporation was observed at the highest labeling concentration, the
decrease in viability associated with this label concentration was deemed not acceptable
for future studies (Fig. 2-2F/G). Therefore, all other experiments that required BMDC to
be labeled with 19F-PFC were conducted at a cell labeling concentration of 5 mg/mL.

Figure 2-1. Representative flow cytometric gating strategy to confirm enrichment of
CD11c+ BMDC. Prior to labeling of BMDC with 19F-PFC, CD11c+ BMDC were enriched
Figure
2-1 Representative
flowcentrifugation
cytometric gating
from bone marrow
cell culture
using a Histodenz™
gradient. Following this
+
strategy
to
confirm
enrichment
of
CD11c
BMDC.
enrichment and debris removal (A), singlet (B) cells were selected for to reveal the lack of
CD19+ B cells and CD3+ T cells present following complement depletion of these cell
lineages of day 0 of culture (C). CD3- and CD19- cells were then gated on CD11b and
CD11c to reveal that post enrichment, consistently greater than 80% of cells remaining are
CD11b+CD11c+ BMDC (D).
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Figure 2-2. Increasing concentrations of 19F-PFC does not affect the phenotype of BMDC
but does affect viability at high concentrations. Flow cytometry and appropriate FMO
controls were employed to phenotype CD11c+ BMDC (A) to confirm CCR7 (B) and CD86
+
+
expressionFigure
(C). The2-2.
viability
of CD11c
CCR7+CD86of
BMDC
wasdoes
assessed
using Annexin
19
Increasing
concentrations
F-PFC
not affect
+
V/7-AAD the
discrimination
(D).
CD11c
BMDC
phenotype
remained
unchanged
phenotype of BMDC 19
but does affect viability at high by the
addition ofconcentrations.
increasing concentrations of F-PFC in culture (E). At 2.5 mg/mL and 5.0
mg/mL of 19F-PFC, BMDC viability was largely unaffected by 19F-PFC addition; however,
a 19F-PFC concentration of 7.5 mg/mL was associated with increased cell death using
Annexin V/7-AAD staining and confirmed with trypan blue exclusion (F, colours chosen
to match with quadrant in panel D). NMR spectroscopy revealed that increasing the
concentration of 19F-PFC to 5.0 mg/mL and 7.5 mg/mL resulted in a 1.7- and 1.9-fold
increase in 19F-PFC incorporation compared to 19F-PFC labeling at 2.5 mg/mL (G). Data
shown as means ± SEM, ((F) two-way ANOVA, * p<0.05, (G) one-way ANOVA, *
p<0.05).
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2.4.2

19

F-PFC-labeled BMDC are migration competent as
assessed via 19F cellular MRI quantification of in vivo
migration to secondary lymphoid organs

Previous phenotyping of day 6

19

F-PFC-labeled CD11c+ BMDC demonstrated that they

express the CCR7 chemokine receptor that mediates DC migration to lymph nodes and
express the cell surface marker CD86. The next logical step was to determine the in vivo
capacity of

19

F-PFC-labeled BMDC to migrate from the hind footpad injection site to

draining lymph nodes as assessed by 19F cellular MRI 48 hours after injection. Migration
of 19F-PFC-labeled BMDC was detected and quantified in the iliac lymph node (1.1x105
cells, Fig. 2-3 top panel), inguinal lymph node (2x105 cells, Fig. 2-3 middle panel) and
popliteal lymph node (2.15x105 cells, Fig. 2-3 bottom panel). This quantification of BMDC
migration indicated that 19F-PFC-labeled BMDC are migration competent in vivo.
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Figure 2-3. 19F-PFC-labeled BMDC can be detected and quantified in draining lymph
6 19
nodes 48 hours post
footpad
Following
hindcan
footpad
injection
Figure
2-3. 19injections.
F-PFC-labeled
BMDC
be detected
andof 2.5x10 F-5
PFC-labeled BMDC,
BMDC in
candraining
be detectedlymph
and quantified
in the
iliac (top
quantified
nodes 48
hours
postpanel, 1.1x10
5
cells), inguinal (middle
panel,
2x10
cells)
and
popliteal
(bottom
panel,
2.15x105 cells)
footpad injection.19
lymph nodes two days later using F cellular MRI. R (top panel) is a reference tube of
known concentration of 19F atoms required for quantification of in vivo signal.
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2.4.3

With

19

19

F MRI lymph node signal is the result of originally injected
cells and using fluorescence microscopy, 19F-PFC-labeled
BMDC and control BMDC have the same migration capacity
in vivo
F-PFC-labeled BMDC in vivo migration being quantified, it was important to

establish that the migration of

19

F-PFC-labeled BMDC compared to control unlabeled

BMDC was not substantially different. To compare in vivo migration of 19F-PFC-labeled
BMDC to control unlabeled BMDC, BMDC from both conditions were first phenotyped
to confirm similar maturation and migration status. Greater than 95% of control unlabeled
CD11c+ BMDC and CD11c+

19

F-PFC BMDC stained for CCR7 (Fig. 2-4A/B, middle

panel) and although lower than what is normally observed (>90%), the CD86+ percentage
for both cell populations is comparable (Fig. 2-4A/B, right panel). To track in vivo
migration, both the control unlabeled and 19F-PFC-labeled BMDC were also labeled with
the fluorescent membrane intercalating dye, CFSE, immediately prior to injection. The
incorporation of CFSE into control BMDC (Fig. 2-4C) and 19F-PFC-labeled BMDC (Fig.
2-4D) was 100% and also labeled both cell populations with similar intensity. Thus, CFSElabeling of both cell populations was equal.
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Figure 2-4. 19F-PFC-labeled and unlabeled BMDC have a similar phenotype and label
similarly with CFSE prior to adoptive cell transfer. Control unlabeled BMDC (A) and 19F19
PFC-labeled Figure
BMDC 2-4.
(B) express
a similar phenotype
as assessed
through
CD11c,
CCR7
F-PFC-labeled
and unlabeled
BMDC
have
a
and CD86 expression.
CD11c
dot
plots
were
gated
on
viable
cells.
All
other
dot
plots
are
similar phenotype and label similarly with CFSE prior to
+
19
gated on viable
CD11ccell
cells.
F-PFC does not affect the expression of CD11c, CCR7, or
adoptive
transfer.
CD86 when compared to unlabeled BMDC. In addition, no differences were found in
CFSE labeling between control BMDC (C) and 19F-PFC-labeled BMDC (D), with CFSElabeled BMDC from each condition presented as black histogram compared to CFSEunlabeled BMDC (blue histograms). Flow plots are representative of two independent
experiments.
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In vivo migration studies were then performed in which CFSE+ 19F-PFC-labeled BMDC
were injected into one footpad and an equal number of CFSE+ 19F-PFC-unlabeled BMDC
were adoptively transferred into the contralateral footpad. This was performed for both a
low (1x106) and high (2.5x106) injection condition (N=2, n=2 per condition). After 48
hours, the popliteal lymph nodes were then removed to quantify fluorescence by digital
morphometry as a readout of cell migration. Representative images of CFSE+

19

F-PFC-

labeled BMDC for both low and high injection conditions are shown in Figure 2-5A and
2-5C, respectively. The same is illustrated for low and high injection doses of CFSE+
control BMDC in Figure 2-5B and Figure 2-5D. These images reveal the presence of
originally injected CFSE+ BMDC in the central areas of the lymph node, which is where
BMDC need to migrate in order to interact with T cells and initiate an immune response.
Quantification of this migration demonstrates that

19

F-PFC does not impede the in vivo

migration capacity of 19F-PFC-labeled BMDC compared to control unlabeled BMDC for
both low (Fig. 2-5E) and high (Fig. 2-5F) injection doses. It should also be noted that
migration appears to occur in a dose-dependent manner, as the quantification of
fluorescence signal increases with increasing the number of injected BMDC.
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Figure 2-5. 19F-PFC does not impede BMDC in vivo migration. Mice were given
subcutaneous hind footpad injections of 19F-PFC-labeled BMDC (n = 7, 1.0x106 cells; n =
7, 2.5x106 cells; combined data from 2 independent experiments). Equal numbers of
control BMDC were injected into contralateral hind footpads of the same mice. Prior to
injection, both populations were labeled with CFSE to provide fluorescent detection. Two
19
Figure 2-5.
F-PFC
doesnodes
not impede
BMDC in
vivo migration.
days after injection,
popliteal
lymph
were removed,
cryosectioned
and analyzed by
+
digital morphometry to determine the area of CFSE fluorescence per area of interest.
Images were taken at 100X magnification (scale bar = 300 μm) and the experimenter was
blinded before digital morphometry was performed. Representative images for both 19FPFC-labeled BMDC (A & C) and control unlabeled BMDC (B & D) populations at both
injection concentrations are shown. Quantification of migration for both the low injection
concentration (E) and high injection concentration (F) was conducted and compared
between 19F-PFC-labeled and control unlabeled BMDC populations. Data shown as means
± SEM (t-test, p > 0.05).
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While conducting the previous experiment, a question arose as to whether

19

F-PFC and

CFSE could interact with each other inside the cell and affect migration. A similar
experiment was conducted as in Figure 2-5; however, CFSE was not used as an intracellular
fluorophore. Instead, transgenic mice that express a variant of red fluorescent protein,
DsRed337, in all cell lineages were used to generate red fluorescent BMDC without the need
to introduce an external fluorescent label. DsRed+

19

F-PFC-labeled BMDC (2x106 cells,

Fig. 2-6A) were injected into one footpad and DsRed+ control BMDC of equal number
were injected into the contralateral footpad of non-fluorescent mice of the same C57Bl/6
background (Fig. 2-6B). Quantification of migration to the popliteal lymph node 48 hours
later was determined by digital morphometry (Fig. 2-6C) and confirmed that

19

F-PFC-

labeled BMDC and control BMDC migrated equally to draining lymph nodes and home to
central lymph node regions as well.
Figure 2-6. 19F-PFC does not impede the in
vivo migration of DsRed+ BMDC. Mice were
given subcutaneous hind footpad injections of
19
F-PFC-labeled DsRed+ BMDC (n = 4, 2.0 x
19 DsRed+ BMDC were
106 Figure
cells). 2-6.
Control
F-PFC does not
injected
at equal
into contralateral
impede
the innumber
vivo migration
of
+
hindDsRed
footpads.
Two
days
post-injection,
the
BMDC.
popliteal lymph nodes were removed,
cryosectioned and analyzed using digital
morphometry to determine the area of DsRed
fluorescence per area of interest. Images were
taken at 100X magnification (scale bar = 300
μm) and the experimenter was blinded prior to
conducting
digital
morphometry.
Representative images for both 19F-PFClabeled DsRed+ BMDC (A) and control
DsRed+ BMDC (B) are shown. No significant
difference in migration quantification was
observed (C). Data shown as means ± SEM (ttest, p > 0.05).
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2.4.4

Pre-treatment of draining popliteal lymph node with murine
IL-1b does not appear to increase migration of 19F-PFClabeled BMDC in vivo

It has been shown that the number of DC that migrate to a lymph node post injection is
directly proportional to the ensuing immune response launched in vivo. Thus, it was of
interest to determine whether one can increase DC migration by pre-treating the popliteal
lymph node area with murine IL-1b (mIL-1b, 300 ng) as a means to increase the efficacy
of a DC-based immunotherapy. In this experiment, three hours after injecting the popliteal
lymph node area with mIL-1b, 3 C57Bl/6 mice received footpad injections of 3x106 19FPFC-labeled BMDC. Another group of 4 C57Bl/6 mice received the same injection but did
not receive a pre-injection of murine IL-1b into the popliteal lymph node area. Both sets
of mice were left for two days and then imaged using 19F cellular MRI to detect migrated
cells. 19F-PFC-labeled BMDC produced signal in the footpad (Fig. 2-7A, red arrow) and
popliteal lymph node (Fig. 2-7A, green arrow). An overlay of a 1H MRI with a
pseudocoloured 19F MRI (hot-iron colour scale shown in Fig. 2-7A), in conjunction with a
reference signal of known concentration of 19F atoms (denoted “R” in Fig. 2-7A) permits
the quantification of signal observed in the popliteal lymph node to be calculated as a
number of migrated cells. For mice that did not receive murine IL-1b pre-injection, 19FPFC-labeled BMDC were detected in the popliteal lymph node on 4 of 6 occasions ranging
from 4 300 ± 600 cells to 17 000 ± 2 000 cells (Fig. 2-7B; excluding two lymph nodes that
did not have quantifiable signal). For mice that did receive murine IL-1b pre-injection,
migration was quantified in 5 of 8 popliteal lymph nodes and ranged from 4 000 ± 800 to
20 000 ± 3 000 cells (Fig. 2-7B). After averaging the number of migrated cells for each
condition in which migration was able to be quantified, there was no significant increase
in cell migration associated with the pre-injection of the popliteal lymph node areas with
murine IL-1b (Fig. 2-7C).
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Figure 2-7. The migration of 19F-PFC-labeled BMDC to the draining popliteal lymph
node can be detected using 19F MRI. Three mice (M1 – M3, panel B), did not receive a
pre-injection of mIL-1β three hours prior to BMDC footpad injection while four mice (M4
– M7, panel B) did receive a pre-injection of mIL-1β (300 ng) into both left and right
popliteal lymph node regions. 19F-PFC-labeled mature BMDC were injected
subcutaneously into the hind footpads (3 x 106 cells/footpad). Forty-eight hours after
BMDC injection, 19F and 1H MRI scans were performed to reveal 19F-PFC-labeled BMDC
migration. The 19F and 1H MR overlay composite image for mouse M2 is shown in (A).
The 1H images are rendered in grey-scale and 19F images rendered in ‘hot-iron’
pseudocolour. The 19F reference tube (R) is denoted by a white circle, with the red arrow
19
Figure 2-7.
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Composite MR images of both left and right popliteal lymph node regions
48 hours after
BMDC footpad injection for all mice imaged in this study are shown in (B). The numbers
at the bottom of each panel represent the number of BMDC that migrated to a target lymph
node as assessed by 19F MRI. MR images in which BMDC migration was below the
threshold of detection are denoted with a star (*). (C): Average number of MRI detectable
BMDC that migrated to a target lymph node between untreated (n= 4) and mIL-1β treated
(n = 5) populations as assessed by cellular MRI. To calculate the average number of
migrated BMDC for both untreated and mIL-1β treated groups, the total number of
migrated DC (as assessed by cellular MRI) within each group was totaled, then divided
by the total number of lymph nodes within each group that had a detectable signal (n = 4
and n = 5 for untreated and mIL-1β treated groups, respectively). Lymph nodes in which
the number of migrated BMDC was below the threshold of detection were not included
in the calculation of these averages. Data in (C) shown as means ± SEM (t-test, p > 0.05).
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2.4.5

The ability of BMDC MHC Class I to be loaded with a model
tumor peptide antigen and initiate an antigen-specific
immune response in vivo is unaffected by 19F-PFC labeling

Upon determination that

19

F-PFC-labeled BMDC are capable of migrating to and being

detected in the popliteal lymph node, assessing the functionality of

19

F-PFC-labeled

BMDC to present antigen and initiate an antigen-specific response was compared to control
unlabeled BMDC. As conducted previously, the phenotype of both control BMDC and
19

F-PFC-labeled BMDC on day 6 of culture was first assessed using CD11c, CCR7 and

CD86 expression. CD11c+ BMDC in both conditions were found to be nearly identical in
their high expression of CCR7 and CD86, which was calculated to be greater than 96% in
all cases (Fig. 2-8A-C and Fig. 2-8a-c). Surface expression of H-2Kb in general was also
determined to be nearly 100% for both control BMDC (Fig. 2-8D) and 19F-PFC-labeled
BMDC (Fig. 2-8d). Next, the percentage of BMDC from each condition that are able to
present the immunogenic peptide (SIINFEKL) of ovalbumin in the context of MHC Class
I (H-2Kb of C57Bl/6 mice) following co-incubation with this peptide was determined using
flow cytometry and an antibody specific for SIINFEKL peptide bound to H-2Kb. 19F-PFC
does not alter surface peptide presentation of a model tumor antigen, SIINFEKL, in the
context of H-2Kb on BMDC as 99.9% of both control BMDC (Fig. 2-8E) and 19F-PFClabeled BMDC (Fig. 2-8e) presented this peptide. Taken together, this data suggests that
the current six-day BMDC protocol can be employed to efficiently present SIINFEKL:H2Kb complex peptide for both control unlabeled and 19F-PFC-labeled BMDC.
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Figure 2-8. 19F-PFC does not affect
BMDC phenotype or its ability to
present
SIINFEKL
peptide.
Unlabeled control (A) and 19FPFC-labeled (a) CD11c+ BMDC
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control (D) and 19F-PFC-labeled
(d) conditions express MHC Class
I (H-2Kb). Following a 2 hour
incubation
with
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peptide, an antibody detected
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the context of H-2Kb for unlabeled
control (E) and 19F-PFC-labeled (e)
BMDC. All gating is based on
appropriate FMO controls.
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To assess a CD8+ T cell antigen-specific response in vivo, 2.5x106 BMDC not presenting
SIINFEKL peptide were injected into the hind footpads of 5 mice and served as the
negative control (Fig. 2-9A). SIINFEKL-presenting unlabeled BMDC (2.5x106 cells) were
injected into the hind footpads of 7 different mice (Fig. 2-9B), while the same number of
SIINFEKL-presenting 19F-PFC-labeled BMDC were injected into the hind footpads of a
third cohort of mice (Fig. 2-9C, n=7 mice). All mice were then left for 7 days for a
SIINFEKL-specific CD8+ T cell immune response to be initiated in the draining popliteal
lymph nodes. Following euthanasia, both popliteal lymph nodes were removed and pooled
together for each individual mouse. Tetramer staining to identify CD8+ T cells whose T
cell receptor recognizes SIINFEKL peptide in the context of H-2Kb was performed. Once
single cell suspensions of pooled lymph nodes were generated for each mouse, singlet
CD3+CD8+ T cells were selected for using flow cytometry, followed by further gating to
identify tetramer+ cells in each other the three aforementioned injection conditions, BMDC
not presenting SIINFEKL (Fig. 2-9D), SIINFEKL-presenting BMDC (Fig. 2-9E) and 19FPFC-labeled SIINFEKL-presenting BMDC (Fig. 2-9F). No significant difference was
noted in the percentage of tetramer+ CD8+ T cells between control unlabeled BMDC
injections and 19F-PFC-labeled BMDC injections that were presenting SIINFEKL peptide
(Fig. 2-9G). It is important to note that the percentage of tetramer+ CD8+ T cells for each
of the two injection conditions that included SIINFEKL peptide presentation were
significantly higher than the non-specific staining observed in the negative control BMDC
injection condition (Fig. 2-9G, white circles). Therefore, the SIINFEKL-specific immune
response launched as a result of SIINFEKL-presenting BMDC labeled with or without 19FPFC was equivalent.

53

54

Figure 2-9. 19F-PFC labeling of BMDC does not affect the antigen-specific CD8+ T cell
response induced following vaccination. BMDC not loaded with SIINFEKL (A), control
unlabeled BMDC loaded with SIINFEKL (B) and 19F-PFC-labeled BMDC presenting
SIINFEKL (C) were stained with an antibody to detect SIINFEKL:H-2Kb complex
expression following
a 2 hour
incubation
with SIINFEKL
culture.
injections
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response to develop against SIINFEKL peptide. After 7 days, popliteal lymph nodes were
removed, pooled for each mouse and digested into single cell suspensions. To identify
SIINFEKL-specific CD3+CD8+ T cells, flow cytometry was performed on lymph node
cell suspensions for mice that received vaccinations consisting of unlabeled BMDC not
presenting SIINFEKL (D), unlabeled BMDC presenting SIINFEKL (E) and 19F-PFClabeled BMDC presenting SIINFEKL (F). Regardless of whether SIINFEKL-presenting
BMDC were unlabeled or labeled with 19F-PFC (G, grey squares and black triangles,
respectively), the magnitude of the ensuing SIINFEKL-specific CD8+ T cell response did
not differ and was significantly greater than the non-specific flow cytometric staining
levels measured with BMDC vaccination in the absence of SIINFEKL peptide (G, white
circles). Data is representative of 4 independent experiments. Data in (G) is shown as
means ± SEM (one-way ANOVA, * p > 0.05).
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2.4.6

The murine B16-F10 melanoma cell line can be engineered
to stably express the model tumor antigen, ovalbumin, GFP
and luciferase

An experiment to stably transfect a B16-F10 melanoma cell line to express ovalbumin
protein, which contains the immunogenic model tumor epitope, SIINFEKL, was
performed. Plasmid DNA encoding for ovalbumin was transfected into B16-F10
melanoma cell line and transfected cells were selected for G418 resistance. A western blot
analysis to detect full length ovalbumin was performed on 3 individual transfected B16F10 cell lines, with purified ovalbumin serving as the positive control and untransfected
B16-F10 cell lysate serving as the negative control. Ovalbumin was detected strongly in
one of the three transfected cell lines (Fig. 2-10A, black arrow) at its predicted molecular
weight of approximately 45 kDa. The same band was observed in the positive control and
absent in the untransfected B16-F10 cell lysate negative control (Fig. 2-10A, white arrow).
Using flow cytometry, 99.4% of B16-F10 cells surface express H-2Kb (Fig. 2-10B, black
histogram) compared to unstained cells of the same origin (Fig. 2-10B, blue histogram).
This transfected cell line was transduced with a lentiviral particle encoding luciferase and
GFP. One hundred thousand transfected and transduced B16-F10 cells in an Eppendorf
tube were resuspended in D-luciferin. After overlaying with 1% agarose, GFP (Fig. 2-10C,
top tube) and bioluminescence (Fig. 2-10C, bottom tube) expression confirmed successful
lentiviral transduction. To verify constitutive expression of GFP and luciferase in a more
biologically relevant context, a tumor developed on the back of a C57Bl/6 mouse following
subcutaneous injection of 2x105 B16-F10 ovalbumin+ luciferase+ cells. D-luciferin
substrate was intraperitoneally injected into the mouse and bioluminescent imaging was
used to image the tumor (Fig. 2-10C).
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Figure 2-10. The B16-F10 melanoma cell line was transfected to stably express chicken
ovalbumin as well as stably transduced with a lentiviral particle coding for luciferase and
GFP. Cell lysates from 3 individual cell populations were generated following transfection
with plasmid DNA
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the untransfected negative control cell lysate (U/T) (A, white arrow). This band corresponds
with the molecular weight of ovalbumin (~45 kDa) and thus, the TfR3 B16-F10 cell
population was used for all subsequent experiments. Flow cytometry confirmed that 99.4%
of B16-F10 cells surface express H-2Kb (B, black histogram) compared to unstained B16F10 cells (B, blue histogram). An Eppendorf tube containing a 105 transfected and transduced
B16-F10 cell pellet was overlaid with 1% agarose. Imaging on a IVIS Lumina XRMS in vivo
imaging system detected GFP (C, top tube) and luciferase (C, bottom tube) expression. A
GFP+ ovalbumin+ luciferase+ B16-F10 tumor developed from subcutaneous injection of
2x105 cells into the back of a C57Bl/6 mouse. Following intraperitoneal administration of Dluciferin, bioluminescence imaging identified the tumor (C, BLI radiance scale depicted on
the right (p/sec/cm2/sr)).
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Correlating 19F-PFC-labeled SIINFEKL-presenting BMDC
migration to the lymph node with the ensuing immune
response to a model tumor antigen, ovalbumin (OVA), in a
mouse model of melanoma

2.4.7

The end goal of the research presented in this chapter is to correlate

19

F-PFC-labeled

SIINFEKL-presenting BMDC migration to the draining popliteal lymph node with the
magnitude of the ensuing SIINFEKL-specific immune response and confirm that this
response is not different when using unlabeled SIINFEKL-presenting BMDC. The
experimental approach is outlined in Figure 2-11. On day -2, C57Bl/6 mice were inoculated
with 2x105 B16-F10 luciferase+ ovalbumin+ cells. Two days later, using flow cytometry,
19

F-PFC-labeled and unlabeled control BMDC SIINFEKL peptide presentation was

confirmed (Fig. 2-11, grey and black histograms, respectively) and compared to the third
injection group that consists of BMDC without SIINFEKL peptide (Fig. 2-11, blue
histogram). BMDC from each of the aforementioned conditions were formulated into
3x106 BMDC doses for injection into the hind footpads of tumor-bearing mice. Mice that
received

19

F-PFC-labeled BMDC injections underwent

preliminary experiment,

19

F/1H MRI detected 2.2x104

19

F/1H MRI two days later. In a

19

F-PFC-labeled BMDC in the

popliteal lymph node (Fig. 2-11, yellow arrow), with 2.2x106 injected cells persisting at
the injection site (Fig. 2-11, red arrow). Tumor-bearing mice then underwent
bioluminescence imaging every second day to determine the viability and size of the tumor
in each BMDC vaccine condition. Currently, two mice in each condition have been
completed and popliteal lymph node signal was quantified in the popliteal lymph nodes of
both mice. Bioluminescence imaging was performed until the pre-determined experimental
endpoint was reached (tumor ³ 600 mm3). Whole body perfusion was performed after
euthanasia and tumors were removed and placed in 4% PFA for future histological
analysis. This experiment will be repeated such that a total of 10 mice per injection
condition is achieved.
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Figure 2-11. Correlating 19F-PFC-labeled SIINFEKL-presenting BMDC migration to the
lymph node with the ensuing antigen-specific immune response to a model tumor antigen
OVA in a mouse model of melanoma. Two days prior to BMDC footpad injection (day 2, green box), C57Bl/6 mice were inoculated with 2x105 B16-F10 Luc+ OVA+ cells (same
19
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cytometry
(A). 19
mice and tumor growth was monitored as presented in the timeline. Two days after BMDC
injection, mice that received 19F-PFC-labeled BMDC underwent a 19F/1H MRI scan to
detect and quantify migration to the draining popliteal lymph node (B). This migration was
measured to be 2.2x104 19F-PFC-labeled cells in the popliteal lymph node (yellow arrow),
with 2.2x106 19F-PFC-labeled cells remaining at the injection site (red arrow). From day 2
onwards, all tumor-bearing mice undergo bioluminescence imaging until experimental
endpoint is reached (tumor volume ³ 600 mm3), which is denoted in the timeline by Day
X (C).
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2.5 Discussion
2.5.1

BMDC can be labeled with 19F-PFC without affecting
viability, phenotype and in vivo migration capacity

Initial experiments were conducted using BMDC prepared using an enrichment step for
CD11c+ immature BMDC (Fig. 2-1) prior to labeling with

19

F-PFC. After labeling, the

immature BMDC underwent a maturation step in the presence of a cytokine and TLR
agonist cocktail207, 211, 212, 213. This maturation step was confirmed through phenotyping
analysis of the cocktail-cultured BMDC prior to adoptive transfer to ensure they are
migration competent (CCR7) and mature (CD86). In addition to phenotyping, the viability
of BMDC was measured over a range of concentrations of 19F-PFC (2.5-7.5 mg/mL) and
compared to unlabeled control BMDC. BMDC that were co-cultured with 5 mg/mL 19FPFC labeled efficiently at approximately 1.78x1012
comparable to labeling observed for BMDC with a

19

F spins/cell on average, which is

19

F perfluoropolyether emulsion299

(~5x1012) and also comparable to labeling observed in human DC ranging from 1012 19F
spins/cell to 1.73x1013
therapeutic cells with

19

19

F spins/cell291,

310

. As demonstrated previously, labeling of

F-PFC plateaus at a certain label concentration, for example 10

mg/mL for a PLGA-encapsulated

19

F-PFC141, and any increase in label concentration

thereafter results in decreased viability without increased label incorporation. For BMDC
labeling in this chapter, we believe the saturation point was reached at 5 mg/mL 19F-PFC,
as the 7.5 mg/mL culture condition did not significantly increase label incorporation but
did result in a viability decrease. Therefore, BMDC were able to efficiently incorporate
19

F-PFC label without affecting maturation status and viability, which is important to note

as 19F-PFC label incorporation is directly related to in vivo detection sensitivity using 19F
cellular MRI. Lastly, within the context of APC-based cancer vaccine immunotherapies,
BMDC maturation status must be known prior to adoptive transfer as immature DC are not
efficient at migrating to secondary lymphoid organs, can result in tolerogenic immune
responses towards a TAA and even prevent a future successful immune response from
being launched against that same TAA139, 202, 212, 213.
19

F-PFC is added to immature BMDC to take advantage of its high endocytic capacity

compared to mature BMDC, which excel more at antigen presentation and migration119, 139,
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140, 167, 338

. Although efficient labeling of BMDC was observed in vitro, it was yet to be

determined if 19F-PFC labeling of murine BMDC was sufficient enough to allow for in vivo
detection and migration to a lymph node at 9.4 T without compromising the inherent
migration and immunological capacity of these professional APC. The only other previous
study using primary murine BMDC and 19F cellular MRI was conducted using a verticalbore 11.7 T MRI299. More importantly, as mature BMDC express CCR7167, and because
iron oxide MRI cell labeling agents, SPIO and MPIO, were found to physically impede the
ability of DC to migrate to lymph nodes322, 339, it was important to demonstrate that 19FPFC did not inhibit BMDC migration. Adoptive transfer of 19F-PFC-labeled BMDC into
the footpad of mice permitted the detection and quantification of 19F signal using a 9.4 T
MRI scanner in the draining popliteal lymph node, the inguinal lymph node and the iliac
lymph node. Detection of

19

F-PFC-labeled BMDC in multiple lymph nodes from one

injection was an infrequent occurrence. Although 19F-PFC-labeled BMDC are migrationcompetent in vivo, their migration capacity must be compared to unlabeled BMDC from
the same source to ensure that migration is equivalent between both BMDC conditions.
Direct in vivo migration comparisons between 19F-PFC-labeled and unlabeled DC has not
been conducted in previous studies77,
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and thus, these studies failed to address the

immunological issues associated with differences in migration capacities of therapeutic
cells between unlabeled and labeled conditions.
To compare in vivo migration capacities, BMDC from both 19F-PFC-labeled and unlabeled
control conditions were labeled with an intracellular fluorophore, CFSE, immediately prior
to adoptive transfer performed via footpad injection. Thus, quantification of fluorescence
in the draining lymph node as a result of BMDC migration 48 hours post injection was
used as an accurate means of comparing migration between both cell conditions. For both
low and high injection dose conditions, the migration of

19

F-PFC-labeled BMDC and

control BMDC was not statistically different, suggesting that 19F-PFC does not physically
impede migration of therapeutic cells to secondary lymphoid organs. Furthermore, note
that BMDC from both conditions reach the central paracortical regions of the lymph node
where high concentrations of T cells are located217. Migration to these in vivo locations is
essential for DC-based vaccine immunotherapy to be successful, as stable cell-cell
interaction between DC and T cells is required to initiate a cell-mediated adaptive immune
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response. To control for any type of interaction between an externally introduced
fluorophore (CFSE) and

19

F-PFC that could alter migration, a similar in vivo migration

experiment was performed; however, transgenic mice that express DsRed in all cells were
used to generate fluorescently-labeled BMDC337. The results from this experiment
determined that 19F-PFC did not interfere with BMDC migration to a lymph node nor does
it interfere with intranodal migration to immunologically relevant locations, which
coincides with previously published data regarding intranodal DC localization196. Finally,
19

F-PFC and intracellular fluorescent labels do not interfere with each other or hinder

migration of BMDC from a distal location to a secondary lymphoid organ.
Taken together, detection and quantification of in vivo migration of

19

F-PFC-labeled

BMDC to immunologically-relevant locations are feasible using pre-clinical

19

F cellular

MRI. With the current clinically available MRI technology, 19F cellular MRI is a superior
means of quantifying therapeutic cell migration. In comparison to other cell labeling
agents, such as iron oxide-based contrast agents, it is difficult to quantify the signal and
relate it directly to the cell number as not all cells uptake label and the relation of in vivo
signal to cell quantification is not always linear297, 298. Furthermore, the chemical shift
artifact created by the surrounding fat pad that interfaces with the edge of the lymph node
often confounds the interpretation of what is and what is not iron-induced signal loss
observed in standard 1H MRI scans. Lastly, if relying solely on 1H MRI to detect iron
oxide-labeled DC in the lymph node, some lymph nodes can be overlooked due to the lack
of contrast with surrounding tissues340.

2.5.2

Increasing DC in vivo migration

As the main limiting factor hampering the effectiveness of DC-based cancer vaccines is
the sub-optimal percentage of cells that migrate to secondary lymphoid organs post
injection183, 198, 199, 215, 216, 217, a study was designed to attempt to increase BMDC migration
to the lymph node. Subcutaneous footpad injections were administered to two groups of
mice, a control group and one in which the popliteal lymph node area was pre-treated 3
hours prior with the pro-inflammatory cytokine, IL-1b. Previous research has shown that
using pro-inflammatory cytokines like TNFa and IL-1, or TLR agonists such as LPS that
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induce pro-inflammatory cytokine secretion, to pre-condition tissue in close proximity to
the injection site stimulates and/or increases DC migration to draining lymph nodes. It also
promotes DC retention within the lymph node, which further increases DC:T cell
interactions that contribute to effective induction of subsequent antigen-specific immune
responses199. TNFa pre-conditioning greatly improves the migration capacity of DC when
a low dose injection number is used (105 cells). Although, increasing the number of
migrating DC by injecting higher cell numbers (³106 cells) diminishes the effect preconditioning has on increasing migration as DC migration reaches a plateau at which point
the lymph node appears unable to accept further migrating DC199, 341, 342. Pre-conditioning
with IL-1b did not significantly increase the amount of

19

F-PFC-labeled BMDC that

reached the popliteal lymph node two days post injection (Fig. 2-7). A possible explanation
is that the injection number in this study was 3x106 19F-PFC-labeled BMDC, which could
be too high of a dose to observe the benefits associated with tissue pre-conditioning with
pro-inflammatory cytokines. Tissue pre-conditioning increases migration to the lymph
node by causing the up-regulation of CCL21199, 343, which is one of the main ligands that
drives DC migration in vivo, the other being CCL19168, 169, 170, 344. Pre-conditioning with
combinations of pro-inflammatory cytokines, or even a pre-conditioning injection of DC
that produce similar cytokines would be of interest considering that this increase in
migration could be immunologically significant, as it has been shown to contribute to a
greater antigen-specific CD4+ T cell response in the lymph node four days after injection.
The other alternative is the injection of cytokines to pre-condition the tissue such that
resident or injected DC are surrounded by a pro-inflammatory environment that is
conducive to promoting DC migration168, 199, 345. Although not addressed in this chapter as
19

F MRI was only performed at one timepoint, tissue pre-conditioning has been reported

to accelerate DC migration to a secondary lymphoid organ and was associated with an
increased number of activated CD4+ TH cells in the lymph node capable of secreting TNFa
and IFNg199. Therefore, even though increased BMDC migration was not observed
following IL-1b pre-conditioning in our study, it remains to be elucidated if it resulted in
enhanced pro-inflammatory cytokine secretion.
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2.5.3

19

F-PFC labeling of BMDC does not hinder subsequent
antigen-specific immune response

The effectiveness of BMDC-based immunotherapies to elicit an antigen-specific immune
response is dictated by the number of antigen-presenting BMDC that reach a lymph
node199. Therefore, it is important that we track and quantify peptide-presenting 19F-PFClabeled BMDC migration to the lymph node using

19

F cellular MRI. Furthermore, this

study is unique in that antigen-specific immune responses were directly measured and
compared following immunization with either antigen-presenting 19F-PFC-labeled BMDC
or antigen-presenting unlabeled BMDC using the well-characterized MHC Class I (H-2Kb)
immunogenic peptide (OVA257-264, SIINFEKL) derived from ovalbumin protein, a model
pseudo-tumor antigen261, 346, 347, 348, 349. Although not included in the research described in
this chapter, a well-defined MHC Class II peptide (OVA323-339) also exists for ovalbumin,
which allows for possible examination of TAA-specific CD4+ T cells if deemed
necessary350,

351

. After confirming that

19

F-PFC-labeled BMDC and control unlabeled

BMDC have a similar mature BMDC phenotype as measured through CCR7 and CD86
cell surface expression, a fluorescent antibody that specifically recognizes SIINFEKL in
the context of H-2Kb352,

353

cell surface presentation was used to confirm surface

presentation of peptide using flow cytometry prior to adoptive transfer via footpad
injection. The percentage of SIINFEKL-specific CD8+ T cells in the draining lymph node
using tetramer staining revealed that compared to unlabeled BMDC, 19F-PFC did not affect
BMDC H-2Kb presentation of SIINFEKL peptide and yielded the same SIINFEKLspecific CD8+ T cell-mediated immune response in vivo. This demonstrated that the ability
of BMDC to initiate an antigen-specific immune response is unaffected as a result of 19FPFC label incorporation. Also, the percentage of SIINFEKL-specific CD8+ T cells for both
unlabeled and

19

F-PFC-labeled BMDC was significantly higher than in the control

condition in which BMDC not presenting SIINFEKL peptide were adoptively transferred
into the footpads. This confirmed that an immune response was launched as a result of
BMDC injection and set the stage to investigate that 19F-PFC-labeled BMDC and unlabeled
control BMDC both presenting SIINFEKL peptide launch and effective and equivalent
anti-tumor response in mice bearing an ovalbumin-expressing B16-F10 melanoma tumor.
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Prior to conducting experiments in tumor-bearing mice, the B16-F10 cancer cell line was
modified via introduction of three transgenes: ovalbumin as a pseudo-tumor antigen and
luciferase and GFP as imaging biomarkers to monitor tumor growth. A western blot was
performed on B16-F10 cell lysate to confirm ovalbumin expression, and flow cytometry
revealed that this cell line does not down-regulate H-2Kb and thus, is able to present
SIINFEKL peptide on the cell surface in the context of H-2Kb. With bioluminescence
imaging, tumors implanted on the back of mice were visualized after intraperitoneal
administration of luciferin substrate and tumor growth/regression was monitored
quantitatively until the pre-determined experimental endpoint was reached. This tumor
experiment was designed such that correlating the quantification 19F-PFC-labeled BMDC
migration to immunologically relevant locations with objective tumor response is possible
upon completion. With the current study design, metastases were not observed or measured
using BLI before the tumor volume endpoint was reached. The B16-F10 cell line appears
to grow too fast to conduct an in-depth analysis of metastases, which are commonly seen
in the lungs323, 354, 355. Therefore, future experiments can include removing the primary
tumor as it approaches an endpoint volume and continuing to monitor the animals for
metastases thereafter356.
The B16-F10 melanoma cell line was chosen for this murine tumor experiment as it is an
immunogenic cancer that has previously been shown to respond to IL-2 therapy333 and cellbased cancer vaccine immunotherapies targeted against B16-F10 melanoma have resulted
in both tumor-specific humoral and cell-mediated immune responses357. With respect to
B16-F10 melanomas expressing ovalbumin as a pseudo-tumor peptide, many studies have
taken advantage of the OT-I mouse model. These mice are transgenic such that all CD8+ T
cells express a TCR that specifically binds SIINFEKL peptide in the context of H-2Kb 358,
359

. The tracking of CD8+ SIINFEKL-specific T cells to a lymph node has been observed

if that lymph node contains ovalbumin and incomplete Freund’s adjuvant307. With
cellular MRI,

19

19

F

F-labeled OT-I T cells have been detected in the liver, lung and spleen

following injection, but not in an ovalbumin-expressing B16 tumor261. Moreover, naïve
CD8+ SIINFEKL-specific T cells do not inhibit tumor growth in a tumor-bearing mouse
unless they are properly activated360, for example with a professional APC, like a DC,
presenting SIINFEKL peptide361. 19F cellular MRI failed to detect ex vivo-activated OT-I

65

CD8+ T cell migration to a tumor, most likely as a result of the combination of poor 19Flabeling of T cells and extensive T cell proliferation diluting

19

F label below in vivo

detection threshold261. 19F-labeled NK cells ex vivo-stimulated with IL-2 also could not be
detected migrating to a tumor post injection314.
DC-based immunotherapies in B16-F10 tumor-bearing mouse models have also been
extensively investigated. DNA vaccination of B16-F10-specific TAA that resulted in DC
uptake and antigen presentation were associated with delayed B16-F10 tumor growth,
reduced lung metastases and extended overall survival of C57Bl/6 mice362, 363. DC cultured
with B16-F10 cell lysate and poly(I:C) have induced B16-F10-specific CD8+ T cells and
decreased tumor growth333; however, without a TLR agonist, DC culture with B16-F10
cell lysate did not inhibit melanoma progression. These sub-optimal results, in combination
with the notion that a DC-based immunotherapy has not been monitored using 19F cellular
MRI in B16-F10 tumor bearing mice, outline the need for further research to elucidate the
in vivo fate of injected therapeutic cells following injection109, 264. This newly acquired
knowledge can then be used to improve upon the effectiveness of cell-based
immunotherapies and non-invasively predict tumor outcome without issues such as T cell
division and low labeling of lymphocyte lineages.

2.5.4

Conclusions

Data presented above demonstrates that murine BMDC can be efficiently labeled with 19FPFC to permit detection and quantification of their in vivo migration using

19

F cellular

MRI. 19F-PFC labeling incorporation occurs without affecting viability, phenotype, in vivo
migration and ability of BMDC to function as an adjuvant in initiating tumor-specific
immune responses in the context of APC-based cancer immunotherapies. Future research
should focus on confirming that

19

F cellular MRI is a suitable platform for quantifying

differences in therapeutic cell migration between different cancer vaccine formulations as
it relates to anti-tumor immune responses. Also, investigating if this imaging technique can
serve as a suitable non-invasive surrogate marker for assessing the effectiveness of
combination therapies can only aid in the battle between up-regulating the immune system
to combat a tumor and tumor immune evasion strategies.
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Chapter 3

3

Mixed APC-based cancer immunotherapies
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3.2 Introduction and Rationale
Prostate cancer is the third leading cause of cancer death in men364. Traditional therapies
utilized during early stage cancer are surgical resection and radiation therapy, followed by
further surgical and radiological interventions along with androgen deprivation therapy
(ADT) during late stage treatment241, 365. Unfortunately, patients who progress to metastatic
hormone-refractory prostate cancer, which is the stage responsible for virtually all prostate
cancer-related deaths6, have few treatment options and as a result, the 5 year survival rate
for metastatic prostate cancer is 28%366. Docetaxel is a possible treatment option available
at the metastatic stage; however, treatment with this chemotherapeutic agent is not suitable
for all prostate cancer patients. This highlights the need for novel approaches and strategies
to combat metastatic prostate cancer5, 6.
Previous research has found that basal immune responses to PAP, a TAA, have been
detected in prostate cancer patients prior to immunotherapeutic-related interventions242, 367,
368

. This, in combination with the knowledge that prostate cancer progresses slowly and

has well-defined TAA, makes prostate cancer a platform well-suited for cancer
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immunotherapy development8,

40, 41, 42, 44

.

Multiple immunotherapies have been

investigated, such as DCVAC/PCa which consists of mature DC pulsed with PSAexpressing LNCaP cancer cells369,

370, 371

, PROSTVAC, a pox viral-based PSA

immunotherapy delivered in conjunction with co-stimulatory molecules and GM-CSF372,
373, 374

, and BDCA-1+ BDC-01+, a CD1c+ blood-derived DC-based vaccine pulsed with

PAP- and PSA-based peptides375. Although these immunotherapies have demonstrated
promising pre-clinical results, a mixed APC-based immunotherapy, Sipuleucel-T, is the
only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer
(CRPC)7.
Sipuleucel-T functions by potentiating established basal immune responses a prostate
cancer patient has to PAP to level that overcomes tumor-induced immunosuppression and
results in tumor recognition and destruction120, 241, 242, 243. It is formulated by ex vivoculturing PBMC with a proprietary fusion protein containing PAP, a TAA present in the
vast majority of prostate cancer tumors and primarily restricted to prostate tissue376, 377,
fused to GM-CSF, a cytokine that activates APC contained within PBMC7, 241, 249, 378. In
this manner, APC are rendered TAA-specific via PAP and activated as a result of GM-CSF
upon fusion protein internalization379. Surface expression of CD54 is used as a readout to
determine APC activation43,

246

and upon autologous reinfusion, APC are properly

activated to boost existing responses as well as launch an anti-tumor immune response,
which includes activation of naïve CD4+ and CD8+ T cells192,

241, 251

. Sipuleucel-T

prolonged overall survival of prostate cancer patients by 4.1 months in a phase III clinical
trial; however, further research and improvements to this immunotherapy must take place
in order to reach a therapeutic level whereby significant prolongation of progression-free
survival takes place244, 245.
As Sipuleucel-T is derived from prostate cancer patient PBMC, it contains a heterogeneous
mixture of immune cells, each with their own in vivo function and own propensity to home
to a specific in vivo location and exert their function120, 247. Not only is in vivo CD54+ large
APC migration important when considering Sipuleucel-T, but other cell lineages, such as
B and T lymphocytes, are contained within the infusion product and can be activated during
ex vivo-culture120. TNFa produced as a result of B and T cell activation can further
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potentiate APC activation following administration and lead to the production of IL-1b120,
380, 381

. Therefore, knowledge acquisition pertaining to in vivo migration and persistence of

all cell lineages within therapeutic PBMC preparations can aid in fully understanding and
thus, improving upon this APC-based immunotherapy. In this chapter, we aimed to
efficiently label the main cell lineages contained within both murine and human PBMC
formulations with a

19

F-PFC cell labeling agent without affecting PBMC viability or

phenotype. Research then focused on detecting and quantifying 19F-PFC-labeled murine
PBMC in vivo migration in an immunocompetent mouse model and detecting and 19F-PFClabeled human PBMC in vivo migration in an immunocompromised mouse model using
19

F cellular MRI.

Considering the data we present in this chapter, 19F cellular MRI has the potential to be
applied to non-invasively detecting and quantifying the migration of T, NK or NKT cells
to the tumor, which has been histologically-associated with increased survival in previous
studies125, 129, 162, 163, 185, 382, 383, 384, 385. Furthermore, as the proportions of immune cell
lineages within a heterogeneous APC-based cancer immunotherapy vary greatly between
apheresis patient products42, 246, 19F cellular MRI can potentially be used to observe which
cell lineage proportions are best-suited for this immunotherapy. This non-invasive imaging
modality can also be employed to compare in vivo migration competencies between
freshly-prepared or frozen vaccine formulations (APC8015F), which have been used as
salvage therapies in Sipuleucel-T clinical trials and demonstrated to be biologically active7,
43

.

19

F cellular MRI can possibly help answer fundamental questions hindering the

advancement of Sipuleucel-T from an immunotherapy that induces T cell activation7,
mobilizes tumor-specific immune cells to the tumor83 yet does not result in progression
free survival245, 386 to an immunotherapy that induces long-term protection against prostate
cancer.

3.3 Materials and Methods
3.3.1

Animal Care

Male nu/nu mice (Crl:NU-Foxn1NU) were purchased from Charles River Laboratories Inc.
(Saint Constant, Canada) at 8-10 weeks old and housed at Robarts Research Institute at the
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University of Western Ontario (London, Canada) in a high efficiency particulate airfiltered (HEPA-filtered) barrier cage system. All experiments were pre-approved by the
Animal Use Subcommittee at the University of Western Ontario and conducted in
accordance with an approved protocol from University of Western Ontario’s Council on
Animal Care (Protocol #2015-046). When required, mice were anaesthetized with 2%
isoflurane in oxygen unless specified otherwise.

3.3.2

Participants

The University of Western Ontario Health Sciences Research Ethics Board (REB) preapproved this protocol (REB Protocol #104593). Each healthy volunteer involved in this
study protocol received a REB-approved Letter of Information and provided a signed
Letter of Informed Consent before entering into the study and provided between 50 mL150 mL of peripheral blood. For inclusion in the study, healthy participants had to be 18
years of age or older and free of Human Immunodeficiency Virus (HIV), Hepatitis B or C
Virus or other transmissible diseases. Commercially-available peripheral blood or
leukapheresis cell products (Stemcell Technologies, Seattle, USA) were also used as a
source of PBMC for certain experiments. Certificates of analysis were provided to confirm
a viability of >90% of cell product and each donor was negative for HIV, Hepatitis A and
Hepatitis B. Cell count, volume and type of anti-coagulant used for each sample was
provided as well.

3.3.3

Reagents

Aim V® Medium CTS (GMP-grade, Gibco, Burlington, Canada) was supplemented with
100 U/mL of penicillin, 100 µg/mL of streptomycin and 0.3 mg/mL L-Glutamine
(ThermoFisher Scientific, Burlington, Canada). HBSS, PBS, human AB serum, Trypan
Blue, CellTraceTM CFSE, CellTraceTM Violet and CellTraceTM Far Red cell proliferation
kits and LIVE/DEAD™ fixable aqua dead cell stain were purchased from ThermoFisher
Scientific and BSA was obtained from Calbiotech (Spring Valley, USA). Lymphoprep™,
human CD3, human B cell and human monocyte negative selection kits were purchased
from Stemcell Technologies (Vancouver, Canada). NGS was purchased from Jackson
ImmunoResearch (West Grove, USA) while human GM-CSF and murine IL-1b were
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obtained from PeproTech (Montreal, Canada). CD15-PE/Cy7 (clone W6D3), CD11c-APC
(3.9), CD16-Alexa Fluor 700 (3G8), CD19-APC/Cy7 (HIB19), CD56-BV605 (HCD56),
CD3-PE (HIT3a), CD19-PE (HIB19), CD20-PE (2H7), CD45-FITC (HI30), CD3APC/Cy7 (SK7), CD11b-Alexa Fluor 647 (M1/70), CD20-PE/Cy5 (2H7), CCR7-PE/Cy7
(G043H7), CD40-BV421 (5C3), CD54-PE (HA58), CD83-Alexa Fluor 488 (HB15e),
CD86-PerCP/Cy5.5 (IT2.2) and FITC Annexin V Apoptosis Detection kit with 7-AAD and
were purchased from Biolegend (San Diego, USA), while anti-human CD14-eFluor450
(61D3) and UltraComp eBeads were acquired from eBioscience (San Diego, USA). The
19

F-PFC cell labeling agents used in this study, Cell Sense CS-1000 and the red fluorescent

version, CS-ATM DM Red (excitation 596 nm, emission 615 nm), were both purchased
from Celsense, Inc. (Pittsburgh, USA). Lastly, PBMC were cultured in ThermoFisher
Scientific Nunc Hydrocell plates (ThermoFisher Scientific).

3.3.4

Human PBMC isolation and 19F-PFC labeling

Following venipuncture and collection of peripheral blood from volunteers or receiving of
purchased cell products collected in the presence of heparin sulfate, samples were diluted
1:1 with room temperature HBSS and subject to density gradient centrifugation using
LymphoprepÔ (Stemcell Technologies, Vancouver, Canada) to isolate PBMC. To assess
uptake of

19

F-PFC, PBMC were labeled at varying cell (2, 5, 10x106 cells/mL) and red

fluorescent 19F-PFC (2.5, 5.0, 7.5 mg/mL) concentrations (Celsense, Inc., USA) at 37ºC,
5% CO2 for 24h in AIM V® Medium CTS™ media. Labeled PBMC (as well as unlabeled
control PBMC) were collected, washed in HBSS and then resuspended in HBSS+0.1%
BSA with 5% (v/v) NGS for 30 minutes on ice. Following washing, surface staining for
lineage markers (CD3/CD19, CD11c, CD14) in HBSS+0.1% BSA was conducted on ice
(4°C) for 25 minutes. Stained PBMC were then washed and resuspended in HBSS+0.1%
BSA, with data being acquired immediately on an LSRII analytical flow cytometer (BD,
Mississauga, Canada) to determine

19

F-PFC label uptake in each cell lineage. Data was

analyzed using FlowJo software (Tree Star, Ashland, USA). Upon completion of
measuring

19

F-PFC uptake at a range of label concentrations and cell culture

concentrations, it was determined that 5x106 cells/mL labeled with 5.0 mg/mL

19

F-PFC

produced the best results with respect to viability and label incorporation and thus, were
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the conditions used for the remainder of experiments. In addition, a 48 hour cell culture
with

19

F-PFC-labeled or control unlabeled PBMC was adopted, which included the

addition of human GM-CSF (PeproTech) at 20 ng/mL for the last 24 hours of culture except
to control conditions that did not receive GM-CSF.

3.3.5

Cell viability

Cell viability was measured during the process of PBMC isolation, culturing and labeling
with 19F-PFC using the trypan blue exclusion assay. The viability of PBMC cell products,
regardless of cell concentration or 19F-PFC label in culture and the addition of GM-CSF
(20 ng/mL) or not was measured using FITC-Annexin V apoptosis detection kit with 7AAD and acquired on a LSRII analytical flow cytometer (BD Biosciences) immediately
after the addition of 7-AAD at room temperature.
To assess the activation, co-stimulation and maturation state of

19

F-PFC-labeled and

unlabeled PBMC cultured in the presence or absence of GM-CSF, PBMC from each
condition were collected and washed in PBS. Two microliters of LIVE/DEAD™ fixable
aqua dead cell stain stock solution (reconstituted in 50 µL DMSO) was added per mL of
room temperature PBS. Next, 250 µL of this diluted solution was added to each FACS tube
and incubated at room temperature for 20 minutes, followed by surface staining (detailed
below) and acquisition using a LSR II analytical flow cytometer (BD Biosciences).

3.3.6

Flow cytometry

The following antibodies were used for phenotyping human PBMC: CD15-PE/Cy7,
CD11c-APC, CD16-Alexa Fluor 700, CD19-APC/Cy7, CD14-eFluor450, CD56-BV605,
CD3-PE, CD19-PE, CD20-PE and CD45-FITC.
In addition to the lineage phenotyping and red fluorescent

19

F-PFC incorporation into

PBMC, further phenotyping was conducted in order to compare between 19F-PFC-labeled
and unlabeled control PBMC, as well as assess phenotypic differences that may arise as a
result of GM-CSF addition to culture. Activation, migration and co-stimulation
phenotyping was first conducted using LIVE/DEAD™ fixable dead cell stain (described
above), followed by surface staining with the following antibodies: CD3-APC/Cy7,
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CD11b-Alexa Fluor 647, CD20-PE/Cy5, CCR7-PE/Cy7, CD40-BV421, CD54-PE, CD83Alexa Fluor 488 and CD86-PerCP/Cy5.5. Irrespective of cell surface markers being
phenotyped, cultured PBMC were blocked on ice for 30 minutes with 5% NGS (v/v) in
HBSS+0.1% BSA and then washed in HBSS. Following washing, cell surface staining of
PBMC was conducted in HBSS+0.1% BSA on ice (4°C) for 25 minutes. Lastly, stained
PBMC were washed in cold HBSS and re-suspended in HBSS+0.1% BSA and 4%
paraformaldehyde for data acquisition on a LSRII analytical flow cytometer (BD
Biosciences).

3.3.7

Adoptive cell transfer of PBMC

Three hours prior to PBMC injection, nu/nu mice were anesthetized and received an
injection in the left popliteal lymph node area of 300 ng murine IL-1b (PeproTech) to
facilitate increased migration of injected cells to the lymph node. To generate

19

F-PFC-

labeled PBMC injections, cells were washed twice in PBS and formulated into a 3x106
injection in 40 µL PBS into both footpads of anesthetized mice. The same injection
procedure was followed for 19F-PFC-labeled PBMC co-cultured with GM-CSF (20 ng/mL)
for the last 24 hours of culture.
and

19

19

F cellular MRI was conducted 48 hours post injection

F-PFC-labeled PBMC migration to the draining lymph node was detected and

quantified upon overlay with an anatomical proton scan to provide anatomical context to
observed in vivo 19F signal.

3.3.8

MRI of PBMC migration

Mouse imaging was performed with a 9.4 T Varian small-animal MRI scanner (Santa
Clara, CA, USA). A 3D-bSSFP sequence was used for both proton and 19F MR imaging.
Animals were imaged alongside a reference tube containing a known

19

F concentration

(3.33x1016 19F/μL or 7.3x1016 19F/μL) suspended in agarose. Mice were anesthetized with
2% isoflurane, with breathing rate and temperature monitored throughout the scan. MRI
was performed using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm),
tuned to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively. For proton
imaging the scan parameters were: TR = 5.0 ms, TE = 2.5 ms, rBW = 78 kHz, FA = 30°,
PC = 4, averages = 3 and resolution = 200x200x200 μm3. For 19F imaging the parameters
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were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25 kHz, FA = 70°, PC = 4, averages = 200 and
resolution = 1x1x1 mm3. To avoid

19

F present in isoflurane confounding the

19

F-PFC

signal, imaging was performed by centering on the 19F-PFC Cell Sense-specific frequency
as was previously described270. The total protocol time for both proton and

19

F imaging

was under 90 minutes.

3.3.9

19

F-loading efficiency and signal quantification

The mean intracellular 19F content of human PBMC was determined by NMR spectroscopy
using a 400 MHz Varian vertical spectrometer. First, a known number of 19F-PFC-labeled
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a
solution containing 100 µL of 5% Triton X-100. After lysing, the cells were transferred to
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA
provides a reference peak for quantifying the number of 19F spins/ cell, since NMR signal
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm.
The number of PBMC detected within MR images was determined with Voxel TrackerTM
software (Celsense Inc, Pittsburgh, PA) 270, 308. Prior to analysis, a signal correction was
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal
contained within a hand-drawn ROI was compared to the average signal produced by the
reference tube containing a known 19F concentration. This information was used alongside
the 19F spins/cell, measured by NMR, to quantify the apparent number of cells located at
the ROI.

3.3.10

Lineage-specific adoptive cell transfer

As PBMC are composed of a heterogeneous mixture of immune cells, the three main
lineages found in PBMC were isolated into homogeneous cultures, differently labeled with
an intracellular fluorescent label and reconstituted back as a heterogeneous population at
physiologic proportion prior to injection and draining popliteal lymph node removal 48
hours later. Briefly, PBMC were isolated from healthy volunteers as described previously
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and subject to negative magnetic selection kits (Stemcell Technologies) and
manufacturer’s instructions such that homogeneous cultures of CD3+ T cells,
CD19+/CD20+ B cells and CD14+CD16+ monocytes could be obtained. These cell lineages
were resuspended at 5x106 cells/mL in AIM V® Medium CTS™ media AIM V and
cultured for 48 hours with 19F-PFC (5 mg/mL), with GM-CSF (20 ng/mL) being added to
all wells for the last 24 hours of culture. All cell conditions were collected separately and
resuspended at 1x106 cells/mL in warm PBS+0.5% human AB serum (ThermoFisher) and
labeled with a unique intracellular fluorophore for 10 minutes at 37°C (T cells were labeled
with CellTrace™ Far Red (1 µM), monocytes with CellTrace™ CFSE (1 µM), and B cells
with CellTrace™ Violet (1 µM) (ThermoFisher Scientific). The reaction was quenched
with ice cold AIM V® Medium CTS™ media and cells were washed in HBSS.
Immediately prior to injection, all 3 cell lineages for both

19

F-PFC-labeled and control

PBMC were recombined back into a heterogeneous population at physiological proportions
(as determined by flow cytometry above) and 3x106 cell footpad injections were performed
as stated above into the left and right hind footpad of anesthetized nu/nu mice. Forty-eight
hours later, draining popliteal lymph nodes were removed from sacrificed mice, fixed with
4% PFA and cryopreserved in sucrose solutions. Upon completion of cryopreservation, 16
µm sections were placed on VWR Microslides Superfrost® Plus (VWR), coverslipped with
PBS and imaged to detect the unique fluorescence of each of the 3 main lineages found
within PBMC.

3.3.11

Statistical analysis

All data was presented as the mean with the standard error of the mean. A paired t-test
(Graph Pad Prism, Version 7, La Jolla, USA) and two-way ANOVA were used and was
defined when statistics were reported. Multiple comparisons were conducted for two-way
ANOVAs.

Significance was considered if p ≤ 0.05. When written, the number of

independent experiments is denoted by (N) while the number of replicates per independent
experiment is defined by (n).
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3.4 Results
3.4.1

Human PBMC cell lineages important for antigen
presentation efficiently label with 19F-PFC without affecting
viability

As human PBMC are composed of multiple cell lineages such as B and T lymphocytes,
monocytes and dendritic cells, initial experiments to determine red fluorescent

19

F-PFC

incorporation into a heterogeneous cell mixture were conducted, as the vast majority of
19

F-PFC labeling is performed on homogeneous cell cultures141, 270, 307, 314, 387, 388, 389, 390. A

range of cell (2-10x106 cells/mL) and 19F-PFC (2.5-7.5 mg/mL) culture conditions were
used to elucidate the optimal concentrations that provide the most efficient

19

F-PFC

labeling without having a deleterious effect on cell viability. After 48 hours in culture,
PBMC were first gated on singlet, live cells using forward-/side-scatter properties and
FITC-Annexin V/7-AAD staining (Fig. 3-1A-C). Regardless of cell lineage or

19

F-PFC

concentration employed, CD11c+CD14-CD16- dendritic cells (Fig. 3-1D/G) CD14+
monocytes (Fig. 3-1E/G) and B and T cell lymphocytes (Fig. 3-1F/G) all label with red
fluorescent 19F-PFC at a high percentage (>70%, Fig. 3-1). However, CD14+ monocytes,
lymphocytes and CD11c+CD14-CD16- dendritic cells all label equivalently at a high
percentage (>88% for each replicate) when a cell concentration of 5x106 cells/mL and 5
mg/mL 19F-PFC was used while also maintaining a high viability at 89.47% ± 2.39% (mean
± SEM, n=3) (Fig. 3-1G). Therefore, the latter culture condition was chosen for all
subsequent experiments presented in this chapter.
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Figure 3-1. All cells important to antigen presentation and ensuing antigen-specific
immune response label efficiently with red fluorescent 19F-PFC. Following incubation for
48 hours with red fluorescent 19F-PFC, live, singlet cells were gated based on scatter and
7-AAD/FITC-Annexin V staining as shown in (A-C) using fluorescent minus one (FMO)
controls and further gated using appropriate FMO control to identify CD11c+ DC (D),
CD14+ monocytes (E) and CD3+ T cells/CD19+ B cells (F). All lineages label to a high
3-1. All to
cells
important
to PBMC
antigen
presentation
and regardless of the
degreeFigure
when compared
unlabeled
control
from
the same donor,
19
ensuing of
antigen-specific
immune response
efficiently
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19
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3.4.2

19

F-PFC-labeled PBMC can be cultured with GM-CSF
without affecting viability, phenotype and 19F-PFC loading

After establishing that human PBMC can be efficiently labeled with

19

F-PFC, we next

sought to determine what effect GM-CSF in culture has on 19F-PFC-labeled PBMC. This
was investigated because our research is modeled after the APC-based immunotherapy,
Sipuleucel-T246, which is generated by co-culturing PBMC with the cytokine GM-CSF
fused to a tumor-associated antigen. First, PBMC were isolated from the blood of healthy
volunteers and cultured at the optimal cell concentration and 19F-PFC concentration, which
are 5x106 cells/mL and 5 mg/mL, respectively. GM-CSF (20 ng/mL) was added to half of
19

F-PFC-labeled PBMC for the final 24 hours of a total 48 hour culture. Upon completion

of culture, PBMC were collected and counted for viability. It was determined that the
viability after GM-CSF addition to 19F-PFC-labeled PBMC culture (85.7 ± 2.31%) did not
significantly differ from the viability of control 19F-PFC-labeled PBMC (88.73 ± 1.87%)
(Fig. 3-2A). The viability between PBMC cultures treated with GM-CSF or left as control
were further analyzed by looking at lineage-specific viability. The viability of CD3+CD20CD11b- T cells, CD20+CD3-CD11b- B cells and CD11b+CD3-CD20- myeloid cells
remained unchanged with the addition of GM-CSF into culture for both 19F-PFC-labeled
PBMC lineages and unlabeled PBMC lineages (Fig. 3-2B).
After assessing the viability of T cells as well as two APC lineages, CD20+ B cells and
CD11b+ myeloid cells in Figure 3-2B, flow cytometry was used to measure surface
expression of activation markers such as CD40, CD54, CD83, migration marker CCR7,
and co-stimulation markers CD83 and CD86. This phenotyping was conducted such that
CD20+ B cells were analyzed for percent expression of the aforementioned surface antigens
(Fig. 3-3A), and CD11b+ cells were analyzed for percent expression following the same
approach (Fig. 3-3B). Furthermore, the intensity of cell surface expression of these markers
was analyzed by using mean fluorescence intensity (MFI) of the positively stained
population for both CD20+ B cells (Fig. 3-3C) and CD11b+ myeloid cells (Fig. 3-3D). The
percentage of cells presenting these markers for both B cell and myeloid cell lineages did
not significantly change as a result of GM-CSF addition to both

19

F-PFC-labeled and

unlabeled conditions. However, the intensity of expression of activation, migration and co-
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stimulation does trend towards increasing upon GM-CSF addition, with significant
increases being observed for CD86+ MFI for CD20+ B cells and CD11b+ myeloid cells as
well as CD54+ MFI for CD11b+ myeloid cells (Fig. 3-3C/D).
The amount of 19F-PFC loading on average per cell was also investigated with cell pellets
from 19F-PFC-labeled PBMC that were cultured in either the presence or absence of GMCSF. NMR spectroscopy was conducted to quantify PBMC loading with 19F-PFC using
the spectra obtained for both control 19F-PFC-labeled PBMC (Fig. 3-4A) and GM-CSFtreated

19

F-PFC-labeled PBMC (Fig. 3-4B) and the equation previously described in

Appendix I, Figure 6-8. Quantification of average 19F-PFC loading (2.17x1011 ± 9.25x1010
19

F atoms/cell) remained unchanged with the addition of GM-CSF in culture (2.27x1011 ±

1.08x1011 19F atoms/cell) (Fig. 3-4C).
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Figure 3-2. 19F-PFC labeling and the addition of GM-CSF in cell culture does not affect
the viability of human PBMC. Following a 24 hour incubation with 19F-PFC (5 mg/mL),
GM-CSF was added (20 ng/mL) to half of cells and PBMC (5x106 cells/mL) were
incubated for 24 more hours. GM-CSF-treated 19F-PFC-labeled PBMC did not differ in
viability when compared to control 19F-PFC-labeled PBMC with data shown as means
± SEM (t-test, p>0.05) (A). A more rigorous analysis of viability using flow cytometry
and LIVE/DEAD™ fixable dye to determine the viability of CD3+CD20-CD11b- T
cells, CD20+CD3-CD11b
B cells and CD11b+CD3-CD20- myeloid cells was conducted.
19
Figure
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lineage. Data is shown as means ± SEM (two-way ANOVA, p>0.05) (B).
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Figure 3-3. Human CD20+ B cells and CD11b+ myeloid cells appear to up-regulate
+
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up-regulate
their
expression
of
maturation
and
activation
Viable B cells (A) and viable myeloid cells (B) were further phenotyped to identify
cells markers
that stain following
positively GM-CSF
for markersaddition.
of activation, migration and co-stimulation. The
intensity of staining for each surface marker was also measured using the MFI of the
positively-gated population for CD20+ B cells (C) and CD11b+ myeloid cells (D)
cultured with or without 19F-PFC and with or without GM-CSF (20 ng/mL). Data is
shown as means ± SEM (two-way ANOVA, * p<0.05).
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Figure 3-4. GM-CSF addition to PBMC culture does not increase 19F-PFC loading.
19 and GMTheFigure
individual
nuclear magnetic
control
PBMC (A)
3-4. GM-CSF
additionresonance
to PBMCspectra
culturefor
does
not increase
F-PFC
CSF-treated
loading. (20 ng/mL) PBMC (B) are required for quantification of the average
number of 19F atoms per cell (C). Data shown as means ± SEM (t-test, p > 0.05).
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3.4.3

GM-CSF addition to PBMC culture allows for consistent
detection and quantification of 19F-PFC-labeled PBMC
migration in vivo

After demonstrating that PBMC efficiently label with 19F-PFC in the presence of GM-CSF
without significantly affecting viability, the next logical step was to assess the in vivo
migration of GM-CSF-treated

19

F-PFC-labeled PBMC compared to

19

F-PFC-labeled

PBMC not cultured with this cytokine. In addition to GM-CSF treatment, the left popliteal
lymph nodes of all mice were pre-treated 3 hours prior to PBMC injection with murine IL1b. Forty-eight hours after hind footpad injection of 3x106
cultured with or without GM-CSF, mice underwent

19

19

F-PFC-labeled PBMC

F/1H MR imaging. Figure 3-5

displays the detection and quantification of 10.1 ± 0.88x104 GM-CSF-treated

19

F-PFC-

labeled PBMC in the left popliteal lymph node that received IL-1b pre-treatment (Fig. 35, orange arrow) and 12.8 ± 0.3x104 GM-CSF-treated 19F-PFC-labeled PBMC in the right
popliteal lymph node that did not receive IL-1b (Fig. 3-5, yellow arrow) upon overlaying
a pseudocoloured 19F MRI to a standard 1H MRI. This experiment was conducted using
PBMC obtained from 4 different healthy volunteers, with each repeat including footpad
injections into 2 immunocompromised mice for both cell culture conditions. Mice injected
with GM-CSF-treated

19

F-PFC-labeled PBMC have the right popliteal lymph nodes

identified by 19F/1H MRI (Fig. 3-6A/C/E/G/I/K/M/O, blue arrows) and the left popliteal
lymph nodes that was pre-treated with IL-1b identified by red arrows (Fig. 36B/D/F/H/J/L/N/P). The right popliteal lymph nodes from mice that received

19

F-PFC-

labeled PBMC not cultured with GM-CSF are identified by blue arrows (Fig. 36Q/S/U/W/Y/a/c/e) and the left popliteal lymph nodes that were pre-treated with IL-1b are
identified by red arrows (Fig. 3-6R/T/V/X/Z/b/d/f). The detection and quantification of 19FPFC-labeled cells in the lymph node is summarized in Table 3-1 and organized identically
to the lymph nodes displayed in Figure 3-6. Upon completion of in vivo migration studies
using 19F/1H MRI for both cell conditions, GM-CSF increases the migration of 19F-PFClabeled PBMC above the detection threshold of 19F MRI such that this migration can be
readily detected, unlike the situation observed for 19F-PFC-labeled PBMC that were not
cultured with GM-CSF. Moreover, IL-1b pre-treatment of the popliteal lymph node area
appears to increase migration of 19F-PFC-labeled PBMC not cultured with GM-CSF such
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that this migration is above the detection threshold and thus, can be quantified (Table 3-1).
As IL-1b pre-treatment does not increase the migration of GM-CSF-treated

19

F-PFC-

labeled PBMC, it appears that these two cytokine pre-treatments do not act synergistically.

19
19
19
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Figure
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of
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F-PFCdays following injection.
labeled PBMC that were co-cultured with GM-CSF (20 ng/mL) during the last 24 hours of
a 48 hour culture. The 19F signal, rendered in “hot-iron” colour scale, detected 10.1 ±
0.88x104 19F-PFC-labeled cells (orange arrow) in the left popliteal lymph node (which was
treated 3 hours prior to injection with 300 ng of murine IL-1b) and 12.8 ± 0.3 x104 19FPFC-labeled cells (yellow arrow) in the right popliteal lymph node.
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(Figure 3-6 continues on next page)
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Figure 3-6. Proof of concept MR imaging approach to increasing PBMC migration to
draining target lymph nodes following adoptive cell transfer. Data is presented as 4 separate
experiments with 2 immunocompromised mice per condition. For PBMC labeled with 19FPFC and cultured with GM-CSF (20 ng/mL), the right popliteal lymph node
(A,C,E,G,I,K,M,O) is indicated by the blue arrow. The left popliteal lymph node
(B,D,F,H,J,L,N,P)
is indicated
red arrowMR
and was
pre-treated
3 hours prior
Figure 3-6.
Proofbyoftheconcept
imaging
approach
to to injection
19
of cells with
300 ng ofPBMC
mIL-1β.
For control
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with
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GM-CSF,following
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(Q,S,U,W,Y,a,c,e)
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adoptive cell transfer.
The left popliteal lymph node (R,T,V,X,Z,b,d,f) is indicated by the red arrow and was pretreated 3 hours prior to injection of cells with 300 ng of mIL-1β. Area defined by R (in green)
and outlined in white indicates the location of a reference tube that is required to quantify in
vivo cell migration. The quantification of popliteal lymph node 19F signal is summarized in
Table 3-1.
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Table 3-1. GM-CSF in cell culture and IL-1b pre-treatment of draining popliteal lymph
node area increase migratory capacity of 19F-PFC-labeled human PBMC.
GM-CSF-treated PBMC*
19
F MRI Quantification
Right Lymph
Node

19

Left Lymph Node
(IL-1b pretreated)

(Figure 3-6 A-D)

Control PBMC*
F MRI Quantification

Right Lymph
Node

Experiment 1

(Figure 3-6 Q-T)

(n=2)
13 ± 3x104
---

(n=2)
10 ± 3x104
19 ± 5x104

(Figure 3-6 E-H)

15 ± 2x104
--Experiment 2

6.3 ± 1x10
3.3 ± 0.8x104

(n=2)
5.4 ± 1x10
---

(Figure 3-6 I-L)

Experiment 3

(Figure 3-6 Y-b)

(n=2)
9.6 ± 1.5x10
7.2 ± 1.2x104

(n=2)
5.2 ± 1.3x10
5.7 ± 1.1x104
4

(Figure 3-6 M-P)

7.7 ± 2x104
6.7 ± 1x104

-----

Experiment 4

(Figure 3-6 c-f)

(n=2)
7 ± 3x104
---

10 ± 2x104
9.8 ± 1.3x104

-----

4

4

11 ± 2x104
---

(Figure 3-6 U-X)

(n=2)
4

Left Lymph Node
(IL-1b pretreated)

(n=2)
-----

-----

12 ± 3x104
13 ± 5x104

* 19F-PFC-labeled PBMC detected at each injection site 48 hours after injection
--- denotes lymph nodes in which 19F-PFC-labeled PBMC migration was below the
detection threshold for 19F cellular MRI
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3.4.4

All three main cell lineages within control and 19F-PFClabeled PBMC can be detected in the draining lymph node
two days after injection

As PBMC are heterogeneous and composed of different cell lineages with varying
immunological functions in vivo, it was important to determine which cell lineage(s)
contained within control unlabeled PBMC and

19

F-PFC-labeled PBMC are migrating to

the popliteal lymph node and producing the observed in vivo signal. To conduct this
experiment, human PBMC were isolated and then subject to flow cytometric analysis to
determine the percentages of each of the 3 main cell lineages present within PBMC. Cells
were first gated for live, singlet, CD45+ PBMC (Fig. 3-7A-C). Further gating ascertained
the composition of PBMC in this representative sample to be 70% CD3+ T cells (Fig. 37D), 3.87% CD19+CD20+ B cells (Fig. 3-7E) and 22.5% CD14+/CD16+ monocytes (Fig.
3-7F, red arrow points to monocyte population). It is important to note that these 3 lineages
represent greater than 96% of total CD45+ PBMC from this donor. Using magnetic bead
negative selection, CD3+ T cells (Fig. 3-8A), CD19+CD20+ B cells (Fig. 3-8B) and
CD14+/CD16+ monocytes (Fig. 3-8C) were isolated from a heterogeneous PBMC cell
suspension with greater than 95% purity. Each lineage was then cultured with 19F-PFC or
left as control unlabeled cells and cultured for 48 hours. GM-CSF (20 ng/mL) was added
to all wells for the final 24 hours of culture. Immediately prior to injection, each of the 3
isolated cell lineages described above was labeled with a different intracellular, membraneintercalating fluorophore. CD3+ T cells were labeled with CellTrace™ Far Red (control
Fig. 3-8D,

19

F-PFC Fig. 3-8d), CD19+CD20+ B cells incorporated CellTrace™ Violet

(control Fig. 3-8E, 19F-PFC Fig. 3-8e), while CD14+/CD16+ monocytes were labeled with
CellTrace™ CFSE (control Fig. 3-8F, 19F-PFC Fig. 3-8f). Regardless of the cell lineage or
culture condition, >99% of cells were successfully labeled with an intracellular fluorophore
(Fig. 3-8D-f, black histograms) compared to an aliquot of cells removed before fluorescent
labeling (Fig. 3-8D-f, blue histograms). Following cytospins of homogeneous cell
populations, fluorescence microscopy images were taken to verify fluorescent cell labeling
of B cells (Fig. 3-9A, pseudocoloured white), T cells (Fig. 3-9B) and monocytes (Fig. 39C). Each of the fluorophore-labeled homogeneous cell preparations was mixed back
together in physiologic proportion based on the data obtained from Figure 3-7D-F to re-
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establish the original heterogeneous PBMC population prior to footpad injection. Either
3x106 control, 19F-PFC unlabeled CellTrace+ recombined PBMC or 3x106 19F-PFC-labeled
CellTrace+ recombined PBMC were injected into the hind footpads of nude mice. Two
days later, the popliteal lymph nodes were removed, underwent cryosectioning and were
examined by digital fluorescence imaging. For both control unlabeled CellTrace+
recombined PBMC (Fig. 3-9D) and 19F-PFC-labeled CellTrace+ recombined PBMC (Fig.
3-9E), all 3 cell lineages were identified in the popliteal lymph node.

Figure 3-7. Flow cytometric analysis of human PBMC to determine cell lineage
Figure 3-7. Flow cytometric analysis of human PBMC to determine
composition. Viable (A), singlet (B), CD45+ (C) PBMC were phenotyped using flow
cell lineage composition.
cytometry to determine the percentages of CD3+ T cells (D), CD19+CD20+ B cells (E) and
CD14+/CD16+ monocytes (F), which are the three main lineages found within PBMC.
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Figure 3-8. Enrichment and differential fluorophore labeling of T cells, B cells and
monocytes from human PBMC. After gating for singlet, viable, CD45+ cells as illustrated
in Figure 3-7A-C, CD3+ T cells (A), CD19+CD20+ B cells (B) and CD14+/CD16+
Figure 3-8. Enrichment and differential fluorophore labeling of T
monocytes (C) were negatively enriched to a purity >95%. Half of each enriched cell
cells, B cells and monocytes from human PBMC.
lineage was labeled with 19F-PFC and the other half served as the control unlabeled
condition. GM-CSF (20 ng/mL) was added for the last 24 hours of culture. Homogeneous
cell populations were labeled with an intracellular membrane-intercalating fluorophore
both when serving as control cells (top panel, D-F) and 19F-PFC-labeled cells (bottom
panel, d-f). CD3+ T cells labeled with the intracellular fluorophore Far Red to >99% (D,d;
black histograms). CD19+CD20+ B cells labeled with the intracellular fluorophore Cell
Trace Violet (CTV) to >99% (E,e; black histograms). CD14+/CD16+ monocytes label
with the intracellular fluorophore CFSE to >99% (F,f; black histograms). Corresponding
non-fluorescent controls are represented by blue histograms (D-F/d-f).
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Figure 3-9. All 3 main cell lineages within PBMC reach the draining popliteal lymph
node twoFigure
days following
celllineages
transfer.within
B cellsPBMC
(A, pseudocoloured
white), T cells
3-9. All 3adoptive
main cell
reach the draining
(B) and popliteal
monocytes
(C) were
selected for
from PBMC
and each lineage was
lymph
nodenegatively
two days following
adoptive
cell transfer.
labeled with a unique fluorophore (A-C, yellow scale bar represents 50 µm). Then, these
3 lineages were recombined at physiological proportions and a footpad injection of 3x106
unlabeled PBMC or 19F-PFC-labeled PBMC was performed. Following removal of
popliteal lymph nodes and cryosectioning, all 3 cell lineages can be detected in the lymph
node for both control PBMC (D) and 19F-PFC-labeled PBMC (E).
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3.5 Discussion
3.5.1

Prostate cancer diagnosis, current treatment options and
progression

Prostate cancer is the most common cancer in men with over 20 000 Canadian males being
diagnosed in 2017391, with frequencies expecting to rise in the coming years given the
ageing population in developed countries and slow progression associated with this
disease392. In the early stages of disease, prostate cancer is diagnosed using an increase in
blood PSA levels and evidence of disease pathology in tissue biopsies8. If detected during
a stage of low aggression, active surveillance is preferred393, 394, 395, 396, followed by surgery
and radiotherapy397,

398, 399, 400, 401

, with the latter two options being associated with

decreased quality of life and sexual dysfunction364. Upon disease progression, ADT is
initiated402,

403, 404, 405

and continues until the prostate cancer develops into metastatic

CRPC406, 407, which usually occurs 12-18 months after initiation of ADT408. During the
metastatic stage, few therapies have proven effective, such as the chemotherapeutic agent
docetaxel. Newly emerging hormone agents and bone-targeting agents to combat
metastatic spread have also been utilized at this stage8, 364.
At various stages of prostate cancer treatment, anti-tumor immune responses have been
observed, albeit at sub-optimal levels11, 12, 63. Biopsies collected from patients undergoing
ADT have identified uncharacterized tumor-infiltrating T lymphocytes409, 410, 411, 412, while
other studies have characterized infiltrating lymphocytes as being CD56+ NK cells,
CD3+CD8+ CTL and CD68+ macrophages, indicating the presence of both innate and
adaptive anti-tumor responses243, 413, 414. Basal TAA-specific immune responses to PAP
have also been measured in prostate cancer prior to any immunotherapy being
administered242,

367, 368

. Also, 53.9% and 35.2% of metastatic CRPC patients have

previously undergone radiotherapy and surgery, respectively. Tumor cell death as a result
of these treatments can contribute to the anti-tumor immune response present prior to
immunotherapeutic intervention

246

. As a result of lymphocyte infiltration into prostate

cancer tumors and TAA-specific immune responses being detected, multiple cancer
immunotherapy strategies have been employed to potentiate the pre-existing anti-tumor
immune responses observed in vivo to a therapeutic level. In fact, prostate cancer is one of
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the few cancers in which immunotherapy is included as standard of care treatment8.
However, unlike melanoma and NSCLC, many gaps in knowledge exist that are hindering
the full understanding of immunotherapy in the context of prostate cancer246, 258.

3.5.2

Sipuleucel-T

In 2010, Sipuleucel-T became the first immunotherapy to gain FDA approval for the
treatment of asymptomatic or minimally symptomatic metastatic CRPC43, 415. PBMC from
prostate cancer patients are enriched using leukapheresis of 1.5-2 blood volumes246 and ex
vivo-cultured with a proprietary fusion protein encoding PAP and GM-CSF for 36-44
hours7,

42, 250, 379

. Ex vivo-culturing and subsequent autologous intravenous infusion

occurred 3 times over the course of 4-6 weeks7, 241, 249, with each infusion required to
contain at minimum 40x106 large cells surface expressing CD54+

246

. Both humoral and

cell-mediated TAA-specific adaptive immune responses have been measured in peripheral
blood and are associated with Sipuleucel-T administration120, 260; however, in a phase III
clinical trial this immunotherapy extended overall survival by 4.1 months and improved
overall 3 year survival to 31.7% compared to 23.0% in the control arm of the study43, 246.
These modest results clearly highlight the need for improvement of this therapy such that
progression free survival can be established in patients. As this immunotherapy is an APCbased vaccine, 19F cellular MRI can non-invasively track and quantify APC migration to
secondary lymphoid organs post injection as a surrogate marker of immunotherapeutic
effectiveness. Furthermore, as Sipuleucel-T is derived from PBMC, tracking and
quantification of other cell lineages contained within the vaccine, such as T cells and NK
cells82, 83, 133, 385, 416, 417, 418, 419, 420, 421, to the tumor could also provide valuable information
with respect to better understanding and improving the immunogenicity of this therapy.

3.5.3

Labeling of human PBMC with 19F-PFC

As all previous studies investigating successful 19F-PFC cell labeling were conducted on
homogeneous cell cultures77, 283, 299, 314, 388, 422, red fluorescent 19F-PFC labeling of human
PBMC isolated from peripheral blood of healthy volunteers was conducted to confirm that
the main cell lineages within heterogeneous PBMC incorporate label. A range of cell
culture concentrations and

19

F-PFC culture concentrations were employed, and nearly
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100% of PBMC (5x106 cells/mL in culture) labeled with 19F-PFC at 5 mg/mL. Similar to
what was observed in Chapter 2 with BMDC,

19

F-PFC labeling plateaued and further

increases in 19F-PFC culture concentration did not result in increased label uptake but did
result in increased cell death. It is also important to note that cell lineages contained within
PBMC important for antigen presentation, such as CD11c+ DC, CD14+ monocytes and
CD3+/CD19+ T and B lymphocytes, all labeled with 19F-PFC to a high percentage (Fig. 31). This is important to note as a prior study has discussed the potential complexity
associated with labeling cells from different sub-populations and how this may affect 19FPFC labeling387. For example, different cell lineages within PBMC may require longer coculture with 19F-PFC to reach maximum labeling. It is also known that larger and highly
phagocytic cells like monocytes uptake more label than smaller cells such as B and T
lymphocytes; however, it is unknown if highly phagocytic cells indirectly interfere with
label uptake by smaller, less phagocytic cells in heterogeneous PBMC culture. Even
considering this added complexity, our results that show near 100% label incorporation
suggest that in vivo tracking of PBMC is possible using 19F cellular MRI. In stark contrast
to the data presented here, one other published study investigated labeling of a
heterogeneous murine splenocyte population with

19

F-PFC261. Following 18 hours of

labeling with 19F-PFC (10 mg/mL), 3.70 ± 0.21% of CD3+ cells and 44.93 ± 3.76% of CD3cells contained within splenocyte cell culture incorporated fluorescent

19

F-PFC label261.

Although a different source of cells than human PBMC, murine splenocytes after FicollPaque™ gradient centrifugation contain the same 3 main cell lineages, CD3+ T cells,
CD19+ B cells and CD11b+ myeloid cells. Furthermore, murine PBMC were also labeled
with red fluorescent 19F-PFC in a preliminary experiment in our laboratory (see Appendix
II) and >72% of CD3+ T cells and >96% of CD3- cells (containing CD11b+ myeloid cells
and CD19+ B cells) incorporated red fluorescent 19F-PFC following overnight culture. This
low labeling percentage observed by Gonzales et al. could be due to increased death caused
by using a 40 µm cell strainer to generate splenocyte cell suspensions compared to a 70
µm strainer used in the methods described in this chapter. Additionally, Ficoll-Paque™
centrifugation was used to remove dead cells; however, splenocytes that incorporated large
amounts of 19F-PFC could have an altered cell density that results in these cells pelleting
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alongside dead cells. Lastly, a 19F-PFC concentration of 10 mg/mL, when used for murine
splenocytes labeling, resulted in increased cell death (unpublished data).
Heterogeneity within cell populations labeled with

19

F-PFC is an important concept to

discuss as ideally, a cell labeling agent should serve to label all cells to a high percentage
without affecting viability, phenotype and function203. On average, Sipuleucel-T infusions
contain 62.3% CD3+ T cells, 18.3% APC of which the majority are CD14+, 11% CD56+
NK cells and 4.7% CD19+ B cells. The relative proportions of cells between infusions from
the same patient were consistent120; however, large differences in cell lineage proportions
have been observed between patients (our own unpublished data). This observation is in
agreement with a previous study that found PBMC lineage ranging from 18.7-71.4% for T
cells, 7.14-45.3% for monocytes, 3.36-27.7% for B cells and 2.26-21.8% NK cells238. With
respect to 19F-PFC incorporation, labeling can be up to 10 000 times greater in large cells
such as monocytes/macrophages and DC when compared to smaller cells containing very
little cytoplasm, such as T cells423. In the context of cellular immunotherapy, this labeling
difference has been reported to be much lower, with small cells like T, B and NK cells
labeling on the low end of 1012 19F spins424 per cell and larger cells like CD14+ monocytes
and DC labeling on the high end of 1012 to the low end of 1013 19F spins per cell291, 299 (and
unpublished data). Although labeling human PBMC with

19

F-PFC as a whole is near

100%, differences in lineage composition between patients must be taken into account
when considering the sensitivity and location of

19

F cellular MRI in vivo detection. At

present, it must be assumed that the relative cell lineage proportions in a participant’s
PBMC NMR sample prior to adoptive cell transfer remain unchanged compared to the cell
lineage proportions of migrated PBMC detected in the lymph node. While experiments to
determine lymph node-migrated PBMC cell lineage composition are ongoing, this
assumption represents a limitation of this non-invasive imaging modality with respect to
accuracy of in vivo cell quantification.

3.5.4

Human 19F-PFC-labeled PBMC cultured with GM-CSF as a
model of Sipuleucel-T

Following the observation of near 100% labeling of human PBMC from healthy volunteers
with

19

F-PFC, GM-CSF was added to culture medium to mimic Sipuleucel-T ex vivo
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culture and verify that it did not interfere with 19F-PFC incorporation. By adding GM-CSF
in culture to PBMC, simulation of PA2024 fusion protein uptake seen in Sipuleucel-T that
induces efficient antigen presentation, activation and up-regulation of co-stimulation
molecules250, 425 can be studied.
GM-CSF exerts its function by binding its receptor, CD116, which is expressed on myeloid
and epithelial cells, such as both professional and non-professional APC. The receptor is
composed of a unique alpha chain and a common beta chain that is shared with the IL-3
and IL-5 receptor251 and has been demonstrated to enhance the tumoricidal function of
monocytes426. Immunogenic cancers, such as melanoma, NSCLC, pancreatic cancer, renal
cell carcinoma and prostate cancer have been found to secrete GM-CSF427 and formed the
premise for the early immunotherapy strategy in which tumors were genetically modified
to secrete GM-CSF, known as GVAX428, 429. A prostate cancer-specific therapy (prostate
GVAX) was developed by modifying LNCaP and PC3 cell lines to secrete GM-CSF and
was met with limited success430, 431. GM-CSF is superior to fms like tyrosine kinase 3
(FLT3) for promoting DC expansion and CD80 up-regulation, yet if administered in high
doses can result in a blockade of an immune response mediated by myeloid-derived
suppressor cell (MDSC) expansion that induce regulatory T cells (Treg) and defects in DC
function427,

432, 433

. With Sipuleucel-T, GM-CSF interaction with its cognate receptor

initiates the activation of APC and also, with each subsequent infusion, APC activation
increases further, with a 6.2 fold activation being measured upon first infusion and a 10.5
fold activation observed after the third infusion120. Along with increased antigen processing
and presentation as a result of APC activation, up-regulation of co-stimulatory surface
markers, such as CD54, occurs.
CD54, also known as intracellular adhesion molecule-1 (ICAM-1) is a member of the IgG
superfamily, participates in immune surveillance and by binding with LFA-1, facilitates
and provides stability to the immunological synapse between an APC and T cell42, 379, 427,
434

. The stability of the peptide:MHC complex within an immunological synapse is related

to the immunogenicity of the ensuing peptide-specific immune response435 and thus, CD54
serves as a predictor of APC activation and their capacity to induce a potent in vivo immune
response.
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Prior to 19F cellular MRI in vivo imaging studies, the effect of GM-CSF in culture on 19FPFC-labeled human PBMC was investigated. First, the viability of 19F-PFC-labeled bulk
PBMC was unaffected by GM-CSF addition in culture. Further data analysis demonstrated
the viability of the main three lineages contained within PBMC, CD3+ T cells, CD20+ B
cells and CD11b+ myeloid cells, did not differ as a result of GM-CSF addition for both
unlabeled control PBMC and 19F-PFC-labeled PBMC.
Following PBMC viability assessment with respect to 19F-PFC and/or GM-CSF addition
in culture, the percentage expression and intensity of expression (determined using MFI)
of activation, co-stimulation and migration cell surface markers were measured for both
CD20+ B cells and CD11b+ myeloid cells cultured in or without 19F-PFC and GM-CSF. In
all culture conditions evaluated, the activation marker CD40 and co-stimulatory marker
CD86 were present on both B cells and myeloid cells and is in agreement with a previously
published report42 that demonstrated CD54+ APC express CD40 and CD86 as well as HLAA,B,C and HLA-DR. The latter two are required for peptide presentation that induce CD8+
and CD4+ T cell activation and proliferation, respectively42, 436. GM-CSF results in modest
but similar increases in activation, co-stimulation and migration marker expression for both
control unlabeled and

19

F-PFC-labeled PBMC, with significant up-regulation being

observed for CD86 in CD20+ B cells and for CD86 and CD54 in CD11b+ myeloid cells.
Therefore, this suggests that GM-CSF in culture is biologically active in our current system
as evidenced by CD54 up-regulation in CD11b+ myeloid cells following GM-CSF
addition. Lastly, CD11b+ CD54+ myeloid cells in our culture system closely resemble the
CD54+ large APC population within Sipuleucel-T infusion products246.
As expected, given inter-patient variability in relative cell lineage compositions in PBMC,
a range of average 19F-PFC labeling per cell was noted for different participant samples;
however, GM-CSF addition to the culture did not result in significant changes to 19F-PFC
incorporation. PBMC were ex vivo-cultured for a total of 48 hours, with GM-CSF being
added 24 hours into culture. It was presumed that maximum label incorporation would be
reached prior to GM-CSF addition and the associated changes in the activation state of
APC did not hinder

19

F-PFC label incorporation. Thus, this permitted the consistent

detection and quantification of a therapeutically relevant cell number in the draining
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popliteal lymph node of immunocompromised mice two days post footpad injection using
19

F cellular MRI.

3.5.5

Implications of 19F-PFC-labeled PBMC in vivo migration to
lymph nodes

GM-CSF addition to 19F-PFC-labeled PBMC in ex vivo culture increased migration such
that consistent detection and quantification of cell migration to the draining popliteal lymph
node was possible. As described previously in Chapter 2, tissue pre-treatment with IL-1b
three hours prior to

19

F-PFC-labeled cell injection was included in

19

F cellular MRI

imaging studies in an attempt to increase cell migration to the lymph node199. IL-1b pretreatment did not work synergistically or additively with GM-CSF to consistently improve
migration of 19F-PFC-labeled cells to popliteal lymph nodes; however, this pre-treatment
did appear to increase

19

F-PFC-labeled PBMC not cultured with GM-CSF above the

detection threshold for in vivo 19F cellular MRI detection. Considering that GM-CSF in coculture did not increase the percentage of CCR7+ cells or the intensity of CCR7 expression
(as measured by MFI), GM-CSF may have activated APC such that when they reach the
draining lymph node, they remained there longer without undergoing apoptosis or leaving
via the lymphatics. Also, a positive feedback loop has been demonstrated whereby GMCSF-induced maturation of APC results in IL-12 and IFNg secretion by APC, which then
activate NK and T cells, promoting IFNg and TNFa release. Increased IFNg and TNFa can
then function in a paracrine manner to further activate APC437, 438, 439, 440, 441. To further
elucidate this positive feedback loop, cytokine secretion profiles of culture supernatant as
well as cytokine secretion upon APC reaching the lymph node would need to be analyzed.
Nonetheless, increased activation and secretion of pro-inflammatory cytokines could
present as increased quantification of migration 48 hours after injection and would be
expected to result in the induction of a more potent TAA-specific immune response
compared to control

19

F-PFC-labeled PBMC. With respect to consistent and efficient

quantification of therapeutic cell migration following injection, 19F cellular MRI appears
to be a suitable, non-invasive imaging technique for use within the context of cell-based
immunotherapies.
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Detection and quantification of 19F-PFC-labeled PBMC in the draining lymph node post
injection led to discussion as to which cell lineage contained within PBMC were
responsible for producing the observed in vivo signal. From an imaging standpoint,
questions arose relating to whether 19F-PFC labeling altered the relative cell proportions
within PBMC when compared to control unlabeled PBMC from the same participant. From
an immunological perspective, the proportion of cell lineages reaching the lymph node
compared to pre-injection proportions was important to learn such that deficiencies in
migration of certain cell lineages could be assessed. Also, as B and T lymphocytes,
monocytes, DC and NK cells vary with respect to their in vivo functions, knowledge of
which cells reach the draining lymph node is necessary to understand the immunological
implications of this measured migration83, 378, 385. For example, with APC-based cellular
immunotherapies, APC migration is absolutely necessary as the quantification of lymph
node migration is directly proportional to the ensuing immune response199. Other cells
within this formulation, like T cells, are also important in the context of immunotherapy as
CD4+ TH1 cells have been shown to release cytokines that can lead to further APC
activation and cytokine release, affecting both the strength, persistence and type of immune
response that is subsequently launched380, 381.
Differential intracellular fluorescent labeling of CD3+ T cells, CD19+CD20+ B cells and
CD14+/CD16+ monocytes prior to footpad injection and recombination at physiologic
proportions permitted lymph node removal and fluorescence microscopy analysis
following detection of

19

F-PFC signal in the popliteal lymph node. Although not yet

quantified for measurement of relative proportions of cell lineages, qualitatively it can be
said that each fluorescently-labeled cell lineage was observed to be present in the draining
popliteal lymph node 48 hours post injection for both

19

F-PFC-labeled and control

unlabeled PBMC co-cultured with GM-CSF. A more rigorous, quantitative analysis could
be conducted by flow cytometry. Taken together, this data suggests that 19F-PFC labeling
does not affect the viability or in vivo migration capacity of the 3 main PBMC lineages and
can be conducted with GM-CSF activation of APC in culture without any deleterious
effects.

100

As fluorescence microscopy was employed to confirm which cells were producing the
observed in vivo

19

F signal in the lymph node, tissue sectioning revealed that B and T

lymphocytes reach the lymph node and were dispersed across the central regions of this
organ. Secondly, fluorescence microscopy detected monocytes in the central lymph node
regions as well. This led to considerations regarding whether these fluorescent cells were
still CD14+ monocytes or whether culturing with GM-CSF induced differentiation into
CD11c+ CD123- moDC that were capable of migrating into paracortical lymph node
regions. The biological implications of this potential differentiation are promising from an
immunological perspective, as moDC are professional APC known to stimulate potent and
long-term immune responses upon interacting with and activation of naïve T cells125, 285.

3.5.6

Conclusions

This chapter demonstrated that a high percentage of human PBMC, which are the source
of cells for mixed-APC based cancer vaccine immunotherapies, incorporated 19F-PFC cell
labeling agent without affecting PBMC viability and phenotype. GM-CSF can also be
added to culture to mimic the culture conditions of mixed APC-based cancer vaccine
immunotherapies without having any deleterious effect on viability, phenotype or in vivo
migration. In fact, we reported that GM-CSF addition to culture activated APC contained
within human PBMC such that their migration to secondary lymphoid organs following
injection was reliably above the detection threshold of 19F cellular MRI and permitted the
quantification of in vivo migration. Post-19F cellular MRI analysis of draining lymph nodes
illustrated that all main cell lineages within PBMC are migration-competent and are
responsible for the detected in vivo

19

F signal. Therefore, we propose that this imaging

technique can be used in conjunction with an established APC-based cancer
immunotherapy model83 to serve as a surrogate marker for assessing and improving upon
the therapeutic benefit that this immunotherapy currently provides. For example,

19

F

cellular MRI can be employed to non-invasively determine the enhanced effect of APCbased immunotherapies in combination with other immunotherapies or previously
established anti-tumor treatment strategies442, 443, 444. It is also broadly applicable such that
19

F cellular MRI can serve as a non-invasive imaging technique to measure and improve
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upon the effectiveness of other emerging APC-based cancer vaccine immunotherapies for
metastatic breast, ovarian and colorectal cancer445, 446 as well as renal cell carcinoma447, 448.
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Chapter 4

4

Clinical translation and GMP-compliant processing of
human mixed APC-based cancer immunotherapies
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4.2 Introduction and Rationale
Cancer immunotherapy is an emerging research area that relies on one’s own immune
system to combat the cancer. Early research focused on non-specific up-regulation of the
immune system using interleukins or adjuvants in an effort to elicit an anti-tumor
response449. More recently, specific anti-tumor immune responses have been developed
using TAA-specific vaccine approaches450, 451. An example of such an immunotherapy is a
TAA-specific APC-based cancer vaccine. In order for APC, such as B cells, monocytes,
macrophages and DC452 to function as adjuvants in cancer vaccines, they must seed
secondary lymphoid organs such as a lymph node or spleen in order to interact with and
activate CD4+ and CD8+ T cells203. With such therapies, it is advantageous to prepare
properly matured, activated and TAA-loaded APC ex vivo to avoid the harsh
immunosuppressive environment induced by a tumor in vivo that prevents proper APC
priming, maturation and activation192, 453. Following completion of ex vivo culture, APC
are infused back into the patient and exert their anti-tumor function upon reaching
secondary lymphoid organs. This ex vivo approach has proven safe and non-toxic7, 72 and
has led to improvements in quality of life and overall survival times73, 74, 76, 454; however,
improvements to this type of immunotherapy are needed in order for long-term progression
free survival to be achieved in cancer patients455, 456.
Previous research has demonstrated that only 3-5% of originally injected therapeutic APC
reach the lymph node post injection, which is a major factor limiting the effectiveness of
mixed APC- and DC-based cancer vaccines183, 198, 199, 215, 216, 217. As the quantity of TAApresenting APC that reach a secondary lymphoid organ and interact with T cells is directly
proportional to the ensuing TAA-specific T cell response elicited in vivo199, there is a
pressing need to confirm and non-invasively quantify this migration. Knowledge gained
through in vivo tracking of therapeutic cells to and persistence in secondary lymphoid
organs109,
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can function to predict immunotherapeutic effectiveness and also alert

researchers of cell migration to unexpected in vivo locations, which could explain the suboptimal effectiveness currently associated with APC-based immunotherapies.
MRI is a promising approach for tracking APC in vivo203, 278. Various types of cell labeling
agents are available for pre-clinical cell tracking by MRI that include iron oxide,
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gadolinium, manganese and

19 457

F

. However, only

19

F incorporated into a

19

F-PFC is a

commercially available formulation designed specifically for in vivo cell tracking that can
stably label many cell types141, 270, 307, 314, 388, 389, 390. This 19F-PFC has been approved as an
investigational new drug by the U.S. Food and Drug Administration for human use as a
cellular MRI tracking agent308 and has been employed to track human DC in mice291, 310
and in one human clinical trial77. This type of cellular MRI labeling agent is attractive
because it provides a quantifiable, positive signal in the absence of any endogenous 19F
signal following an in vivo 19F MRI scan. This allows for the unambiguous detection of
greater than 104 19F-PFC-labeled cells per voxel291 and when combined with 1H MRI, the
anatomical 3-dimensional location of this observed 19F signal can be determined307, 308, 310.
Previous research from our laboratory that is presented in Chapter 3 demonstrated that
nearly 100% of human PBMC, which is the source of leukocytes used in a FDA-approved
mixed APC-based cancer vaccine246, 458 can incorporate 19F-PFC in a pre-clinical setting.
Moreover, 19F-PFC labeling did not affect human PBMC viability, phenotype or function,
and 19F-PFC incorporation was sufficient to permit the in vivo detection and quantification
of a therapeutically-relevant number of human PBMC in secondary lymphoid organs in an
immunocompromised murine model.
Although we reported efficient 19F-PFC labeling of human PBMC in a pre-clinical setting,
our intent is to conduct a clinical trial to detect and quantify autologous 19F-PFC-labeled
human PBMC following injection using
isolation, culture and

19

19

F cellular MRI. Therefore, human PBMC

F-PFC labeling must be performed under GMP-compliant

conditions, which are a set of standards and reagents with respect to processing cell
products intended for injection into humans that must be met. Additionally, all quality
assurance, sterility and purity tests mandated by Health Canada before autologous infusion
takes place must be passed with respect to

19

F-PFC labeling. Therefore, we designed a

protocol to label human PBMC under GMP-compliant conditions that included all
associated quality assurance tests required for autologous reinjection; however, until
clinical trial approval, imaging GMP-cultured

19

F-PFC-labeled human PBMC was

conducted in a pre-clinical immunocompromised mouse model. The nearest GMPcompliant cell manufacturing facility is nearly 3 hours away from where patients will have
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their blood drawn and undergo MR imaging upon clinical trial approval. Therefore, it was
necessary to also test the effect of a lengthy transportation on 19F-PFC-labeled PBMC and
compare these results to unlabeled cells that were cultured under GMP-compliant
conditions. Finally, in a parallel experiment, optimization of

19

F cellular MRI detection

using a clinical MR set-up and hardware was performed in preparation for imaging patients
following autologous injection.
This study investigates the suitability of using a 19F-PFC as a MRI cell labeling agent for
a heterogeneous APC population, as found in a PBMC-based cancer vaccine platform, such
that they are detectable in vivo. Successful labeling of individual leukocyte and nonleukocyte lineages has been reported307, 310, 388. However, while

19

F-PFC labeling of all

cells in a heterogeneous population might be anticipated, it has not been successfully
reported in the literature261 until our lab demonstrated near 100% labeling (Chapter 3).
Vaccines composed of a heterogeneous mixture of leukocytes, like PBMC, which form the
basis of a FDA-approved therapy for prostate cancer246, 458, contain both non-professional
APC (T and NK cells) in addition to professional APC, such as B cells, monocytes and
circulating DC459, 460. This pre-clinical validation study was performed as a step towards a
clinical trial. The main purpose of this chapter was to determine if we could label the major
blood leukocyte lineages within PBMC with

19

F-PFC under GMP-compliant conditions

while maintaining viability, functionality and 19F-PFC label retention that meets the predetermined criteria for autologous re-injection. We demonstrate that

19

F-PFC-labeled

human PBMC processed under GMP-compliant conditions are detectable and migrationcompetent in a pre-clinical murine model. Lastly, translation to a 3 T clinical MRI scanner
using a dual-tuned 1H/19F switchable RF coil suitable for use in human studies permitted
the detection and quantification of 19F-PFC-labeled human PBMC in a mock human in vivo
system.

4.3 Materials and Methods
4.3.1

Animal care

Male nu/nu mice (Crl:NU-Foxn1NU) were purchased from Charles River Laboratories Inc.
(Saint Constant, Canada) at 8-10 weeks and housed in a pathogen-free barrier at Robarts
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Research Institute at the University of Western Ontario (London, Canada). All experiments
were pre-approved by the Animal Use Subcommittee at the University of Western Ontario
and conducted in accordance with an approved protocol from the University of Western
Ontario’s Council on Animal Care (Protocol #2015-046). Mice were anaesthetized with
2% isoflurane in oxygen.

4.3.2

Participants

The University of Western Ontario Health Sciences REB pre-approved this protocol (REB
Protocol #104593). Each participant involved in this study protocol received a REBapproved Letter of Information and provided a signed Letter of Informed Consent before
entering into the study. For inclusion in the study, healthy participants were required to be
18 years of age or older and free of medical conditions that precluded participation in the
study. Potential participants who were undergoing treatment with an immunosuppressive
drug (eg. steroids) or infected with Human Immunodeficiency Virus, Hepatitis B or C
Virus or other transmissible diseases were excluded from the study. Participants with
prostate cancer were required to have castrate resistant, non-metastatic prostate cancer with
normal or rising PSA levels. Prostate cancer patients on hormone therapy were permitted
to participate but were excluded from the study if they were undergoing active
chemotherapy and radiation therapy, being treated with immunosuppressive drugs (eg.
steroids), were infected with HIV, Hepatitis B or C or other transmissible disease.

4.3.3

Reagents

Aim V® Medium CTS (GMP-grade, Gibco, Burlington, Canada) was supplemented with
100 U/mL of penicillin, 100 µg/mL of streptomycin and 0.3 mg/mL L-Glutamine
(ThermoFisher Scientific, Burlington, Canada). HBSS, PBS, LIVE/DEAD® Fixable Aqua
Dead Cell Stain Kit and CellTrace™ CFSE cell proliferation kit and human AB serum
were purchased from ThermoFisher Scientific and BSA was obtained from Calbiotech
(Spring Valley, USA). Ammonium chloride lysis buffer, human CD3+ positive selection
kit and human CD3+ negative selection kits were purchased from Stemcell Technologies
(Vancouver, Canada). Ficoll-Paque™ PREMIUM (GMP-grade) was acquired from GE
Healthcare Bio-Sciences (Pittsburgh, USA) and NGS was purchased from Jackson
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ImmunoResearch (West Grove, USA). Anti-human CD45-FITC (Clone HI30), CD45-PE
(HI30), CD3-PE (HIT3a), CD3-APC/Cy7 (SK1), CD4-PerCP (RPA-T4), CD8-PE (SK1),
CD19-PE (HIB19), CD20-PE (2H7), CD11b-Alexa Fluor 488 (M1/70), CD16-Alexa Fluor
700 (3G8), CD11c-APC (3.9), CD56-BV605 (HCD56), purified anti-human CD3 antibody
(OKT3) and FITC Annexin V Apoptosis Detection kit with 7-AAD were purchased from
Biolegend (San Diego, USA), while anti-human CD14-eFluor450 (61D3) and UltraComp
eBeads were acquired from eBioscience (San Diego, USA). The

19

F-PFC cell labeling

agents used in this study, Cell Sense CS-1000 (suitable for clinical use) and the red
fluorescent version, CS-ATM DM Red (excitation 596 nm, emission 615 nm), were both
purchased from Celsense, Inc. (Pittsburgh, USA). Lastly, PBMC were cultured in
ThermoFisher Scientific Nunc Hydrocell plates (ThermoFisher Scientific).

4.3.4

Pre-clinical 19F-PFC-labeled PBMC functional and in vivo
migration assessment

In Chapter 3, human PBMC were isolated, viability assessed and labeled efficiently with
19

F-PFC such that they can be detected in vivo in a murine model. Before progressing to

GMP-compliant

19

F-PFC-labeling, experiments to determine PBMC functionality and

verification of in vivo signal were conducted.

4.3.5

Mixed lymphocyte reaction (MLR)

PBMC were obtained from a healthy volunteer (as described in Chapter 3 methods) and
using a human CD3 positive selection kit (Stemcell Technologies) and manufacturer’s
instructions, T cells were removed from cell suspension. The remaining cells were cultured
overnight as previously described with or without

19

F-PFC (5 mg/mL). Following

overnight culture, cells were collected and washed in HBSS. Cells were then re-suspended
in AIM V® Medium CTS™ media at 2.5x106 cells/mL and serially diluted starting from
2.5x105 cells per well in triplicate. Then, PBMC were obtained from different volunteers
(n=3) and using a human CD3 negative selection kit (Stemcell Technologies) and
manufacturer’s instructions, T cells were enriched from PBMC. Isolated T cells were resuspended at 1x106 cells/mL in warm PBS+0.5% human AB serum (ThermoFisher
Scientific) and labeled with CellTrace™ CFSE (1 µM) for 10 minutes at 37°C. The reaction
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was quenched with ice cold AIM V® Medium CTS™ media and cells were washed in
HBSS. Lastly, T cells were re-suspended at 3x106 cells/mL in media and 100 µL was
aliquoted to each well and a MLR was carried out for four days at 37°C/5% CO2 (positive
control wells were coated overnight with anti-CD3 antibody (2 µg/well). After four days
of incubation, wells were washed in buffer and following the same staining procedure as
listed above, cells were stained for CD4 and CD8 and CFSE dilution was used as a readout
to assess allogeneic T cell proliferation.

4.3.6

T cell proliferation assay

T cells from healthy volunteers (n=3) were enriched from PBMC as described previously
and cultured with or without 19F-PFC (5 mg/mL) overnight at 5x106 cells/mL in AIM V®
Medium CTS™ media. The following day, T cells were collected and labeled with CFSE
as outlined above. Lastly, T cells were re-suspended at 3x106 cells/mL in AIM V® Medium
CTS™ media and 100 µL was plated in triplicate. Negative control wells were uncoated
while positive control wells were coated overnight with anti-CD3 antibody (2 µg/well).

4.3.7

Pre-clinical confirmation of 19F MRI popliteal lymph node
signal

Although 19F MRI signal detection in the draining popliteal lymph node has been presented
in Chapter 3 with human PBMC, verification that this signal is the result of originally
injection PBMC was still to be determined. PBMC were isolated from healthy volunteers
and labeled with

19

F-PFC as described above. However, immediately prior to injection,

PBMC were labeled with CFSE as described previously. Dual-labeled 19F-PFC+ CFSE+ as
well as CFSE+ control PBMC were then wash and formulated into a 3x106 cell injection in
40 µL of PBS into the left and contralateral footpad of anesthetized nude mice,
respectively. Immediately following

19

F cellular MRI 48 hours later, draining popliteal

lymph nodes were removed from sacrificed mice and either fixed with 4% PFA and
cryopreserved in sucrose solutions or pushed through a 70 µm strainer (VWR) to obtain a
single cell suspension. Cell suspensions were then re-suspended in HBSS+0.1% BSA,
surface stained with human CD45-PE for 25 minutes on ice (4°C) and data was acquired
immediately on a LSRII analytical flow cytometer (BD Biosciences) to identify CFSE+
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CD45+ human PBMC. For lymph nodes that were cryopreserved, 16 µm sections were
placed on VWR Microslides Superfrost® Plus (VWR) and coverslipped with Vectashield®
Hard Set mounting medium with 4’,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, CA, USA) to stain nuclei. Fluorescence microscopy was then performed to
confirm popliteal lymph node

19

F signal was from originally injected

19

F-PFC-labeled

PBMC through CFSE detection, as well as confirm that these cells were intact via DAPI
staining of nuclei.

4.3.8

GMP-compliant human PBMC isolation

PBMC were procured from a healthy volunteer (n=1, subject 4) and prostate cancer patients
(n=4; subjects 1, 2, 3, 5) who consented to a protocol approved by the University of
Western Ontario Health Sciences Research Ethics Board (London, ON, Canada).
Approximately 100-160 mL of blood was drawn into sterile vacutainer tubes containing
di-potassium ethylenediaminetetraacetic acid (EDTA). Each vacutainer was labeled with a
unique identifier as well as harvest date and time. The vacutainers were placed in a
transport container capable of maintaining a constant temperature between 15-25ºC for
transport (2-3 hours) in accordance with the Transportation of Dangerous Goods Act from
London, Ontario to a University Health Network (UHN, Toronto, Ontario) cell
manufacturing facility that operates under GMP principles. Upon receipt, PBMC were
isolated by a density gradient centrifugation using GMP-grade Ficoll®-Paque (GE
Healthcare Cat # 17-1440-02 or equivalent).

4.3.9

Cell safety

The following safety tests were performed on each PBMC preparation.
Fourteen-day sterility testing: Sterility was performed on the supernatant of

19

F-PFC-

labeled PBMC. Briefly, 19F-PFC-labeled PBMC were collected in 15 mL conical tubes by
gentle scraping using a cell scraper and were centrifuged at 300xg for 10 minutes at room
temperature. One mL of the culture supernatant from the tubes was inoculated each into
thioglycollate and tryptone Soya tubes. Inoculated tubes were sent to a certified
microbiology laboratory (Mt. Sinai Hospital) for analysis as per United States
Pharmacopeia (USP) Chapter 71461.

112

Endotoxin testing: The presence of endotoxin was measured by a Health Canada approved
Endosafe®-PTS Portable Test System (Charles River). Briefly, a 1 mL aliquot of cell
culture supernatant was collected after the final wash of 19F-PFC-labeled PBMC. Samples
were processed as per manufacturer recommendations, including a reference standard
spike-in (positive control).
Mycoplasma Testing: Mycoplasma testing was done on final 19F-PFC-labeled PBMC using
a validated qPCR method as per USP Chapter 63462. Testing was done on 2-3x106 cells/mL
collected along with supernatant collected after harvesting but prior to washing.

4.3.10

Human PBMC 19F-PFC labeling

PBMC were labeled with the 19F cell labeling agent, a 19F-PFC having a total concentration
of 120 mg/mL. The average nanoemulsion droplet size was 180 nm and was formulated
with excipients that expedite entry of the nanomaterial into all cell types, regardless of their
endocytic and phagocytic capacity. Approximately 50 million PBMC isolated by FicollÒPaque density gradient separation were plated in 75 cm2 ultra low attachment flasks
(Corning, NY, USA) in defined serum-free AIM V® Medium CTS™ media (GMPcompliant). PBMC were labeled with 5 mg/mL of

19

F-PFC by co-incubation for 16-24

hours (overnight) at 37ºC, 5% CO2 in certified incubators at the UHN cell manufacturing
facility. The

19

F-PFC-labeled PBMC were collected in 15 mL conical tubes by gentle

scraping using a cell scraper (BD Biosciences) and washed with PBS (ThermoFisher
Scientific) 3 times.

4.3.11

Cell viability

Cell viability was measured during the process of PBMC isolation using the trypan blue
exclusion assay. The injection-ready

19

F-labeled PBMC viability was performed more

rigorously by 7-AAD staining and flow cytometric analysis on a LSRII analytical flow
cytometer (BD Biosciences). Alternatively, an aliquot of both

19

F-PFC-labeled and

unlabeled PBMC in HBSS+0.1% BSA were first stained on ice for 25 minutes with antihuman CD45-FITC, then washed and re-suspended in buffer supplied in the apoptosis
detection kit for staining with 7-AAD at room temperature. Data was acquired immediately
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after addition of 7-AAD to the PBMC cell suspension. Data was analyzed to ensure that
the viability of final 19F-PFC-labeled PBMC was >70%.

4.3.12

Flow cytometry

To phenotype both

19

F-PFC-labeled PBMC and unlabeled PBMC, analytical flow

cytometry was performed on whole blood and isolated PBMC samples on the day of blood
draw, as well as on 19F-PFC-labeled and unlabeled PBMC following overnight culture at
the GMP-compliant facility and upon return to Robarts Research Institute. In this manner,
cell lineage composition could be compared between labeled and unlabeled PBMC
populations and between the lineage composition from the initial blood draw on day 0 to
the PBMC post GMP-compliant processing. Isolated PBMC were blocked on ice for 30
minutes with 5% NGS (v/v) in HBSS+0.1% BSA and then washed in HBSS and stained
with LIVE/DEAD® dye for 20 minutes at room temperature. Following washing in HBSS,
cell surface staining with the antibodies mentioned previously was conducted on PBMC in
HBSS+0.1% BSA on ice (4°C) for 25 minutes. Lastly, stained PBMC were washed in cold
HBSS and re-suspended in HBSS+0.1% BSA for data acquisition on a LSRII analytical
flow cytometer (BD Biosciences). Staining of whole blood was performed as mentioned
above without a blocking step. Also, red blood cells were lysed by the addition of
ammonium chloride lysis buffer following antibody and LIVE/DEAD® staining.

4.3.13

Adoptive cell transfer of PBMC

For PBMC to be injected into mice, PBMC were washed twice in PBS and these final
injection-ready PBMC, depending on yield post-GMP processing, were divided into a low
(1x106) and high (4-6x106) injection number for both

19

F-PFC-labeled and unlabeled

PBMC. Labeled or unlabeled PBMC in 100 µL PBS were adoptively transferred
subcutaneously into the upper left flank and contralateral flank of anaesthetized nude mice,
respectively.

4.3.14

MRI of PBMC migration

Mouse imaging was performed with a 9.4 T Varian small animal MRI scanner (Santa Clara,
CA, USA). A 3D-bSSFP sequence was used for both proton and 19F MR imaging. Animals
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were imaged alongside reference tubes containing a known 19F concentration (3.33x1016
19

F/μL or 7.3x1016

19

F/μL) suspended in agarose. Mice were anaesthetized with 2%

isoflurane, with breathing rate and temperature monitored throughout the scan. MRI was
performed using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm), tuned
to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively. For proton imaging
the scan parameters were: TR = 5.0 ms, TE = 2.5 ms, rBW = 78 kHz, FA = 30°, PC = 4,
averages = 3, resolution = 200x200x200 μm3, and number of excitations (NEX) = 3. For
19

F imaging the parameters were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25 kHz, FA = 70°, PC

= 4, averages = 200, resolution = 1x1x1 mm3, and NEX = 200. To avoid 19F present in
isoflurane confounding the
19

19

F-PFC signal, imaging was performed by centering on the

F-PFC Cell Sense-specific frequency as was previously described270. The total protocol

time for both proton and 19F imaging was under 90 minutes.

4.3.15

Clinical MRI Protocol

Optimization was performed with an array of PBMC pellet phantoms produced by
centrifugation of 1, 3, 10, and 20 x106

19

F-labeled PBMC in Eppendorf tubes. The

supernatant was discarded and the remaining cell pellets were overlaid with 1% agarose to
prevent dispersion. Mock human imaging was performed by intradermal injection of 1.5,
4.5, 10.5, and 20x106 PBMC into a ham shank. An additional 4.5x106 PBMC were
administered intramuscularly 1.2 cm below the dermal layer to measure imaging depth
sensitivity. Samples were imaged with a GE MR750 (GE Healthcare, Milwaukee, WI,
USA), 3 T MRI scanner equipped with a multinuclear pre-amplifier. Samples were first
imaged with the built-in proton body coil to identify ROI. Site-specific imaging was then
performed by placing a dual proton/19F-tuned switchable surface coil (4.3 cm x 4.3 cm)
manufactured by Clinical MR solutions (Brookfield, WI, USA), directly on the ROI for
optimum sensitivity. The dual-tuned surface coil is approved for human use under
Investigational Testing Authorization from Health Canada as well as approved by the
University of Western Ontario Health Sciences Research Ethics Board as an investigational
human MR imaging protocol (#2137). A 2D fast gradient echo (Fast GRE) sequence was
used for proton imaging with the following scan parameters: TE = 2.6 ms, TR = 100 ms,
FOV = 15 cm x 15 cm x 5 cm, image matrix = 256x256, slice thickness = 5 mm, rBW =
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83 kHz, NEX = 3, and FA = 20°. Following proton imaging, the coil was switched to 19Fmode and the same FOV was scanned. The 19F images were obtained with a broad-banded
3D bSSFP based on the GE FIESTA-C sequence. The scan parameters were: TE = 2.2 ms,
TR = 4.4 ms, FOV = 15 cm x 15 cm x 5 cm, image matrix = 46x46, slice thickness = 5mm,
rBW = 10 kHz, NEX = 425 and FA = 70°. 19F imaging time was 15 minutes, with a total
protocol time under 25 minutes. Images from the body coil were analyzed and lymph node
volume was measured using OsiriX image analysis software (Pixmeo, Geneva,
Switzerland).

4.3.16

19

F loading efficiency and signal quantification

The mean intracellular 19F content of human PBMC was determined by NMR spectroscopy
using a 400 MHz Varian vertical spectrometer. First, a known number of 19F-PFC-labeled
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a
solution containing 100 µL of 5% Triton X-100. After lysing, the cells were transferred to
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA
provides a reference peak for quantifying the number of 19F spins/ cell, since NMR signal
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm.
The number of PBMC detected within MR images was determined with Voxel TrackerTM
software (Celsense Inc, Pittsburgh, USA)270, 308. Prior to analysis, a signal correction was
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal
contained within a hand-drawn ROI was compared to the average signal produced by the
reference tube containing a known 19F concentration. This information was used alongside
the 19F spins/cell, measured by NMR, to quantify the apparent number of cells located at
the ROI.

4.3.17

Statistical analysis

All data was presented as the mean with the standard error of the mean. A one-way or twoway ANOVA (Graph Pad Prism, Version 7, La Jolla, USA) was used with multiple
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comparisons being assessed. Significance was considered if p ≤ 0.05. When written, the
number of independent experiments is denoted by (N) while the number of replicates per
independent experiment is defined by (n).

4.4 Results
4.4.1

The function of human PBMC is unaffected by the
incorporation of 19F-PFC cell labeling agent

In the previous chapter, we were able to establish the optimal cell concentration in culture
and 19F-PFC concentration in culture such that human PBMC from healthy volunteers can
be efficiently labeled with

19

F-PFC without affecting viability and in vivo migration

capacity. However, the effect of 19F-PFC on PBMC functionality and verification that in
vivo signal is the result of originally injected

19

F-PFC-labeled cells have yet to be

elucidated. To address APC functionality, a MLR was conducted to compare the
functionality between control and 19F-PFC-labeled APC. No significant differences in APC
functionality were observed as a result of

19

F-PFC labeling (Fig. 4-1A) with respect to

stimulating allogeneic CD8+ (Fig. 4-1B) and CD4+ (Fig. 4-1C) T cell proliferation using
CFSE dilution as a readout, regardless of the APC to T cell ratio. Next, the proliferative
capacity of unlabeled and

19

F-PFC-labeled T cells was compared using a T cell

proliferation assay to assess function. Using anti-CD3 coated plates, no difference in T cell
proliferation was measured for both CD8+ and CD4+ T cells (Fig. 4-1D) using CFSE
dilution as a readout of proliferation (Fig. 4-1E/F).
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Figure 4-1. APC and T cell functionality is not affected as a result of 19F-PFC labeling.
PBMC from healthy volunteers were either labeled with 19F-PFC overnight (5 mg/mL) or
+ affected as a result of 19FFigure
4-1. APC
cell functionality
is not
remained
unlabeled
and and
wereT then
subjected to CD3
T cell positive selection removal.
PFC labeled
labeling.
Remaining
and unlabeled APC were then employed in a MLR (A) by co-culturing
with allogeneic CFSE+ T cells obtained from 3 different healthy volunteers. Flow
cytometry was used to assess CD3+ T cell proliferation using CFSE dilution as a readout
for both CD8+ (B) and CD4+ T cells (C). Alternatively, CD3+ T cell functionality was
assessed using CFSE dilution for 19F-PFC-labeled and unlabeled T cells as a result of CD3
crosslinking (D) for both CD8+ (E) and CD4+ (F) T cells. Data shown as means ± SEM
((A) two-way ANOVA, p > 0.05 and (D) one-way ANOVA, p > 0.05).
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4.4.2

19

F cellular MRI in vivo signal is the result of originally
injected human PBMC

Although detection and quantification of

19

F signal has been measured in the popliteal

lymph node, it cannot definitively be said that this observed signal is the result of originally
injected intact, live 19F-PFC-labeled PBMC. Therefore, experiments were performed with
human PBMC labeled with both 19F-PFC and CFSE prior to injection into nude mice to
verify that in vivo 19F signal is the result of originally injected cells. Two days following
injection of 3x106 human

19

F-PFC-labeled PBMC into the footpad of nu/nu mice (N=3,

n=4/experiment), 19F MRI detected 1.31 ± 0.2x105 cells (Fig. 4-2A, yellow arrow) in the
draining popliteal lymph node. Following MR imaging, CFSE+ human

19

F-PFC-labeled

PBMC were detected in cryosections of the same popliteal lymph node (Fig. 4-2B, green
arrows, counterstained with DAPI and pseudocoloured red). In a similar experiment, two
days after injection of 3x106 CFSE+

19

F-PFC-labeled PBMC, draining popliteal lymph

nodes were removed, single cell suspensions prepared and subsequently counterstained
with an antibody for human CD45. Flow cytometry identified CFSE+ human CD45+ cells
(0.8778% ± 0.176%, N=3, n=4 per experiment) in the popliteal lymph node, with a
representative figure being shown in Figure 4-2C. Therefore, cryosections of a lymph node
after CFSE+

19

F-PFC-labeled PBMC and counterstaining with DAPI to detect nuclei

demonstrates that originally-injected cells are producing the signal observed in vivo and
furthermore, because CFSE+ cells in the lymph node were also human CD45+, this
eliminates the possibility that originally-injected cells have died and been phagocytosed by
resident lymph node phagocytes.
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Figure 4-2. Human CFSE+CD45+ 19F-PFC-labeled PBMC are the source of 19F MRI signal
in the popliteal lymph node. Two days after the injection of 3x106 human 19F-PFC-labeled
PBMC into the footpad of nu/nu mice, mice were subjected to 19F MRI and positive 19F
5
+ 19
MRI signal
detection
of 1.31±0.2x10
cells
(yellow
arrow) resided
within
Figure
4-2. Human
CFSE+CD45
F-PFC-labeled
PBMC
are the
the popliteal
19 n=4/experiment; scale bar=5 mm) (A). Following MRI, lymph nodes
lymph source
node (N=3,
of F MRI signal in the popliteal lymph node.
were removed, cryosectioned and fluorescent microscopy revealed the presence of CFSE+
19
F-PFC-labeled human PBMC (representative of n=8 that did not undergo MRI). The 100X
magnification sections were counterstained with DAPI to reveal nuclei (pseudocoloured
red; scale bar =10 μm) (B). In a similar experiment, draining popliteal lymph nodes were
removed two days after injection and single cell suspensions were prepared and
counterstained with anti-human CD45 to reveal originally-injected cells in the draining
popliteal lymph node using flow cytometry (C, representative of N=3, n=4 per experiment).
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4.4.3

Human PBMC can be efficiently labeled with 19F-PFC cell
labeling agent under GMP-compliant conditions without
affecting viability

Upon establishing that human PBMC from healthy volunteers can be labeled with 19F-PFC
without affecting their viability, function or in vivo migration capacity, a protocol was
developed whereby PBMC from prostate cancer patients would be obtained and labeled
with 19F-PFC under GMP-compliant conditions at the UHN Cell Therapy Program Facility.
During this processing as outlined in Figure 4-3, all quality control, safety and viability
tests required by Health Canada for autologous re-injection into humans were conducted.
While in the process of gaining approval from Health Canada to conduct a clinical trial in
humans, human PBMC were processed under GMP-compliant conditions and instead of
autologous injection back into the host,

19

F-PFC-labeled PBMC injections into

immunocompromised mice were imaged using 19F cellular MRI while other preliminary
experiments were conducted to optimize a clinically-approved
human 3 T MRI.

19

F MRI protocol in a
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Figure 4-3. Outline of events for GMP-compliant processing, safety testing and
transport of 19F-PFC-labeled human PBMC.
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As the nearest GMP-compliant cell therapy facility is located in Toronto and is
approximately 2.5 hours away from Robarts Research Institute in London, the viability of
cell product both before and after transportation was measured to confirm protocol
suitability for approval of autologous cell injection into humans. 7-AAD staining for
viability post-transport for the first two participant samples was less than 60%, revealing
that the transportation conditions were sub-optimal and below the generally acceptable
limit (70%) observed by Health Canada463. The incipient volume the GMP-processed cells
were shipped in was increased to 15 mL in a tube filled with Plasma-Lyte A solution for
participants 3-5 in this study. With this change in place, the viability of the last 3 participant
post-transport samples for 19F-PFC-labeled and control PBMC was 88.75 ± 1.55% and 87.1
± 4.57%, respectively (Fig. 4-4A). A small but non-significant decrease in viability was
noted between pre- and post-transport between the cell manufacturing facility and Robarts
Research Institute. Also, with respect to the viability of both pre-transport or post-transport
time points, the viability between control and 19F-PFC-labeled PBMC is not statistically
different, suggesting that when appropriate transport protocols and

19

F-PFC labeling

protocols are adhered to, the viability of PBMC cell products is suitable for autologous
injection into humans (Fig. 4-4A).
We next sought to qualitatively assess

19

F-PFC labeling by mimicking GMP-compliant

labeling and retention of this label during transportation as outlined in Figure 4-3. Using
the red fluorescent version of 19F-PFC, an aliquot of PBMC was labeled overnight (~20
hours). The shift in mean fluorescence intensity of the fluorescently-tagged

19

F-PFC

indicates that 99.8% of viable singlet PBMC were labeled and thus, all cell lineages
contained within PBMC were labeled. In a separate set of experiments (N=3 different
PBMC donors), labeling was conducted as described above but after overnight labeling
with the fluorescent version of 19F-PFC, half of the cells were assessed immediately for
fluorescent label incorporation, while the other half was left at room temperature to
simulate the combined 2.5 hour transport time and post-arrival processing time. Flow
cytometry revealed that 98.1 ± 1.2% of PBMC were labeled with red fluorescent 19F-PFC
overnight (Fig. 4-4B) and that the percentage of labeled cells remains unchanged (98.3 ±
0.76%) approximately 3 hours later (Fig. 4-4C). There was no significant difference
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(p=0.43) in the median fluorescence intensity between pre- and post-transport samples for
the 3 donors. A quantitative assessment to determine the average number of 19F atoms per
cell was conducted for each participant using NMR spectroscopy (Fig. 4-4D). For all 5
participants in this study, 19F loading values ranged from 5.14x1010 to 1.16x1011 19F atoms
per cell. For the last three participants whose viability was greater than 87%, an average
loading of 7.55x1010 19F atoms per cell was calculated.
In addition to measuring the viability of all cell products both before and after transport
using 7-AAD, a LIVE/DEAD™ vital dye can also be employed. Here, an aliquot of
participant peripheral blood on day 0 of culture (Fig. 4-5A), PBMC on day 0 of culture
(Fig. 4-5B) and then unlabeled and

19

F-PFC-labeled PBMC post GMP-compliant

processing (Fig. 4-5C) was first gated to identify CD45+ cells, followed by gating on live
cells using the FMO control for LIVE/DEAD™ vital dye. Figure 4-5 is a representative
image from one participant; however, a similar analysis was conducted for all participant
samples.
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Figure 4-4. Human PBMC labeled efficiently with 19F-PFC under GMP-compliant
conditions and transported without significant loss of viability. Following overnight
culturing of PBMC with and without the 19F-PFC cell-labeling agent (5 mg/mL) under
19
GMP-compliant
F-PFC-labeled
and unlabeled
PBMC
19 transported back
Figureconditions,
4-4. Human
PBMC
labeled
efficiently
withwere
F-PFC
19
to London,under
Canada.
The
viability
of
F-PFC-labeled
PBMC
and
unlabeled
GMP-compliant conditions and transported withoutPBMC was
determinedsignificant
using 7-AAD
staining
before and after transport. There was no significant
loss of
viability.
decrease in viability because of transport (approximately 2.5 hours or 250 km distance) as
well as no significant difference in viability between 19F-PFC-labeled and unlabeled cells
with data shown as means ± SEM (two-way ANOVA, p > 0.05) (A). PBMC were labeled
overnight with the red fluorescent version of the 19F-PFC cell labeling agent. A flow
cytometry analysis was performed on half of the cell suspension and it was determined that
99.8% of PBMC were positively labeled with the red fluorescent version of the 19F-PFC
agent compared to unlabeled PBMC from the same donor (blue histogram) (B). The second
of half of the labeled PBMC were left for 3 hours to simulate the transportation process
back to London, Canada. Flow cytometry revealed that 99% of the PBMC retained the red
fluorescent 19F-PFC compared to unlabeled PBMC from the same donor (blue histogram)
(C). In order to quantify in vivo cell migration, a quantitative assessment of 19F-PFC
incorporation must also be ascertained using NMR spectroscopy on a known number of
PBMC. For the last three participants, an average of 7.55x1010 19F spins were incorporated
per cell (denoted by the white circles) and are the participants for which MR image data is
provided (D).
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Figure 4-5. Viability and CD45+ purity assessment of human peripheral blood and PBMC
cell products using flow cytometry. An aliquot of peripheral blood is phenotyped to
+
calculate the percentage of cells that are CD45
on day 0 of culture (top left panel) and the
+
Figure
4-5.
Viability
and
CD45
purity
assessment
of human
peripheral
FMO control for LIVE/DEAD™ aqua vital dye (top
middle panel)
was used
to determine
blood
and
PBMC
cell
products
using
flow
cytometry.
+
the viability of CD45 cells (top right panel) (A). The same analysis for CD45+ and
viability percentage was performed on day 0 after peripheral blood was subject to gradient
centrifugation to enrich PBMC (B). Both day 1 control PBMC and 19F-PFC-labeled
PBMC cultured under GMP-compliant conditions were also assessed for percentage of
CD45+ cells and percentage viability (C). Representative flow cytometry gating is
displayed for one participant sample; however, all 5 participant cell products were subject
to a CD45+ and viability percentage flow cytometry analysis.
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GMP-compliant processing of control and 19F-PFC-labeled
PBMC meet all requirements outlined by Health Canada to
permit autologous injection into humans upon clinical trial
approval

4.4.4

After ensuring that human PBMC can be labeled with

19

F-PFC under GMP-compliant

conditions without affecting viability, quality control and safety testing required for
investigational, autologous use of PBMC in humans was evaluated. For all 5 participant
samples, assessments were conducted for safety through rapid Gram staining, cultureexpanded sterility and mycoplasma testing. The purity and identity were also measured to
ensure that the cell product for each participant contains greater than 80% CD45+ cells
while confirming that impurities were not contained in any cell product as assessed via the
absence of endotoxin. This data is summarized for each participant in Table 4-1.

Table 4-1. Cell products from each participant passed all requirements outlined by Health
Canada to allow for injection into humans upon clinical trial approval.
Participant 1
Unlabeled

Participant 2

Participant 3

Participant 4

Participant 5

19

F-PFC Unlabeled 19F-PFC Unlabeled 19F-PFC Unlabeled 19F-PFC Unlabeled 19F-PFC
Labeled
Labeled
Labeled
Labeled
Labeled

Stat Gram
Stain

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Endotoxin

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

CD45
Percentage

99.3%

99.7%

84.4%

92.5%

78.9%

96.0%

94.7%

97.1%

98.4%

98.2%

14-day
Sterility

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Mycoplasma

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

Pass

+
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4.4.5

19

F-PFC labeling does not alter the PBMC cell lineage
composition

Each cell lineage found in PBMC serves a different immunological purpose within a
heterogeneous cell-based cancer vaccine. Therefore, the cell lineage composition and
phenotype of individual participants’ PBMC preparations were characterized. Both whole
blood and PBMC were examined to not only compare

19

F-PFC-labeled and unlabeled

PBMC populations, but also to verify that 19F-PFC labeling did not significantly alter cell
lineage composition when comparing peripheral blood drawn on day 0 to PBMC after
GMP-compliant processing. Single, live CD45+ unlabeled or 19F-PFC-labeled PBMC (Fig.
4-6A-C) were analyzed. After debris removal (Fig. 4-6D), B and T cell lymphocytes were
grouped together using antibodies to CD3, CD19 and CD20 that are all conjugated to the
same fluorophore, while myeloid cells were gated on using CD11b+ selection (Fig. 4-6E).
Myeloid cells were further analyzed using CD14 and CD16 surface expression (Fig. 4-6F)
as well as CD11c+ surface expression (data not shown). NK cells were then analyzed using
CD56 on cells negative for CD3/CD19/CD20 and CD11b (Fig. 4-6G). The summary of
cell lineage phenotyping for the last 3 participants after cell transportation optimization is
presented in Table 4-2. The lymphoid cell lineage and the CD11b+CD16+ lineage of
monocytes, although different between participants, appears to be similar for both labeled
and unlabeled conditions within the same participant. However, within the myeloid lineage
there was a decrease in the percentage of CD11b+CD14+ cell recovery post-labeling.

128

Figure 4-6. Phenotyping of GMP-compliant processed 19F-PFC-labeled and unlabeled
19
Figure
Phenotyping
GMP-compliant
F-PFCcontrol human
cell4-6.
products.
Blood orofisolated
PBMC wereprocessed
analyzed for
cell lineage
labeled
and
unlabeled
control
human
cell
products.
composition using the gating strategy outlined. Briefly, hematopoietic cells were selected
for using CD45+ (A), followed by gating on live (B), singlet cells (C). After debris removal
(D), remaining cells were gated on CD11b for myeloid cells or CD3/CD19/CD20 for
lymphoid cells (E). For CD11b+ and CD3/CD19/CD20- cells, further gating for CD16 and
CD14 to analyze monocytes was conducted (F). For cells that are CD11b- and
CD3/CD19/CD20-, gating for CD56 to identify NK cells was performed (G). Lastly, cells
that are CD11b+ but CD14/CD16- were gated on CD11c to identify dendritic cells (data
not shown). All cell surface marker gates were assigned based on their respective FMO
controls.
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Table 4-2. PBMC cell lineage comparison between 19F-PFC-labeled (L) and unlabeled
control (UL) PBMC.
Surface Antigen (percentage of live, singlet, CD45+ cells)
CD45+

Participant
Sample
Identifier

UL

CD45+,
CD11b-,
CD3+,
CD19+,
CD20+

CD45+,
CD11b+,
CD3-,
CD19-,
CD20-,

CD45+,
CD11b+,
CD3-,
CD19-,
CD20-,
CD16+

CD45+,
CD11b+,
CD3-,
CD19-,
CD20-,
CD14+

CD45+,
CD45+,
+
CD11b ,
CD11b-,
CD3-, CD19- CD3-, CD19-,
, CD20-,
CD20-,
CD14-,
CD14-,
CD16-,
CD16-,
+
CD11c
CD56+

L

UL

L

UL

L

UL

L

UL

L

UL

L

UL

L

Participant 3 78.9

96.0

79.2

83.7

15.6

6.90

10.7

3.95

3.12

0.36

1.52

2.60 0.625 1.89

Participant 4 90.5

95.0

83.8

87.7

13.6

8.96

0.22

0.42

9.12

0.53

ND

ND 0.0002 0.08

Participant 5 89.6

93.2

77.2

67.4

19.2

21.9

12.9

17.4

3.56

0.42

7.80

4.52 0.003 7.87

Note: We reported the CD45+, CD11b+, CD3-, CD19-, CD20-, CD14-, CD16-, CD11c+
cell population percentage is displayed as a percentage positive from previous gate. ND
not determined.
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19

F-PFC-labeled human PBMC can be detected using 19F
cellular MRI in an immunocompromised mouse model

4.4.6

19

The number of

F atoms determined for each participant’s

19

F-PFC-labeled PBMC

preparation was generally lower (Fig. 4-4D) than reported for other cell types (1010-1011 vs
1012)310, 387. To determine if the
vivo by cellular MRI,

19

19

F-PFC-labeled PBMC preparations were detectable in

F-PFC-labeled PBMC from participants 3-5 were injected

subcutaneously into the flanks of nude mice to mimic the location of autologous adoptive
cell transfer pending clinical trial approval. 19F-PFC-labeled PBMC were formulated into
low and high cell number injection preparations, in which cell numbers varied based on
individual participant yield. This information and quantitative

19

F MRI results are

summarized in Table 4-3. MR images were obtained at ~2 hours and 2 days post injection.
As expected, no

19

F signal was detected at the unlabeled PBMC contralateral flank

injection sites or in the draining lymph nodes. For the two mice injected with 1x106 and
6x106

19

F-PFC-labeled PBMC from participant 4 (healthy volunteer), MR imaging

detected 6 ± 0.3x105 and 5.21 ± 0.2x106 19F-PFC-labeled cells at the injection sites on day
0, with the 5.21 ± 0.2x106 injection being illustrated in Figure 4-7A, blue arrow). Also, in
this mouse on day 0, 2 ± 0.3x105 cells were detected in the draining popliteal lymph node
approximately 2 hours after subcutaneous injection (Fig. 4-7B, yellow arrow). On day 2,
the number of detectable cells at both the injection site and draining popliteal lymph node
decreased, with 4.11 ± 0.2x106 cells detected at the injection site (Fig. 4-7C, blue arrow)
and the number of cells remaining in the popliteal lymph node fell below the detection
threshold of 19F cellular MRI (Fig. 4-7D, lymph node identified by yellow arrow). For mice
injected with

19

F-PFC-labeled PBMC from participants 3 and 5 (both prostate cancer

patients) 19F signal was detected only after the high cell dose injection on day 0 and day 2
but not in any of the draining lymph nodes. Following high dose injection of 5.7 ± 0.1x106
labeled PBMC from participant 3, 1.13 ± 0.3x106 and 7.5 ± 0.3x105 PBMC were detected
at day 0 and day 2, respectively. With respect to participant 5, the high dose injection of
4x106 labeled PBMC permitted the detection of 1.11 ± 0.2x106 PBMC at the injection site
on day 0 and 5.9 ± 1.6x104 PBMC on day 2. The latter was the lowest cell number detected.
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Table 4-3. 19F-PFC-labeled PBMC detection by 19F cellular MRI following subcutaneous
injection into immunocompromised mice.
Participant 3
Injection Cell
Number
Subcutaneous
Flank
Day 0
Detection

5.7x106

1x106

6x106

1x106

4x106

No

Yes

Yes

Yesb

No

Yes

(1.13x106)

(6x105)

(5.21x106)

Yes

Yes

Yes

(7.5x105)

(2.0x105)

(4.11x106)

No

Injection Site
Note: aDay 0 scan completed ~2h post injection
b

Participant 5

1x106

Injection Sitea
Day 2
Detection

Participant 4

Day 0 scan also detected 2x105 cells in the popliteal lymph node

(1.11x106)
No

Yes
(5.9x104)
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Figure 4-7. MRI detection of 19F-PFC-labeled human PBMC after subcutaneous flank
19
administration
an immunocompromised
murine model. The
overlay
produced
Figurein4-7.
MRI detection of 19F-PFC-labeled
human
PBMC
afterfrom F
1
6 19
and H subcutaneous
MR images following
subcutaneous flank
of 6x10 F-PFC-labeled
flank administration
in injection
an immunocompromised
19
PBMC from
participant
murine
model. 4 on day 0 permitted the detection of a F signal in both the
flank (blue arrow, A) and at the popliteal lymph node (yellow arrow, B). Forty-eight
hours after subcutaneous administration, the 19F signal was decreased but visible in the
flank (C), but not detectable in the lymph node (D). The reference tube required to
quantify the number of PBMC is marked with R in panel C. Scale bar = 5 mm.
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4.4.7

MR imaging of 19F-PFC-labeled PBMC under clinical
conditions at 3 T

In an attempt to translate pre-clinical

19

F cellular MRI at 9.4 T to a clinically-approved

protocol at 3 T, PBMC were isolated from the blood of a healthy volunteer and labeled
overnight with 19F-PFC. The next day, 1x106, 5x106 and 10x106 19F-PFC-labeled PBMC
were pelleted in an Eppendorf tube and overlaid with 1% agarose to create 19F phantoms
(Fig. 4-8A). To mimic MR scanning of a patient, these cell pellets were placed on the
surface of the thigh of a volunteer and then scanned to optimize 19F imaging parameters at
3 T. Under optimal labeling conditions with 4.2x1011 19F atoms per cell, as few as 1x106
PBMC could be detected (Fig. 4-8B).

Figure 4-8. Human 19F-PFC-labeled PBMC pellet phantoms as low as 1x106 cells can be
detected at 3 T using a surface coil and clinical MR parameters. PBMC were obtained from
19 with 19F cell labeling agent overnight (5.0 mg/mL). Cell
a healthyFigure
volunteer
labeled
4-8. and
Human
F-PFC-labeled PBMC pellet phantoms as low
6
6 19
6
phantoms
by centrifuging
5x106 aand
10x10coil
F-PFC-labeled
aswere
1x10created
cells can
be detected 1x10
at 3 T, using
surface
and clinical PBMC
and overlaying
with
1%
agarose
in
an
Eppendorf
tube
(A).
PBMC
phantoms
were scanned
MR imaging protocols.
at 3 T using a clinically-approved surface coil and all 3 phantoms described in (A) were
detected using 19F cellular MRI (B), with a hot-iron colour scale used to display 19F MRI
signal. Point spread function artifact is visible from the largest cell phantom (10x106
PBMC).
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Further imaging optimization experiments were conducted on three volunteers to detect
human inguinal lymph nodes, which appear as dark spheres within the bright fat pad in the
upper thigh. A representative image (Fig. 4-9a/b) reveals that multiple inguinal lymph
nodes can be detected with an average volume of 390 ± 290 mm3 and at an average depth
of 1.5 ± 0.3 cm below the skin. These MR images were used to localize the target imaging
area, after which a 1H/19F dual-tuned surface coil (Fig. 4-9c) would be placed in the centre
of this area to detect in vivo

19

F signal. As a proof on concept,

19

F-PFC-labeled human

PBMC were injected into a ham shank (of comparable size to an average human thigh).
The 1H/19F dual-tuned surface coil was then placed on the surface of the ham shank above
the target location (Fig. 4-9d). The 19F-PFC-labeled human PBMC (1.2x1011 19F atoms per
cell) were administered intradermally in 3 doses: 1.5, 4.5 and 20x106. The two higher
injection doses were detectable and quantifiable (Fig. 4-9e/f, yellow arrows) but not the
lowest dose (1.5x106 cells). The subcutaneous injection of 4.5x106 19F-PFC-labeled PBMC
that was administered 1.2 cm below the intradermal dose was also visible (Fig. 4-9f).
Quantification of the number of cells indicated 4.11x106 cells at the site of the 4.5x106
intradermal injection, 17.6x106 cells at the site of the 20x106 cell intradermal injection and
3.76x106 cells at the site of the 4.5x106 subcutaneous injection (Fig. 4-9f, blue arrow).
Human 1H images (n=2) of the inguinal lymph node area using the 1H/19F dual-tuned coil
showed the location of a lymph node in the target area to be similar to that observed in the
ham shank. A representative 1H human image shows a lymph node 0.71 cm below the
surface (Fig. 4-9g).
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Figure 4-9. Clinical 3 T MRI detection and quantification of 19F-PFC-labeled human
PBMC. A T1-weighted, coronal orientation MR image obtained using a body coil reveals
human inguinal lymph nodes as dark spheres (blue arrows) within the fat of the upper
Figure
Clinical
T MRI detection
quantification
of 19that
F-PFCthigh (a).
The 4-9.
red dashed
line3 indicates
the locationand
of the
axial MRI slice
identifies
the depth
labeled
of anhuman
inguinal
PBMC.
lymph node to be approximately 1.5 cm below the skin (b, red
scale bar). PBMC were obtained from a healthy volunteer and labeled overnight with the
19
F-PFC cell labeling agent before injection into a ham shank. Imaging was performed by
placing the 1H/19F switchable RF (c) coil on the ham shank as shown in (d). 19F-PFClabeled PBMC were administered intradermally with the MR image shown for a 20x106
injection (e, yellow arrow). 4.5x106 19F-PFC-labeled PBMC were injected both
intradermally (f, yellow arrow) and subcutaneously (f, blue arrow). Both injections were
detected and quantified, with the subcutaneous injection visible at a depth of 1.2 cm as
measured from the MR image. A representative human 1H image taken with the same
parameters closely resembles the ham shank images with respect to tissue appearance,
subcutaneous fat deposition and depth of inguinal lymph nodes (g).
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4.5 Discussion
4.5.1

19

F-PFC labeling and label retention in human PBMC

The aim of this investigation was to develop a clinical protocol to label therapeutic cells of
a non-homogeneous nature, such as PBMC238, with a 19F-PFC cell labeling agent approved
for use in humans. Other cell labeling and contrast agents were widely used in the past,
such as iron-based labeling agents to track therapeutic cells in pre-clinical and clinical
models196, 203. However, in contrast to

19

F cellular MRI that employs a perfluorocarbon

formulation, such iron-based labeling agents have not been reported to label all human
leukocyte subsets, are difficult to quantify, and do not always provide unambiguous in vivo
detection of labeled cells203. Previous work revealed that the quantity of APC that migrated
to a lymph node following injection is directly proportional to the magnitude of the ensuing
immune response199. By using 19F-PFC cell labeling agents, the quantitative distribution of
a PBMC-based immunotherapeutic APC cancer vaccine to secondary lymphoid organs,
such as a lymph node, may provide valuable biomarker information that is predictive of
treatment efficacy. The labeling of a homogeneous cell population, such as DC that are
naturally endocytic, with 19F-PFC-based cell labeling agents at levels that support in vivo
detection by cellular MRI is easily achieved274,

291

. In comparison, labeling non-

homogeneous populations of cells, such as PBMC, presents difficulties as each cell type
has varying endocytic/phagocytic activity and inherent differences in cell volumes that
limit 19F-PFC label uptake capacity.
The cell density,

19

F-PFC concentration and labeling time to achieve optimal

19

F-PFC

labeling of PBMC were based in part on previously published reports, advice from the
manufacturer of the

19

F-PFC cell labeling agent, as well as our own dose response

experiments presented previously in Chapter 377,

261, 310, 314

preliminary stages took into consideration that GMP-processed

. Logistics planning in
19

F-PFC-labeled PBMC

needed to be shipped back from the manufacturing site to ensure that autologous infusion
of PBMC product and subsequent 19F/1H MRI scan takes place at a reasonably convenient
time of day. After accounting for this, our data demonstrate that the main leukocyte subsets,
including those known to function as APC, are labelled with a 19F-PFC cell labeling agent
under GMP-compliant conditions to a high percentage using cell culture conditions that we
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have previously defined. Using a red fluorescent version of a 19F-PFC labeling agent and
flow cytometry, 99% of PBMC were found to be labeled after the overnight labeling
period. We also determined that 99% of the labeled PBMC retained 19F-PFC label over the
approximate three hour period required to ship the labeled PBMC from the UHN
manufacturing site (Toronto, ON) to Robarts Research Institute in London, ON and process
them for flow cytometric analysis. The average MFI of samples from three donors was not
different pre- and post-transport; however, one donor did exhibit a decrease in MFI. The
reason for the apparent decrease in MFI is unclear as the manufacturer claims the 19F-PFC
is stably retained in viable cells. As leukocytes are known to produce exosomes464, 465, 466
it is possible that over time a portion of the 19F-PFC is lost in released exosomes. Additional
experiments are required to resolve this issue and are considered outside the context of this
thesis.

4.5.2

Variability of 19F-PFC labeling of heterogeneous human
PBMC

As is important for all cell labeling agents,

19

F-PFC incorporation occurred without

affecting the functionality of the blood-derived APC or T cells within the PBMC mixture
as assessed by a MLR and T cell proliferation assay. Although the PBMC labeling
percentage was near 100% for each participant, some heterogeneity in the average amount
of label incorporation was observed. This heterogeneity is attributable to the different cell
lineages within PBMC. For example, smaller cells such as T cells and B cells with a small
cytoplasmic volume have been shown to label with 19F-PFC labeling agents on the low end
of 1012 19F spins per cell307. Larger leukocytes, such as monocytes and DC, label on the
high end of 1012 to the lower end of 1013 19F spins per cell291, 299 (and unpublished data).
Furthermore,

the

macropinosomes303,

19
307

F-PFC

labeling

agent

incorporates

into

multilamellar

, so cells like DC and monocytes that are highly endocytic or

phagocytic in nature accumulate more

19

F-PFC label in culture. However, the

aforementioned results were obtained in studies using homogeneous cell populations77, 283,
299, 314, 388, 422

and thus, did not consider the effect of labeling of individual cell populations

within a heterogeneous cell population. This likely explains why loading in these studies
is higher than what is observed with our PBMC labeling method, as other preliminary
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studies in our lab have shown increased labeling of each cell lineage (B cells, T cells,
monocytes) following negative selection and culturing each separately as mono-cultures
(unpublished data). The only other reported study on

19

F-PFC labeling a heterogeneous

hematopoietic mixture of cells was performed on murine splenocyte cell suspension and
reported 3.70 ± 0.21% labeling of CD3+ T cells261. This is in stark contrast to labeling
observed in a homogeneous T cell culture, in which 90% of CD3+ T cells incorporated 19FPFC422.
Variability within the number of average

19

F spins per cell was also observed between

participants in this study, ranging from 5.14 × 1010 to 1.16 × 1011 19F spins per cell. A
potential explanation for this is the differences that exist in relative cell lineage proportions
between participant PBMC samples, which have been shown to be highly variable238. For
example, a patient with a higher percentage of B and T cells and a lower percentage of
monocytes would have a lower average loading than a patient with a higher percentage of
monocytes in their PBMC. The age and/or health status of the donor may also be a factor
as intracellular loading was highest within a younger, healthy control (Participant 4)
compared to older (60–90 years of age) prostate cancer patients (Participants 1, 2, 3 and
5). Considering the small number of participants in this study, a more extensive study is
needed to verify this observation.

4.5.3

GMP-compliant human PBMC processing

After establishing protocols for labeling PBMC with 19F-PFC, it was necessary to consider
the inter-city logistics in the design of a GMP-compliant processing protocol (Figure 4-3).
This protocol involves drawing blood from patients in one location (London Regional
Cancer Program, London, ON), transporting it to a GMP-compliant cell manufacturing
facility (UHN, Toronto, ON) 2.5 hours (250 km) away and then returning the cell product
back to Robarts Research Institute (London, ON) the next day. Furthermore, this study was
designed to ensure GMP-compliant cell processing satisfies all requirements outlined by
Health Canada for autologous injection back into humans463. All tests results passed Health
Canada’s requirements, except for the PBMC viability of Participants 1 and 2. In the case
of Participants 1 and 2, shipment of PBMC samples back to Robarts Research Institute post
labeling were sent in small pre-determined volumes in individual vials intended to be used
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directly for injection or for further safety testing. Thus, 19F-PFC-labeled PBMC recovery,
in particular, was low and the viability fell below requirements for injection into humans.
Cell loss greater than 35% during GMP culturing is an important concept as it is associated
with significant increases in production cost467. While Participant 2 (prostate cancer
patient) had a low lymphocyte count (predominant cell type in PBMC) and a low yield, the
yield did not seem to be necessarily dependent on lower immune cell counts as Participant
3 (prostate cancer patient) had a good yield but a low immune cell count. We rectified the
yield problem by subsequently shipping all the PBMC in one 15 mL polypropylene Falcon
tube fully filled with Plasma-Lyte A solution. This change alone greatly increased the
viability of post-transport samples to levels deemed acceptable by Health Canada.
PBMC viability was also not significantly affected by 19F-PFC labeling when compared to
unlabeled PBMC and was unaffected by shipment time, distance traveled and the external
temperature. The viability following

19

F-PFC labeling in the current study is similar to

what has been reported in other studies using DC and T cells77, 308. This is an important
finding with respect to cell labeling agents and cell-based cancer vaccines as their purpose
is to permit in vivo detection of cell migration without affecting viability and/or phenotype
that could alter the immunogenic potential of the vaccine457, 468. FicollÒ-Paque density
centrifugation has been used to pellet dead cells and debris from cell suspension such that
the cell product meets or exceeds a pre-determined viability percentage required for
injection388, 469; however, this additional step was not required in this investigation as the
viability percentages reported for Participants 3-5 cell products exceeded the predetermined viability cut-off.
With heterogeneous cell-based vaccines, each cell lineage within the PBMC mixture serves
a different immunological purpose154, 470, 471, 472. Therefore, it was of interest to determine
whether

19

F-PFC labeling of PBMC affected any cell lineage within the PBMC

formulation. Our flow cytometry analysis revealed that, although differences in
percentages of lymphocytes and CD11b+CD16+ monocytes occurred between participants,
the percentages between labeled and unlabeled PBMC for each participant was similar. A
decrease in the CD11b+CD14+ monocyte population post labeling was noted in the current
study. We have observed that

19

F-PFC labeling tends to increase the propensity of
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monocytes to adhere to plastic even when highly hydrophobic, non-adherent plastic was
used, thereby resulting in a reduction of this cell type in the final cell suspension and not
necessarily indicating CD11b+CD14+ cell death as a result of labeling. Alternatively, CD14
receptor internalization may have resulted from uptake of the

19

F-PFC nanoparticle

emulsion, as has been suggested for CD36 on murine dendritic cells following iron oxidebased labeling agent phagocytosis and CD14-mediated macropinocytosis339, 473. This could
account for a transient decrease in CD14 on the cell surface of these monocytes. CD56+
NK cells exhibited differences between labeled and unlabeled populations in each of the 3
participants PBMC assessed. The reason behind the decrease in the unlabeled population
is not clear but may have to do with the lack of proper cytokine support needed for
maintaining cultured NK cells474, 475, 476 as well as low CD56+ cell counts considering the
extensive flow cytometry gating performed prior to gating for CD56 expression. Although
broad cell lineage composition was assessed in this study, a detailed phenotypic assessment
of individual leukocyte subsets was not assessed.

4.5.4

Pre-clinical 19F cellular MRI

Pre-clinical in vivo imaging studies in mice were conducted to determine the sensitivity of
detection for 19F-PFC labeled PBMC and development of protocols in pre-clinical models
prior to application in human studies. In a future clinical trial, autologous PBMC injection
into patients is expected to follow the same processing and set-up protocols as the in vivo
mouse imaging studies presented here. In all sites receiving 19F-PFC-labeled PBMC high
dose injections and for one low injection (Participant 4),

19

F-PFC labeled cells were

detected on day 0. These are cells that have either not migrated in the 2 hour time frame
following injection or could also represent a dead cell population as a result of shearing
during expulsion through the 28G1/2 syringe needle. This will be of less relevance in
corresponding human PBMC injections as the needle gauge will be increased and cells can
be injected in a greater volume of excipient solution. Quantification at the site of injection
2 days later was always possible if day 0 detection was present, albeit at a lower cell
number. This can be attributed to two factors; cells migrating away from an area of
quantified signal to a distal site and also to dying/dead cells releasing the 19F-PFC which
will rapidly dissipate or be phagocytosed by murine macrophages261 and cleared from the
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area of signal quantification. Only live cells retain the 19F-PFC387. In addition, migration
from the flank injection site to a draining popliteal lymph node (quantified to be 2 × 105
cells) was observed in one animal. This suggests that, although a small drop in viability
occurs as a result of labeling and transport,

19

F-PFC-labeled PBMC were still able to

migrate to biologically-relevant sites after injection. This is the first demonstration of in
vivo migration detected by 19F cellular MRI of 19F-PFC-labeled cells cultured under GMP
conditions. This strengthens the case that 19F-PFC labeling in Biosafety Containment Level
2-approved laboratory under pre-clinical conditions, as evidenced in Chapter 2, and
labeling under clinical GMP-compliant conditions can be conducted and still render human
PBMC migration competent in vivo. Also, migration to the lymph nodes likely occurred in
additional cases, but in insufficient numbers to reach the threshold needed for 19F cellular
MRI detection. Knowledge regarding in vivo migration after injection is important to note
as lymphatic transport differs depending on the site of administration477, 478. Furthermore,
differences in cell lineage proportions, such as DC subsets, exist not only between the
spleen and lymph nodes but also between lymph nodes in different locations, such as the
axillary, mesenteric, inguinal and popliteal lymph nodes200, 479, 480. This highlights the need
to track therapeutic cells in vivo as it is predictive of the magnitude of an immune response
as well as the type of immune response, which could depend on cell subset proportions
present in the secondary lymphoid organ where

19

F-PFC-labeled therapeutic cells were

detected.
We did not activate the PBMC in any way to stimulate migration to and, in particular,
retention in secondary lymphoid tissues as has been done for the PBMC-based
immunotherapy, ProvengeÒ, using granulocyte-macrophage colony stimulating factor246,
481

. This lack of activation due to the absence of GM-CSF in culture may also have resulted

in a reduced number of detectable PBMC in any given draining lymph node. Furthermore,
the injections were performed subcutaneously in the flank area, which can drain to multiple
lymph nodes such as the popliteal and inguinal lymph nodes. This is in contrast to what we
presented in vivo for human DC123 and as shown in Chapter 3 for PBMC, in which
migration from footpad to popliteal lymph was observed as it is the only lymph node that
drains immediately from the footpad. However, no migration to other more distant
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secondary lymphoid tissues was detected by cellular MRI. This may be a limitation of
the mouse model in which the number of leukocytes injected is much lower than what can
be done in humans481,

482

. Regardless, detection and quantification of cell migration

observed following a low-dose injection in mice is a positive result when considering
clinical translation.

4.5.5

Clinical 19F cellular MRI optimization and detection

The translational potential of 19F-cellular MRI was investigated with a clinical GE MR750
3 T MRI scanner. Preliminary experiments were performed on

19

F-PFC-labeled human

PBMC cell pellets of known number, with imaging experiments progressing towards the
use of a fresh ham shank as a mock human leg due to strong tissue similarities. The largest
factor governing successful detection of PBMC was the number of

19

F spins/cell. Mean

intracellular loading of PBMC ranged from 1010–1011 between participants, representing
an order of magnitude difference in cell detection threshold (107 vs 106 PBMC,
respectively). While in the developmental stages of clinical 19F MRI, it may be necessary
to pre-screen patients based on intracellular

19

F-PFC loading. In comparison to other

clinical 19F MRI studies, PBMC were observed to label on average one order of magnitude
lower than dendritic cells (3.9 × 1012 19F spins/cell)310 and stromal vascular fraction cells
(SVF) (2.8 ± 2 × 1012 19F spins/cell)387. This translates into a proportional decrease in signal.
Yet, despite this inherent drawback, the minimum number of detectable cells in the current
study was comparable to previous studies (DC: ~5 × 106, SVF: 2 × 106, PBMC: 4.5 × 106)77,
387

. The clinical protocol and hardware used when imaging the ham shank represents a 10

times improvement in sensitivity compared to previously reported studies. This
improvement is largely due to the small size and high sensitivity of the surface coil used,
as well as the higher number of imaging averages employed compared to similar studies77,
387

. To provide higher detection sensitivity, we chose a MRI radiofrequency surface coil,

but at the cost of limiting the imaging field of view compared to a volume coil. However,
due to the superficial location of the proposed injection sites and shallow depth of the target
lymph nodes, imaging at depths greater than 1.5 cm is currently not necessary.
Improvements in acquisition with different MRI sequences, such as ultrashort echo time
(UTE); advanced array coil configurations; post processing techniques, such as
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compressed sensing; and novel 19F labeling agents141 will be required to increase sensitivity
further than what we report here.

4.5.6

Conclusions

In this study, we present the highest sensitivity for 19F detection reported thus far in the
literature using a clinical scanner and clinical protocol. Moreover, we demonstrate it is
possible to quantify the signal of

19

F-PFC-labeled PBMC at a depth of 1.2 cm using a

clinical protocol and 19F MRI scanner hardware, as the only other study has detected signal
of surface-injected cells77. This type of imaging is valuable when considering that it can be
used as a non-invasive technique to track their anatomical location, their persistence and
potentially lead to improvements in APC-based cancer vaccine efficacy. This imaging
technique can potentially be applied to other types of cell-based cancer therapies, such as
CAR T or NK cell immunotherapies. Furthermore, the in vivo cell tracking of
immunosuppressive regulatory T cell-based therapies to their intended target locations for
the treatment of autoimmune disease and organ transplantation is an unmet need required
to

verify

the

mechanism

behind

such

immunosuppressive

therapies483,

484

.

Immunomodulatory mesenchymal stem cell therapy trials also have a similar
requirement387. Regulatory agencies are considering whether to require cell tracking to
establish the anatomical fate(s) and persistence of the therapeutic cells as part of the process
of establishing treatment efficacy. Thus, it is imperative to have a firm understanding of
the advantages and disadvantages of different cell labeling agents such
formulations.

19

F-PFC
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Chapter 5

5

Thesis Discussion

5.1 Data Summary
In Chapter 2 and Appendix I, murine BMDC and human moDC were chosen as a
professional APC therapeutic cell platform to determine if 19F cellular MRI is a suitable,
non-invasive, longitudinal imaging technique sensitive enough to permit correlating
quantification of 19F-PFC-labeled DC migration to the lymph node with the strength of the
ensuing immune response. Greater than 95% of murine BMDC and human moDC labeled
with 19F-PFC at a level capable of detecting and quantifying 19F-PFC labeled DC migration
in vivo without affecting viability, phenotype and function. Moreover, 19F-PFC labeling of
moDC did not affect phenotype or cytokine secretion profiles when compared to unlabeled
moDC cultured under the same maturation cytokine cocktail conditions. 19F-PFC-labeling
of murine BMDC did not alter in vivo migration capacity compared to unlabeled BMDC
cultured under the same conditions nor did it affect the ability of TAA-presenting BMDC
to elicit TAA-specific CD8+ T cell immune responses identified through tetramer staining
of lymph node cell suspensions. A B16-F10 cell line stably expressing luciferase to monitor
tumor growth kinetics and ovalbumin to serve as a model tumor antigen was generated
such that future experiments to correlate the quantification of

19

F-PFC-labeled BMDC

migration to the lymph node with the objective tumor response in a tumor-bearing mouse
model can be employed.
Transitioning from a professional DC-based immunotherapy platform to a mixed APCbased immunotherapy platform was first demonstrated in Appendix II through efficient
labeling of the three main cell lineages found within murine PBMC (CD3+ T cells, CD19+
B cells and CD11b+ myeloid cells) without affecting viability or phenotype. In Chapter 3,
a similar result was observed and measured with human PBMC. Detection and
quantification of

19

F-PFC-labeled murine PBMC in an immunocompetent mouse model

(Appendix II) and detection of 19F-PFC-labeled human PBMC migration to the popliteal
lymph node in an immunocompromised mouse model (Chapter 3) were both demonstrated.
Further in vivo imaging studies using

19

F-PFC-labeled human PBMC revealed that

19

F
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cellular MRI is not only capable of detecting and quantifying the migration of cells in vivo,
but it is also sensitive enough to discern differences in migration associated with varying
ex vivo culture and tissue pre-sensitization conditions. For example, increased migration of
19

F-PFC-labeled human PBMC to the popliteal lymph node was observed when human

PBMC were ex vivo-cultured with GM-CSF as well as when

19

F-PFC-labeled human

PBMC were administered into tissue pre-sensitized with a pro-inflammatory cytokine,
murine IL-1b. Finally, signal detected in vivo was confirmed to be the result of originally
injected PBMC and through differential cell lineage fluorescent labeling, CD3+ T cells,
CD19+CD20+ B cells and CD14+/CD16+ monocytes contained within PBMC were all
detected within the popliteal lymph node.
Previous studies in Chapter 3 outlined that efficient

19

F-PFC labeling of human PBMC

occurs without affecting viability or phenotype. In combination with MLR and T cell
proliferation assays demonstrating no functional changes associated with 19F-PFC labeling
of APC and T cells, respectively, a pre-clinical validation study was performed as a step
towards a clinical trial. Human PBMC viability, function,

19

F-PFC retention, regulatory

authority-mandated quality control tests and associated transportation were all considered
when designing a protocol to label human PBMC with

19

F-PFC under GMP-compliant

conditions. After minor modifications, the protocol outlined in Chapter 4 was suitable for
generating

19

F-PFC-labeled human PBMC under GMP-compliant conditions that are

migration competent in a pre-clinical murine model. In a parallel study, the translation of
pre-clinical 9.4 T MRI knowledge to a 3 T clinical MRI set-up using a dual-tuned 1H/19F
switchable RF coil approved for human use permitted the detection and quantification of
19

F-PFC-labeled human PBMC at an immunologically relevant depth in a mock human in

vivo system.

5.2 Cancer immunotherapy
Cancer is the second most common cause of death in North America, trailing only heart
disease485. In males, prostate cancer is the most prevalent malignancy and in 2018, is
estimated to account for 19% of all male cancers, followed by lung cancer (14%) and
colorectal cancer (9%). From birth until 49 years of age, prostate cancer affects 1 in 403
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males, 1 in 58 males aged 50-59, 1 in 21 males aged 60-69 and 1 in 12 males over 70 years
of age485,

486

. Considering the increased prevalence of prostate cancer with age in

combination with developed countries having ageing populations, research with respect to
improving existing prostate cancer treatment options and the development of novel
strategies is imperative to control and reduce the number of diagnoses in the coming
years392. Research into novel chemotherapeutic, radiotherapeutic and surgical therapies,
the three standard anti-cancer strategies, is currently being conducted and has demonstrated
positive results; however, 30% of patients still progress to metastatic disease, which has a
5 year survival rate of 28%4,

366

. Nearly 100% of prostate cancer-related deaths are

associated with metastatic disease, in which few treatment options are available5, 6, 487.
Therefore, immunotherapeutic strategies to combat prostate cancer, along with other
immunogenic tumors like melanoma and renal cell carcinoma31,

32

are becoming

increasingly popular and represent personalized medicine approaches to harness the power
of the immune system for patients unresponsive or refractory to standard treatments.
In order for tumors to persist in vivo, they develop multiple strategies to evade the immune
recognition9, 10. As these malignant cells are of host-origin, the immune system is naturally
biased towards tolerance and thus, tumors continue to proliferate11, 12, which increases
tumor burden and can potentially result in metastasis to distant organs4, 366. By downregulating MHC Class I expression on the cell surface, tumors are rendered nearly invisible
to CD8+ cytolytic T cells as it cannot interact with a peptide:MHC Class I complex on the
tumor cell surface19, 20, 21, 22. In addition to preventing recognition by the immune system,
tumors induce the surrounding microenvironment to be extremely immunosuppressive23
such that if an anti-tumor immune response were to be initiated, it would quickly be
dampened and skewed towards a tolerogenic response incapable of tumor destruction11, 12,
212, 213, 488, 489

.

The tumor microenvironment establishes immunosuppression and tolerance through the
release of immunosuppressive cytokines like IL-10490, 491 and pro-tumor cytokines such as
transforming growth factor-b (TGFb) and vascular endothelial growth factor (VEGF)9, 492,
493

. Furthermore, the tumor microenvironment gives rise to cell subsets that are regulatory

and suppressive in nature, primarily consisting of CD4+ CD25+ Foxp3+ regulatory T cells
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(Treg) and MDSC338, 494, 495, 496, 497. Collectively, tumor-induced immunosuppression leads
to APC and T cell dysfunction212, 213, 488, 489, 498 as well as the disruption of proper innate
immune cell activation, such as seen with NK cells and macrophages9, 493, 499, 500, 501.
Cancer immunotherapy serves to up-regulate the immune system to overcome one or more
aspects of tumor-induced immune suppression such that a tumor can be recognized and
drive an objective anti-tumor response, ultimately resulting in long-term immunological
memory that prevents tumor re-emergence18, 31, 32. Cancer immunotherapy can be used to
elicit anti-tumor immunity in a multitude of ways. First, non-specific up-regulation of the
immune system can occur through systemic administration of pro-inflammatory cytokines
like IL-263,

64

or through administration of checkpoint inhibitors that bind negative

signaling molecules on an activated T cell, thereby prolonging their immunotherapeutic
window at which to exert anti-tumor effects94, 502, 503, 504, 505. Alternatively, adoptive cell
transfer of ex vivo-activated T cells can be employed. These T cells can consist of ex vivoexpanded TIL87, 506 or genetically engineered CAR T cells and upon infusion back into the
host, induce apoptosis in cancer cells108, 109, 507, 508. Although proven effective and capable
of launching long-term anti-tumor responses, the broad, untargeted prolonging of the T cell
activation state using checkpoint inhibitors and the “on-target off-tumor” destruction of
healthy tissue associated with CAR T cell therapies can result in serious and even fatal
toxicities14, 105, 108, 116, 241. Therefore, APC-based immunotherapeutic strategies have been
employed as an alternative means to induce TAA-specific immune responses in vivo that
led to both partial and durable responses in patients509,

510

and most importantly, are

associated with excellent safety profiles511, 512, 513, 514.
APC link the innate and adaptive immune systems and in the context of cancer
immunotherapy, function as adjuvants120. APC are responsible for the uptake and
processing of TAA in the periphery and presenting TAA to T cells upon migrating to
secondary lymphoid organs in a manner that induces a TAA-specific T cell response62, 120,
159

. Professional APC, like DC, present TAA in conjunction with strong activation

signaling through co-stimulatory molecules and pro-inflammatory cytokine secretion such
that naïve T cells can be activated and proliferate into CD8+ CTL or CD4+ TH cells515, 516.
Non-professional APC-based immunotherapies, for example mixed APC-based cancer
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vaccines generated from PBMC, also exist and function by improving the strength of an
existing basal anti-tumor response to a level that results in improved overall survival7. Due
to the incomparable ability of DC to stimulate robust anti-tumor immune responses, they
have been used extensively in immunotherapies for greater than 20 years210. Although safe
and effective, the results of DC-based clinical trials are sub-optimal and thus, much effort
has focused on improving the immunogenicity of DC-based vaccine formulations. Various
strategies to improve immunogenicity have consisted of determining the ideal DC source,
defining the optimal DC maturation and activation state, most appropriate administration
route, increasing in vivo migration capacity and inducing cytokine secretion that promotes
TH1-mediated CD4+ T cell, CD8+ T cell and NK cell responses517.
As with any cell-based therapy, knowledge pertaining to in vivo migration and persistence
following administration is largely unknown. With respect to APC, and more specifically,
DC, previous research has shown that the number of APC that reach a lymph node
following injection is directly proportional to the outcome of the immune response199, 518.
This highlights the importance of developing a non-invasive imaging technique to
quantitatively monitor in vivo cell distribution and thus, serve as a surrogate marker of
vaccine effectiveness. This thesis outlines the use of 19F cellular MRI as a suitable noninvasive imaging technique to quantify therapeutic cell migration in vivo such that it can
serve as a surrogate marker or readout of effectiveness as a means to compare between
different vaccine formulations or determine the effectiveness of emerging cell-based
immunotherapies. Furthermore, we demonstrate that 19F cellular MRI is sensitive enough
to permit in vivo detection of both human and murine therapeutic cells in a pre-clinical
setting as well as in a clinical setting following GMP-compliant cell manufacturing.

5.3 Source of DC and administration route
Early studies pertaining to DC were conducted via direct isolation of blood-derived DC.
Although possible, blood-derived DC represent a very small population of cells found in
the blood (approximately 1%)519, 520, 521, and the technology at the time was not suitable for
processing multiple blood volumes to obtain enriched DC apheresis products522. Therefore,
monocytes, which are present at much higher proportions in peripheral blood than DC, are
widely used as precursors to generate moDC523, which are then matured using a well-
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characterized standard cytokine maturation cocktail207,

211, 212, 213

. Our laboratory

involvement in a clinical trial evaluating an autologous DC-based cancer vaccine for nonmetastatic castrate-resistant prostate cancer patients with rising PSA123 created a platform
from which we could generate moDC from patient samples. These moDC were then
included in preliminary studies assessing 19F-PFC label incorporation as a means to detect
moDC in vivo using

19

F cellular MRI. In parallel to human moDC experiments, similar

studies were conducted with murine BMDC, which closely resemble human moDC.
DC were chosen for preliminary labeling studies firstly because they are commonly ex
vivo-cultured to avoid tumor-induced immunosuppression523. Ex vivo culturing allows
labelling agent incorporation to be controlled and consistent without concerns regarding
other contaminating cell lineages incorporating signal and producing false positive signal.
Secondly, they represent a terminally differentiated enriched cell population with a high
endocytic capacity203. These characteristics enable DC to incorporate large volumes of cell
labeling agent throughout the cytoplasm and labeling agent dilution due to proliferation is
not a concern524, 525. Furthermore, previous studies had assessed different administration
routes for DC as a means of improving immunogenicity. It was determined that intranodal
administration was associated with the greatest number of DC in the lymph node. However,
this did not result in an increased TAA-specific T cell response as intranodal injections
bypass the natural maturation and activation that DC undergo during migration to a lymph
node, resulting in both immature and incompletely matured and activated DC being
injected in the lymph node64, 198. In the context of cancer immunotherapy, immature DC
presenting TAA leads to tolerogenic responses, which is the opposite of the desired proinflammatory response and in some instances can even be detrimental to the patient201. To
avoid tolerogenic responses, peripheral administration of DC was widely adopted such that
DC migration to the lymph node needed to take place and thus, only properly matured DC
would reach the lymph node200. By incorporating peripheral subcutaneous or intradermal
injection into DC-based immunotherapies, the need to track and quantify DC migration to
secondary lymphoid organs became even more pertinent.
An ideal cell tracking agent should label a high percentage of cells with enough agent to
permit in vivo detection while not having any effect on viability, phenotype or function314,
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526, 527, 528

. Therefore, both human moDC and murine BMDC were cultured with and

without 19F-PFC and I determined, as presented in Appendix I and Chapter 2, that nearly
100% of DC incorporated

19

F-PFC label without affecting viability or phenotype when

compared to unlabeled control DC. Furthermore, I established that the mature moDC
phenotype was unchanged as a result of

19

F-PFC labeling (Appendix I) with respect to

human moDC activation and co-stimulation markers like CD80, CD83, CD86, CD40 and
CD54, as signaling through these surface markers is absolutely required in addition to TAA
presentation for the activation of naïve TAA-specific T cells160. Similar data was obtained
for murine BMDC as presented in Chapter 2. Of equal importance to murine and human
DC maturation is their in vivo migration competency, commonly assessed through surface
up-regulation of CCR7 induced through addition of a maturation cytokine cocktail to ex
vivo culture (Chapter 2 and Appendix I, respectively).

5.4 DC migration
One of the first rationales for conducting the projects presented in this thesis was the desire
by clinicians involved in one of Canada’s first cell-based cancer vaccines clinical trials to
know where injected DC tracked to within the patients following injection. Hence,
assessing DC migration became an important issue as this trial progressed123. CCR7
responds to CCL19- and CCL21-induced chemokine gradients that promote migration
towards secondary lymphoid organs343, 344 and once within lymph nodes, directs migration
towards paracortical T cell-rich regions529, 530, 531, 532. One of the main factors limiting the
effectiveness of DC-based immunotherapies is that only 5% of injected cells reach the
lymph node following injection183, 198, 199, 215, 216, 217. As the number of DC reaching the
lymph node is predictive of the strength of the ensuing immune response199, 518, much focus
has been directed towards increasing DC migration as a means of increasing vaccine
potency. Even though CCR7 surface expression was unchanged for murine BMDC and
human moDC following

19

F-PFC labeling,

19

F MRI imaging studies to detect in vivo

migration from footpad injection to draining popliteal lymph node were conducted and
presented in Chapter 2 and Appendix I123. For both human and murine DC,

19

F-PFC-

labeled cells were detected and quantified in the lymph node. Furthermore, this experiment
was designed to include the addition of a fluorescence marker to DC prior to injection such
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that post

19

F MRI digital morphometric analysis to compare the migration between

19

F-

PFC-labeled DC and unlabeled DC could be conducted. No difference in in vivo migration
capacity was associated with 19F-PFC labeling, which is a stark contrast to previously used
cellular MRI SPIO- and MPIO-based labeling agents that physically impeded DC
migration to secondary lymphoid organs322, 339, 533, 534. The moDC that I prepared from
prostate cancer patients apheresis products in the aforementioned DC-based clinical trial
were demonstrated to be migration competent using

19

F cellular MRI123. This enabled

clinical trial investigators to have some degree of confidence that the autologous vaccine
moDC product administered to clinical trial patients were migration competent.
Lipid mediators, such as PGE2, have been included in DC maturation cocktails to induce
CCR7 up-regulation211 and were a component of maturation cocktails in this thesis for both
murine BMDC and human moDC in Chapter 2 and Appendix I. Some controversy exists
with the inclusion of PGE2 in DC culture because it can result in decreased production of
IL-12p70 by DC when CD40 ligation also occurs535. In an effort to not dampen a
subsequent immune response, I attempted to increase DC migration to the lymph node
using a different method consisting of pre-sensitizing the lymph node region with IL-1b
prior to DC injection. Although pro-inflammatory tissue pre-sensitization has resulted in
increased DC migration at lower dose injections199, 341, 342, I believe our injection dose of
3x106 BMDC was too high to observe the additive effects of tissue pre-sensitization.
However, for both pro-inflammatory cytokine-treated and control injection conditions, 19FPFC-labeled BMDC were detected and quantified in the lymph node 48 hours post
injection. Currently, it appears to be imperative that a DC-based vaccine be matured with
PGE2; however, future research into alternative maturation procedures that do not
compromise IL-12p70 production can use

19

F cellular MRI to quantify migration as a

measure of treatment effectiveness rather than relying on expensive and time-consuming
immunoassays.

5.5 Induction of TAA-specific T cell immunity
For

19

F cellular MRI to serve as a non-invasive surrogate marker for DC-based

immunotherapeutic effectiveness,

19

F-PFC labeling must not interfere with antigen

153

processing machinery and subsequent presentation to naïve CD8+ and CD4+ T cells via
MHC Class I and II molecules in the lymph node. To assess TAA-specific immune
responses in humans to a pre-determined well-characterized peptide, HLA-restriction must
be considered536, 537, 538. Therefore, I chose to assess TAA-specific immune responses in a
murine model of genetically identical mice expressing H-2Kb following administration of
19

F-PFC-labeled BMDC presenting SIINFEKL peptide and unlabeled BMDC presenting

SIINFEKL peptide. The SIINFEKL peptide is the immunodominant H-2Kb-restricted
peptide of the chicken ovalbumin protein (OVA257-264) and was chosen due to its extensive
characterization and commercial availability of a tetramer to detect SIINFEKL-specific
CD8+ T cells261, 346, 347, 348, 349. I determined that 19F-PFC labeling of BMDC did not alter
the induction of a SIINFEKL-specific CD8+ T cell immune response compared to
unlabeled BMDC. Hence, the immunogenicity of the SIINFEKL peptide-loaded cell-based
vaccine was not affected by the presence of
immunogenic TAA in conjunction with

19

19

F-PFC. Additional studies using less

F-PFC labeling of DC needs to be conducted.

Although not utilized in this thesis, the immunodominant MHC Class II peptide of
ovalbumin (OVA323-339) is also well characterized and could be used to assess whether 19FPFC labeling impairs CD4+ T cell responses in the context of ovalbumin as a surrogate
tumor antigen in a cell-based cancer immunotherapy350, 351.
In Chapter 2, I outlined a B16-F10 melanoma tumor cell line transfected to constitutively
produce ovalbumin protein as a model tumor antigen and stably transduced to express
luciferase. Therefore, this tumor model was designed to detect and quantify

19

F-PFC-

labeled SIINFEKL-presenting BMDC migration to the lymph node using 19F cellular MRI
and relate this quantification to the overall anti-tumor response, using bioluminescence
imaging as a readout of tumor growth and persistence. Also, the plasmid selected for
ovalbumin transfection is suitable for investigating the role of both CD4+ and CD8+ T cells
in the context of cancer immunotherapy539, 540. The triple-expressing ovalbumin, luciferase
and GFP B16-F10 cells are currently being used to determine whether 19F-PFC-labeled and
unlabeled BMDC presenting SIINFEKL peptide induce the same anti-tumor response.
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5.6 DC licensing
Much attention related to DC-based vaccines is focused on their ability to induce TAAspecific CD8+ T cells, which is the main cell type responsible for recognition and
subsequent destruction of tumor cells250, 259, 260, 541, 542. However, DC need to interact with
CD4+ TH cells to receive necessary signals and produce cytokines required for potent CD8+
T cell induction543. CD4+ TH cell responses last longer in vivo compared to CD8+ T cell
responses and furthermore, play an integral role in creating an environment suitable for
activating innate immune cells, maintaining TAA-specific CD8+ T cells and establishing
long-term immunological memory435, 544, 545, 546, 547. In addition to DC needing CD4+ TH
cells, moDC matured solely with pro-inflammatory cytokines did not produce sufficient
amounts of polarizing cytokines to drive robust CD8+ T cell activation176, but rather were
associated with an exhaustion phenotype capable of only weakly activating tumor-specific
immune responses548,

549, 550

. To generate DC resistant to promoting a T cell immune

exhaustion phenotype and become properly activated, the high expression of PRR on DC
cell surface or within DC has been exploited in an effort to further induce DC maturation
and up-regulate polarizing cytokine secretion163,

551

. In Appendix I of this thesis, I

experimented with different TLR agonist combinations to include in a cytokine maturation
cocktail for human moDC. Moreover, I also investigated if alterations to the maturation
cytokine cocktail were affected by

19

F-PFC labeling as ideally,

19

F-PFC-labeled moDC

migration to the lymph node could be compared between different vaccine formulations as
a non-invasive means to measure DC migration as a surrogate marker of potential vaccine
immunogenicity.
As presented in Appendix I, TLR agonists such as CpG, poly(I:C), LPS and imiquimod, as
well as combinations thereof, were included in the cytokine maturation cocktail. TLR
agonist addition did not induce significant changes in moDC phenotype but did appear to
increase moDC cytokine secretion with respect to IL-12p70, IFNg and IL-10. IL-12p70
secretion is important in the context of immunotherapy as it skews an immune response in
the TH1 direction and is a potent activator of NK and NKT cells552, 553. Signaling through
TLR also induces IL-10 production, albeit to differing extents depending on the TLR
participating in signaling554. For example, TLR2, TLR4, TLR7 and TLR9 signaling results
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in strong IL-10 induction555, 556, 557 while TLR3 in combination with CD40 ligation yields
minute quantities of IL-10558. With this information, further research is needed to
determine the ideal maturation cocktail as well as research pertaining to how T cells
respond to both pro- and anti-inflammatory secretion during an immune response. 19F-PFC
labeling did not affect moDC phenotype or cytokine secretion when compared to control
moDC cultured under similar conditions, suggest that this imaging modality is suitable for
labeling therapeutic cells under different culture conditions and assessing their subsequent
in vivo migration capacity and immunogenicity.
Once DC reach the lymph node and begin interacting with naïve T cells, the signature of
cytokines that they release during these immunological synapse interactions dictates the
type of immune response launched in vivo176, 207, 211, 212, 213, 440. CD40 ligation of DC by
CD4+ TH cells results in enhanced IL-12p70 and IFNg secretion555, 559, 560 that activates NK
and T cells, promoting further secretion of IFNg and TNFa and induces TH1 proinflammatory immune responses beneficial for anti-tumor immune responses437, 438, 439, 440,
441

. IL-4 production is important for TH2-mediated CD4+ T cell responses, while IL-5 and

IL-13 contribute to induction of both TH1- and TH2-mediated immune responses
simultaneously that lead to cell- and humoral-mediated adaptive immune responses120. IL17 is required for TH17 immunity that is commonly associated with autoimmunity561, 562;
however, from a cancer perspective, it can be both pro-tumor by promoting angiogenesis563,
564

and anti-tumor through enhancement of T and NK cell activity120, 565.

The development of non-invasive imaging modalities to track therapeutic cells post
injection are instrumental in better understanding cancer immunotherapies and can be
exploited to compare the effectiveness of different vaccine formulations. Optimizations of
DC-based vaccines are ongoing with respect to enhanced migration, polarizing cytokine
secretion and involvement of CD4+ TH cells. Immunotherapy is currently at a crossroad in
which cell-based immunotherapies that require little to no cell culture or are even
allogeneic in nature are emerging and gaining popularity7, 387, 467 over potent professional
APC associated with time-consuming and expensive protocols. With non-invasive imaging
being included in immunotherapies, shorter culture times and labeling of large quantities
of therapeutic cells is increasingly favoured.
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5.7 Blood-derived DC
Due to the improvement of techniques for isolating rare cell populations coupled with
increased GMP-compliant grade cell isolation kits566,

567, 568

, blood-derived DC-based

immunotherapies are increasing in popularity. By enriching DC directly, an extended cell
culture is not necessary and with fewer ex vivo manipulations, protocol standardization is
easily achieved566, 569, 570, 571. Blood-derived DC primarily consist of CD1c+ or CD141+
mDC and CD123+ pDC146, 572, 573, 574, 575. Both subsets have been used to elicit robust antitumor responses and can also function synergistically143, 144, 576. pDC are matured following
IL-3 addition to culture while mDC are matured with GM-CSF, giving rise to type I IFN
production by pDC in addition to IL-6 and TNFa production by both subtypes141. Type I
IFN is beneficial in a cancer immunotherapy setting as it promotes tumor apoptosis, cell
cycle arrest and enhances macrophage, lymphocyte and DC anti-tumor activity577, 578, 579,
580

.

5.8 PBMC-derived mixed APC-based immunotherapies and
19
F-PFC labeling
Instead of undergoing a lengthy apheresis procedure and enrichment for monocytes as was
conducted in Appendix I, PBMC can be isolated directly from blood with relative ease581,
582

. Through co-culture with a fusion protein consisting of GM-CSF and PAP, APC within

PBMC such as B cells, monocytes and DC can be activated by GM-CSF and rendered
tumor-specific via uptake, processing and presentation of TAA derived from PAP245, 386,
583, 584

. This mixed APC-based immunotherapy, named Sipuleucel-T, can be manufactured

and ready for autologous re-infusion within 48 hours of peripheral blood collection, is
FDA-approved for the treatment of metastatic CRPC and is associated with significantly
prolonged overall survival246.
Mixed APC-based immunotherapies derived from PBMC function similarly to DC-based
vaccines; however, a very small proportion of PBMC are professional APC, with the
remaining non-professional APC populations consisting of monocytes and B cells238.
Therefore, instead of predominantly eliciting a de novo immune response, they are
designed to primarily enhance a pre-existing anti-tumor response to a level that is effective
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at prolonging overall survival7. Mixed APC-based immunotherapies have yet to result in
progression free survival, indicating the need for further research to increase potency445,
446, 584, 585, 586, 587, 588, 589, 590, 591

but due to their short and relatively simple ex vivo culturing,

there is potential for clinical translation. As this thesis focuses on in vivo cell tracking
within the context of cancer immunotherapy, mixed APC vaccines derived from a
heterogeneous cell population present new challenges with respect to 19F-PFC labeling as
the vast majority of 19F-PFC labeling is performed using homogeneous cell cultures.
19

F-PFC is formulated as an emulsion such that all cells uptake label regardless of

endocytic and phagocytic capacity314, 457, 468, 592. However, B cells, T cells and NK cells
within PBMC have a low cytoplasmic volume and thus, are limited with respect to the
amount of label they endocytose. In addition, the relative proportions of PBMC cell subsets
vastly differ between patients238. Thus, depending on the relative proportions of B and T
cells compared to larger cells like monocytes, the average 19F-PFC incorporation per cell
can also differ significantly between patients. Although one may presume that if 19F-PFC
labeling of the main cell lineages within PBMC have all labeled in a homogeneous culture
that labeling in heterogeneous cultures should not differ; however, this is not the case. This
is well demonstrated by comparing a study labeling human T cells with 19F-PFC, in which
90% of cells incorporated label422, compared to less than 4% of CD3+ T cells that
incorporated 19F-PFC when cultured as a heterogeneous splenocyte cell suspension261.
In preliminary studies that I conducted in Appendix II, murine PBMC isolated from blood
and splenocyte cell suspension following gradient centrifugation were cultured with 19FPFC. CD19+ B cells and CD11b+ myeloid cells labeled to a high percentage with 19F-PFC
and in contrast to a previous study261, greater than 70% of CD3+ T cells incorporated 19FPFC. High

19

F-PFC labeling observed with murine PBMC precipitated translation to

determine human PBMC 19F-PFC incorporation in Chapter 3, which was conducted under
a variety of cell culture conditions and found to be near 100% for CD14+ monocytes,
CD19+ and CD3+ B and T lymphocytes and CD11c+ DC. By demonstrating that all cell
lineages label with 19F-PFC to near 100%, similar labeling percentages should be observed
for all human samples regardless of relative proportions of cell lineages within PBMC.
This was clearly illustrated by the findings reported in Chapter 4 describing the labeling of
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human PBMC under GMP-compliant conditions. Furthermore, for initial clinical studies,
19

participants can be pre-screened and selected for based on average amount of

F-PFC

incorporation into PBMC, which presumably would increase with increasing percentage
of CD14+ monocytes within PBMC.

5.9 Mixed APC activation and functional assessment
To better recapitulate culture conditions seen with Sipuleucel-T, GM-CSF was added to
human PBMC cultures. GM-CSF addition occurred 24 hours into culture such that

19

F-

PFC labeling of PBMC took place before activation with GM-CSF. As expected, GM-CSF
did not alter 19F-PFC incorporation nor did it alter PBMC viability. In Sipuleucel-T, GMCSF serves to activate APC within PBMC and is measured through CD54 surface
expression7, 435. In our labeling procedure, GM-CSF addition to unlabeled PBMC or 19FPFC-labeled PBMC resulted in as much as 40% and 60% up-regulation of CD54 MFI for
CD20+ B cells and CD11b+ APC, respectively and as much as 120% and 55% up-regulation
of CD86 MFI for both CD20+ B cells and CD11b+ APC, respectively. This demonstrates
the bioactivity of GM-CSF in our human PBMC experiments. Moreover, murine and
human APC functionality was assessed via a mixed lymphocyte reaction in Appendix II
and Chapter 4, respectively, and was unaltered by 19F-PFC labeling. Interestingly, CCR7
up-regulation did not occur in response to GM-CSF addition as demonstrated in Chapter
3.

5.10 Mixed APC migration
As observed in DC-based immunotherapies, mixed APC-based immunotherapies exert
their function through APC migration to secondary lymphoid organs to interact with and
activate TAA-specific T cells83, 243, 593. Although GM-CSF did not result in CCR7 upregulation on human PBMC, in vivo

19

F cellular MRI imaging revealed that

19

F-PFC-

labeled PBMC cultured with GM-CSF were consistently detected and quantified in the
popliteal lymph node 48 hours after footpad injection. In contrast, 19F-PFC-labeled control
PBMC migration was mostly below the detection threshold. As the quantification of APC
migration is indicative of the strength of the ensuing immune response199,

518

, we

investigated if tissue pre-sensitization with IL-1b increased both professional APC
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(BMDC) and mixed APC migration. In contrast to what was observed in Chapter 2 with
BMDC, pro-inflammatory tissue pre-sensitization appears to increase the migration of 19FPFC-labeled control PBMC above the detection threshold; however, it did not function
synergistically with GM-CSF to further enhance migration. The results of this study
demonstrate the feasibility of

19

F cellular MRI as an appropriate non-invasive imaging

modality than can discriminate differences in human PBMC migration to the lymph node
associated with differing ex vivo culturing conditions as exemplified with GM-CSF as well
as increased migration associated with tissue pre-sensitization using IL-1b (Chapter 3).

5.11 Characterization of
popliteal lymph node

19

F-PFC-labeled PBMC in the

A common question that arises following 19F-PFC detection in the lymph nodes is whether
the signal is from intact, originally injected cells or if the signal is the result of phagocytosis
of dying

19

F-PFC-labeled cells by resident macrophages. If these resident phagocytes

remain at this location, they produce a false positive signal as a result of bystander uptake.
Co-labeling

19

F-labeled therapeutic cells with an intracellular fluorophore aids in

discriminating true positive from false positive signal using digital morphometry analysis
when combined with lymph node digestion and counterstaining with human CD45 as
described in Chapter 4. This ensures that originally injected therapeutic cells are producing
the observed 19F in vivo signal and are not engulfed by resident phagocytes through positive
human CD45+ staining.
Seeing as my studies presented in Chapter 3 and Chapter 4 are centred around PBMC,
additional questions that arise are which cell lineages from the originally-injected PBMC
are producing the signal detected in the lymph node and how does the migrated relative
proportion of cell lineages compare to pre-injection PBMC cell lineage relative
proportions. From an immunological perspective, this information is vitally important
considering the different roles T cells, B cells and monocytes have in cancer
immunotherapy.
Differential intracellular fluorescent labeling of T cells, B cells and monocytes within
PBMC prior to injection for both 19F-PFC-labeled and unlabeled PBMC permitted post-
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imaging analysis of popliteal lymph node cryosections displayed in Chapter 3. Regardless
of 19F-PFC labeling or not, all three main cell lineages were detected in the lymph node,
with further research being required to compare relative proportions of PBMC lineages.
This information, in combination with a similar experiment conducted in Chapter 4 in
which intact CFSE-labeled cells counterstained with human CD45 were detected in the
popliteal lymph node, implies that live, originally injected PBMC are the source of signal
detected in the popliteal lymph node. Although we cannot definitively say these cells are
alive, the detection of cell migration penetrating into the lymph node suggests that live
cells responded to a chemokine gradient and directed their intralymphatic migration
accordingly529, 530, 531, 532. To minimize quantification errors as a result of differences in
relative cell lineage proportions between participant PBMC samples, NMR spectroscopy
was conducted for each participant sample. This aided in minimizing interparticipant
quantification errors; however, the lineage composition of cells that have migrated in vivo
to immunologically-relevant locations has not been determined. Therefore, it is necessary
to assume that relative cell proportions remain constant following in vivo administration
but it is acknowledged that this represents a source of error with respect to 19F cellular MRI
quantification. A future experiment in which lymph nodes are digested following migration
of fluorescently-labeled cell lineages within PBMC and counterstaining with human CD45
can be used to assess relative lineage proportions as well as confirm that these cells are not
engulfed by murine resident phagocytes.

5.12 Clinical translation
Pre-clinical

19

F-PFC labeling studies of human PBMC as well as murine BMDC and

human moDC that demonstrated a high cell labeling percentage without deleterious effects
on in vivo migration, viability, phenotype or function set the stage for clinical translation.
The 19F-PFC cell labeling agent used throughout this thesis is suitable for use in humans
and in combination with regulatory bodies expressing interest in non-invasive imaging
technologies306, 594, 595, we decided to develop the methodologies whereby human PBMC
are labeled with 19F-PFC under GMP-compliant conditions. In parallel, we also translated
our pre-clinical cellular MRI knowledge to a clinical setting such that MR hardware and
19

F-PFC detection could be optimized prior to conducting a clinical trial.
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5.13 GMP-compliant 19F-PFC labeling of human PBMC
By incorporating a cell labeling agent into cell manufacturing protocols, it will be
necessary to subject the labeled cells to the same quality control tests outlined by regulatory
authorities that need to be met to obtain approval for infusion into patients. Therefore, in
Chapter 4, we designed a protocol to obtain PBMC from prostate cancer patients and a
healthy control that were labeled overnight with
conditions. Following

19

19

F-PFC under GMP-compliant

F-PFC labeling, viability, phenotype and in vivo migration

assessments were conducted and compared to unlabeled PBMC from the same participant.
Lastly, all quality assurance tests that would be required for autologous injection were
performed; however, murine injection studies were performed in our experimental design.
In translational research, it is important to identify possible hurdles that may be faced
during GMP-compliant cell manufacturing. Transportation was identified as a potential
issue for two reasons. Firstly, the nearest GMP-compliant cell manufacturing facility is
three hours away and secondly, the shipping conditions must be suitable to not result in
significantly decreased viable cell yield. Greater than 35% cell loss during GMP-compliant
manufacturing is associated with increased manufacturing costs467, 596. For example, in the
first two participant samples, the cell yield, as well as viability, was low as a result of cells
being transported in small, individual injection-ready aliquots. Fortunately, a simple
protocol modification to transport all manufactured cells in a large media volume in one
vial rather than small aliquots resolved this issue for remaining PBMC participant samples.
Although not an issue in this thesis, shipping cryopreserved cell products would also result
in decreased cell yields596. Finally, as stated in Chapter 4, we employed a short overnight
labeling protocol and thus, minimized cell loss associated with extended cultures. This was
balanced against a four-hour labeling protocol that requires using five times the amount of
19

F-PFC141 at five times the expense. However, with the 6 hours of total transportation time

involved, the labeled cells would have required a future participant to come for their
infusion at an evening time that generally would be inconvenient for most participants,
particularly elderly men involved in a prostate cancer clinical trial. Hence, the protocol
described in Chapter 4 represents the best compromise due to the distance between the
study site and the cell manufacturing site.

19

F-PFC labeling was maintained during
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transport and after the aforementioned protocol modification with respect to transportation,
all quality control tests, including viability, passed, suggesting that our current protocol is
suitable for future clinical trials.

5.14 19F-PFC-labeled PBMC in vivo migration
To confirm the biological activity of GMP-processed PBMC and

19

F-PFC uptake, I, in

conjunction with Dr. Jeffrey Gaudet and Dr. Paula Foster, performed 19F MRI studies in
immunocompromised mice. Previous studies in Chapter 2 and Chapter 3 utilized mouse
footpad injections. As this is not an option in humans, we decided to modify the injection
location. Earlier studies outlined in Appendix II using

19

F-PFC-labeled murine PBMC

injected intraperitoneally appeared to migrate to mesenteric as well as sacral lymph nodes.
Unfortunately, the location of mesenteric lymph nodes can differ and could potentially be
masked with injection site signal. Therefore, we performed subcutaneous flank injections
as this closely mimics what will be conducted in a future clinical trial in which autologous
cell injection will take place in close proximity to the inguinal lymph node area.
Subcutaneous flank administration of GMP-processed 19F-PFC-labeled PBMC permitted
injection site detection as well as migration to the popliteal lymph node approximately two
hours after administration. Utilizing this approach, we demonstrated that GMP-processed
human 19F-PFC-labeled PBMC were migration competent in vivo. It should be noted that
as a proof of principle study, GM-CSF was not included as an additional variable. In
Chapter 3, we showed that cell migration is increased with GM-CSF in culture, most likely
as a result of increased retention of activated APC within the lymph node120, 379, 427, 435,
suggesting that activation with GM-CSF during GMP-processing would have resulted in
enhanced migration.

5.15 Clinical MRI protocol
When transitioning from 9.4 T pre-clinical MRI to a 3 T clinical MRI, the sensitivity of
detection decreases linearly with decreasing magnetic field strength597. To balance the
decrease in detected signal, a dual-tuned surface coil rather than volume coil can be
employed as they are associated with a greater sensitivity of detection with respect to

163

imaging superficial locations77, 387, 598, 599, 600. Moreover, human lymph nodes are larger than
murine lymph nodes and thus, the 19F-PFC voxel size can be increased accordingly. Lastly,
human cell injection doses can be over an order of magnitude greater than injection doses
employed in mouse studies.
A previous clinical study was able to image 19F-PFC-labeled DC in humans at the injection
site but was unable to detect cell migration77. In the context of APC-based cancer
immunotherapies, migration from injection site to lymph node is absolutely required to
achieve a clinical benefit168, 169, 170. Therefore, we designed an experiment using a clinical
MRI set-up to not only detect a superficial intradermal injection but a deeper subcutaneous
injection at a biologically relevant depth, being the depth of a human inguinal lymph node.
Initially studies pertaining to

19

F-PFC cell pellets were important to establish detection

ranges; however, a much more biologically relevant set-up was required to provide
meaningful information. Due to tissue similarities, a ham shank was used to detect and
quantify both surface injected and subcutaneously administered 19F-PFC-labeled PBMC.
The detection of an immunologically relevant number of cells at a biologically relevant
depth highlights the importance of designing experiments that closely resemble what would
occur in humans and allows for early identification of potential hurdles that may be faced
in future clinical trials. It should be noted that the use of a refrigerated ham shank, although
similar in size to a human thigh, would be associated with less cell dispersion following
injection that what would occur in a live patient following autologous

19

F-PFC-labeled

PBMC injection. In conclusion, given the current outlined sensitivity of detection in a
clinical setting and the notion that approximately 5% of therapeutic cells reach the lymph
node following adoptive cell transfer, we can conservatively predict that an adoptive cell
transfer of close to 90x106 19F-PFC-labeled PBMC would be required to detect migration
to the draining inguinal lymph nodes.

5.16 Conclusions and future directions
Irrespective of the type of therapeutic cells employed for cell-based cancer
immunotherapy, the development of novel immunotherapies and improvement to previous
immunotherapies is contingent on knowledge gained regarding where and for how long
cells remain at a given location post administration314, 601, 602, 603. With in vivo cell tracking,
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the effectiveness of immunotherapies could be predicted as soon as hours or days after
therapeutic cell infusion. Moreover, if the cell-based immunotherapy fails based on lack of
cell migration or goes to unexpected locations, the patient could consider alternative
treatment options sooner rather than waiting for lengthy periods of time to indirectly
measure therapeutic outcome, for example using tumor growth at a follow-up
appointment604.
This thesis presented the usefulness of 19F cellular MRI in a pre-clinical setting that appears
suitable for detection and quantification of BMDC migration to a draining lymph node and
relating this migration to an antigen immunogenicity and soon to an anti-tumor response
in a tumor-bearing mouse model. Fluorine cellular MRI is sensitive enough to detect
differences in in vivo migration between GM-CSF-activated and control human PBMC in
a mouse model while also being robust enough to be translated from pre-clinical murine
BMDC studies to GMP-compliant processing and detection of human PBMC in a clinical
MR setting.
Future directions of 19F cellular MRI should be focused on comparing the effectiveness of
GMP-compliant vaccine formulations, such as investigating whether frozen APC-based
cell products, such as cryopreserved Sipuleucel-T (APC8015F) migrate similarly and as
effectively as freshly prepared cell products7, 43. Secondly, 19F cellular MRI can be used to
better understand existing immunotherapies, such as the in vivo migration signature
associated with the first priming infusion of mixed APC-based immunotherapies like
Sipuleucel-T as it compares to the in vivo migration signature of subsequent boost
infusions120. Additionally, it can be easily translated to other immunogenic cancer
platforms, such as a mixed APC-based cancer vaccine including HER2/neu-GM-CSF
fusion protein for metastatic breast, ovarian and colorectal cancers445, 446 and a mixed APCbased immunotherapy employing carbonic anhydrase 9 fused to GM-CSF for the treatment
of renal cell carcinoma447, 448. Knowledge gained through these described studies will help
to shape the path taken to translate pre-clinical immunotherapies into the clinical setting in
the most cost-effective manner without compromising the potent anti-tumor immune
responses associated with cell-based immunotherapies.
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Combination therapies of pre-existing immunotherapies or combination with standard
treatment options are necessary for cancer immunotherapy to gain an advantage over the
immunosuppressive tumor microenvironment and associated immune evasion605, 606. For
example, the excellent safety profile associated with mixed-APC vaccinations83, 244, 246 can
be combined with the potent anti-tumor activity of checkpoint inhibitors94, 503, 504, 505 to
better recognize and subsequently eliminate a tumor. Moreover, the emergence of
personalized medicine can be exploited to identify tumor neo-antigens that will improve
the toxicity issues associated with CAR T cells14, 105, 315, 607, 608, 609, 610, 611, 612, which could
potentially be measured using

19

F cellular MRI by increased migration to tumors that

coincides with decreased migration to unexpected in vivo locations containing normal
tissue613, 614, 615.
By incorporating a non-invasive imaging technique approved for clinical use that has
demonstrated scale up capability422 and can efficiently label, track, and quantify in vivo
therapeutic cell migration, the translation and development of novel GMP-processed
immunotherapies can be better understood and thus, accelerated for clinical use435. The
data presented in this thesis has now been translated into the pre-clinical component of a
Phase I clinical trial application (NCT02921373616) to investigate the feasibility and safety
profile associated with autologous injection of

19

F-PFC-labeled PBMC in 6 healthy

volunteers and 6 prostate cancer patients. In the first cohort of patients, a 3x106 19F-PFClabeled PBMC intradermal injection will be performed with subsequent monitoring for
adverse effects as well as quality control tests mandated by regulatory authorities for
autologous reinjection. If adverse effects are observed at the level of grade 1 or lower, a
higher injection dose of 20-30x106 19F-PFC-labeled PBMC will be performed to detect 19FPFC signal at the injection site as well as detect and quantify 19F-PFC signal in the inguinal
lymph nodes. The clinical trial will hopefully begin in July 2019, with completion being
expected in June 2022.
This imaging modality has broad implications not only for labeling immune cell types of
varying origins but for being employed for therapeutic benefit in a multitude of
immunogenic cancers. Fluorine cellular MRI can be applied to other cell-based therapies
whose effectiveness is hindered by lack of knowledge of in vivo migration post injection.
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For example,

19

F-PFC has been used to label human mesenchymal stem cells617 as

knowledge of their in vivo localization following administration is important when
assessing treatment effectiveness. Furthermore, detection of tolerogenic DC after infusion
can provide useful information with respect to the prevention of graft-versus-host disease
and immune rejection commonly observed with hematopoietic stem cell transplant387, 618.
Tolerogenic DC that are ex vivo-cultured to control maturation status and cytokine
secretion profiles can be used to combat chronic immune system over-activation commonly
observed in autoimmune disorders such as rheumatoid arthritis619. Improved knowledge
regarding tolerogenic DC tracking can aid in improving this immunomodulatory
therapeutic option. Current costs for cell-based imaging approved for clinical use is high;
however, in an era with ever increasing technology, heightened demand for alternative and
novel treatment options and broad usefulness across many disease states, the future of noninvasive molecular imaging and the vital role it plays in advancing novel therapies is
promising.
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Appendix I- Human DC-based cancer immunotherapies

6

Appendix I
6.1

6.1.1

Materials and Methods
Animal care

Male Balb/c severe combined immunodeficiency (scid) mice (6-8 weeks) and male C.B17
mice (6-8 weeks) were purchased from Charles River Laboratories Inc. (Saint Constant,
Canada) and housed at Robarts Research Institute at the University of Western Ontario
(London, Canada) in a pathogen-free barrier. All experiments were pre-approved by the
Animal Use Subcommittee at the University of Western Ontario and conducted in
accordance with an approved protocol from the University of Western Ontario’s Council
on Animal Care (Protocol #2015-046). Where necessary, mice were anaesthetized with 2%
isoflurane in oxygen unless stated otherwise.

6.1.2

Participants

Non-metastatic, castrate-resistant prostate cancer patients with rising PSA levels who were
enrolled in a clinical trial of Tn-MUC1-DC vaccine (clinicaltrials.gov identification
number NCT00852007) provided written consent to have elutriation samples enriched for
PBMC drawn at McMaster University (Hamilton, Ontario) of which a portion was shipped
to Robarts Research Institute at the University of Western Ontario (London, Ontario) for
same day delivery. To be included in this study, prostate cancer patients must have been
18 years of age or older and free of HIV, Hepatitis B or C Virus or other transmissible
diseases and not undergoing steroidal or immunosuppressive therapy at the time of
elutriation sample collection.

6.1.3

Reagents

CellGro® serum-free dendritic cell media (CellGenix®, Freiburg, Germany) was
supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 0.3 mg/mL LGlutamine (ThermoFisher Scientific, Burlington, Canada). HBSS, PBS, Trypan blue,
human IL-1b, and Luminex® cytokine multiplex kit was purchased from ThermoFisher
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Scientific, (Burlington, Canada). BSA was obtained from Calbiotech (Spring Valley,
USA) and NGS was purchased from Jackson ImmunoResearch (West Grove, USA).
EasySepÔ human monocyte enrichment kit without CD16 depletion was obtained from
Stemcell Technologies (Vancouver, Canada) and PeproTech (Montreal, Canada) was the
source of human GM-CSF, human IL-4, human IL-6, and human TNFa. PGE2 was
purchased from Sigma Aldrich (Oakville, Canada) while human CpG ODN 2216, Poly
(I:C), LPS and Imiquimod (R837) were obtained from InvivoGen (San Diego, USA).
CD11c-APC (Clone 3.9), CD15-PE/Cy7 (W6D3), CD123-BV421 (6H6), CD14-APC/Cy7
(M5E2), CD54-PE (HA58), CCR7-PE (G043H7), CD80-PE (2D10), HLA-DR-PE (L243),
CD40-PE (G28.5), CD83-FITC (HB15e), CD86-PerCP/Cy5.5 (BU63) and CD16-Alexa
Fluor 700 (3G8) were purchased from Biolegend (San Diego, California). Vectashield®
mounting media with DAPI was obtained from Vector Laboratories (Burlington, Canada).
Lastly, Celsense, Inc. (Pittsburgh, USA) supplied both 19F-PFC cell labeling agents, CS1000 ATM and CS-1000 ATM DM Red, with the latter being the red fluorescent version
of CS-1000 ATM.

6.1.4

moDC generation and 19F-PFC labeling

Samples from five non-metastatic castrate-resistant prostate cancer patients with rising
PSA were received in this study, with one patient providing two elutriation samples on two
separate occasions. Elutriation samples enriched for PBMC were collected at McMaster
University (Hamilton, Ontario) and a portion was shipped to Robarts Research Institute,
London, Ontario (day 0 of culture). Human monocyte magnetic negative cell enrichment
without CD16 depletion (Stemcell Technologies) was performed in conjunction with
manufacturer’s protocol to yield CD14+ and/or CD16+ monocytes. Monocytes were then
counted using a hemocytometer and resuspended at 5x105 cells/mL in GMP-grade serumfree media, CellGro® (CellGenix) supplemented with 100 U/mL penicillin, 100 µg/mL
streptomycin and 0.3 mg/mL L-Glutamine (all ThermoFisher Scientific). In order for
monocytes to develop into immature moDC, GM-CSF and IL-4 was added to serum-free
culture media at final concentrations of 0.1 µg/mL and 0.05 µg/mL, respectively.
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Monocytes were plated at 5x105 cells/mL in serum-free media such that each well of a 6
well plate contains 4 mL of cell suspension that can be exposed to different treatments
conditions over the course of 6 day ex vivo culture. An aliquot of PBMC both before and
after CD14+ CD16+ monocyte enrichment was collected for flow cytometry phenotyping.
Monocytes were then left untouched for 72h in an incubator at 37°C and 5% CO2.
After incubating for three days, half of the cell suspension was removed, centrifuged to
pellet cells and resuspended in fresh media along with GM-CSF (0.1 µg/mL) and IL-4
(0.05 µg/mL) at the same volume of cell suspension before centrifugation. This fresh cell
suspension was combined with the other half of the cell suspension remaining in cell
culture plates and incubated overnight. On day 4, one well was collected in order to
phenotype the immature moDC. 19F-PFC cell labeling agent (Celsense, Inc.) was added to
19

F-PFC wells (2.5 mg/mL) while unlabeled moDC did not receive 19F-PFC and serve as

control moDC.
Twenty-four hours later on day 5, one 19F-PFC-labeled moDC well and one control moDC
well was collected for phenotyping. All remaining moDC wells then received 1 of 4
cytokine maturation cocktails in order to mature moDC. The standard maturation cytokine
cocktail along with 3 modified cocktails are listed in Table 6-1. On day 6 of culture, all
wells containing all culture conditions were collected individually and phenotyped using
flow cytometry on a LSRII analytical flow cytometer (BD Biosciences).

6.1.5

Human moDC viability assessment

On day 0 of culture both before and after monocyte enrichment, as well as on day 4, day 5
and day 6 of culture, an aliquot of moDC was removed for each culture condition and
subject to a trypan blue exclusion assay (ThermoFisher Scientific) to count both viable and
non-viable cells.

6.1.6

Flow cytometry

The following human antibodies were used for phenotyping: CD11c-APC, CD15-PE/Cy7,
CD123-BV421, CD14-APC/Cy7, CD54-PE, CCR7-PE, CD80-PE, HLA-DR-PE, CD40PE, CD83-FITC, CD86-PerCP/Cy5.5 and CD16-Alexa Fluor 700.

221

An aliquot of PBMC both before and after negative selection for monocytes on day 0 were
phenotyped using CD11c-APC, CD15-PE/Cy7, HLA-DR-PE, CD16-Alexa Fluor 700, and
CD14-APC/Cy7. On day 4, 5 and 6 (prior to injection), phenotyping was performed on an
aliquot from each culture condition using all the antibodies mentioned above. In addition
to phenotyping, on day 6 of culture for the moDC sample labeled with red fluorescent 19FPFC, flow cytometry was used to qualitatively assess 19F-PFC labeling of moDC using a
shift in mean fluorescence intensity as a result of fluorescent label incorporation when
compared to unlabeled control cells from the same patient. All moDC samples were
blocked on ice for 30 minutes with 5% NGS (v/v) in HBSS+0.1% BSA. Following washing
in HBSS (ThermoFisher Scientific), cell surface staining of moDC with the appropriate
antibodies for that day of culture was conducted in HBSS+0.1% BSA on ice (4°C) for 25
minutes. Lastly, stained moDC were washed in cold HBSS and resuspended in
HBSS+0.1% BSA and 4% PFA to fix samples. Phenotyping data acquisition for each day
of culture was performed in one session using an LSRII analytical flow cytometer (BD
Biosciences).

6.1.7

Human moDC cytokine secretion

On day 4, 5 and 6 of moDC culture, culture supernatants were collected for each cell culture
condition and frozen in 500 µL aliquots and -20°C. A Luminex® cytokine multiplex
analysis (ThermoFisher Scientific) along with following manufacturer’s instructions was
performed on supernatant samples that were thawed on ice immediately before use in this
assay. All patient samples were included in the same Luminex® assay and data was
acquired (in duplicate) all at once to minimize assay variability. Supernatant samples were
assayed for IL-2, IL-12p70, IL-10 and IFNg and analyzed using a Bio-PlexTM 200 readout
System (Bio-Rad Laboratories, CA, United States), which utilizes Luminex® xMAPTM
multiplexed immunoassay technology (Luminex Corp., TX, United States). Cytokine
levels were automatically calculated from standard curves using Bio-Plex Manager
software (v.4.1.1, Bio-Rad). IL-2 served as a negative control for all moDC supernatants.
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6.1.8

Adoptive cell transfer of mature moDC

On day of culture, 19F-PFC-labeled moDC from one patient were washed extensively in
PBS (ThermoFisher Scientific) and formulated into two high doses (2x106 moDC) and two
low doses (0.5x106 moDC) for injection, each in 40 µL of PBS. Each C.B17 mouse
received a subcutaneous hind footpad injection of the high dose condition and a
subcutaneous hind footpad injection of the low dose condition in the contralateral footpad.
Two days later, both mice were anaesthetized and
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F as well as 1H MRI scans were

conducted.
One of the five patient samples was co-cultured with a red fluorescent version of 19F-PFC
cell labeling agent (2.5 mg/mL) on day 4 instead of the non-fluorescent labeling agent
previously mentioned. All other procedural steps were identical to what was mentioned
above for mature moDC generation. On day 6 of culture after an aliquot of each moDC
culture condition was collected for phenotyping, the remaining red fluorescent 19F-PFClabeled mature moDC that received the standard cytokine maturation cocktail (Appendix
I, Table 6-1) were counted, washed in PBS (ThermoFisher Scientific) and formulated into
4, 2x106 moDC injections (high dose) and 4, 0.5x106 moDC injections (low dose) in 40 µL
PBS. Two days later, all 4 Balb/c scid mice were anesthetized and 19F as well as standard
proton MRI scans were conducted followed by the immediate removal of draining popliteal
lymph nodes that were fixed in 4% paraformaldehyde (PFA) and cryopreserved in sucrose
solutions.

6.1.9

MRI of moDC migration

Mouse imaging was performed with a 9.4 T Varian small-animal MRI scanner (Santa
Clara, CA, USA). A 3D-bSSFP sequence was used for both proton and 19F MR imaging.
Animals were imaged alongside a reference tube containing a known

19

F concentration

(3.33x1016 19F/μL or 7.3x1016 19F/μL) suspended in agarose. Mice were anesthetized with
2% isoflurane, with breathing rate and temperature monitored throughout the scan. MRI
was performed using a dual-tuned birdcage volume coil (diameter 2.2 cm, length 5.1 cm),
tuned to 400.2 MHz and 376.8 MHz for proton and 19F imaging, respectively. For proton
imaging the scan parameters were: TR = 5.0 ms, TE = 2.5 ms, rBW = 78 kHz, FA = 30°,
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PC = 4, averages = 3, resolution = 200x200x200 μm3, and NEX = 3. For 19F imaging the
parameters were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25 kHz, FA = 70°, PC = 4, averages
= 200, resolution = 1x1x1 mm3, and NEX = 200. To avoid

19

F present in isoflurane

confounding the 19F-PFC signal, imaging was performed by centering on the 19F-PFC Cell
Sense-specific frequency as we previously described270. The total protocol time for both
proton and 19F imaging was under 90 minutes.

6.1.10

19

F-PFC loading efficiency and signal quantification

The mean intracellular 19F content of human moDC was determined by NMR spectroscopy
using a 400 MHz Varian vertical spectrometer. First, a known number of 19F-PFC-labeled
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a
solution containing 100 µL of 5% Triton X-100. After lysing, the cells were transferred to
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher Scientific).
The TFA provides a reference peak for quantifying the number of

19

F spins/ cell, since

NMR signal is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy
parameters were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm
to -93 ppm. The number of moDC detected within MR images was determined with Voxel
TrackerTM software (Celsense Inc, Pittsburgh, PA)
correction was applied to the

19

270, 308

. Prior to analysis, a signal

F datasets by subtracting the signal value of the voxel

containing the lowest signal in the dataset. Once the correction was applied, the total 19FPFC-labeled cell signal contained within a hand-drawn ROI was compared to the average
signal produced by the reference tube containing a known
information was used alongside the

19

19

F concentration. This

F spins/cell, measured by NMR, to quantify the

apparent number of cells located at the ROI.

6.1.11

Post-MRI lymph node histology

Immediately following MRI imaging of Balb/c scid mice that received footpad injections
of 2x106 and 0.5x106 red fluorescent 19F-PFC, both the left and right popliteal lymph nodes
from each animal were removed and fixed in 4% PFA at room temperature. Cryoprotection
of lymph nodes using sucrose gradients step of 10, 20 and 30% for a minimum of 24 hours
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each were conducted at 4°C. The popliteal lymph nodes were then cryosectioned into 16
µm sections (inguinal lymph nodes served as controls), digitally imaged on an Olympus
IX50 phase contrast inverted microscope (Richmond Hill, Canada) and the red fluorescent
19

F-PFC-labeled moDC were quantified using Image-Pro® Plus 5.1 software (Media

Cybernetics, Rockville, USA) and compared between 2x106 and 0.5x106 footpad injection
conditions. Lastly, representative lymph node sections were placed on VWR Microslides
Superfrost® Plus (VWR) and coverslipped with Vectashield® Hard Set mounting medium
with DAPI (Vector Laboratories) to stain nuclei. Overlay images were taken on a Leica
DM IRE2 inverted brightfield microscope (Leica Camera Inc., Allendale, USA).

6.1.12

Statistical analysis

All data was presented as the mean with the standard error of the mean. A paired t-test
(Graph Pad Prism, Version 7, La Jolla, USA) or two-way ANOVA was used. Multiple
comparisons were assessed for all two-way ANOVAs. Significance was considered if p ≤
0.05. When written, the number of independent experiments is denoted by (N) while the
number of replicates per independent experiment is defined by (n).

Table 6-1. Composition of maturation cytokine cocktails added to moDC in culture to
induce maturation on day 5.
Standard
Maturation
Cytokine Cocktail
(CC)
IL-6 (0.1 µg/mL)
IL-1b (10 ng/mL)
PGE2 (106 units)
TNFa (25 ng/mL)

Standard
Maturation CC +
CpG
IL-6 (0.1 μg/mL)
IL-1β (10 ng/mL)
PGE2 (106 units)
TNFα (25 ng/mL)
CpG (4 μg/mL)

New Maturation
CC
IL-1β (10 ng/mL)
PGE2 (106 units)
TNFα (25 ng/mL)

New Maturation
CC + LPS +
Poly(I:C) +
Imiquimod
IL-1β (10 ng/mL)
PGE2 (106 units)
TNFα (25 ng/mL)
Poly(I:C)
(5 µg/mL)
LPS (20 ng/mL)
Imiquimod
(10 µg/mL)
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6.2
6.2.1

Results
An established 6 day protocol to generate human moDC in
conjunction with 19F-PFC labeling yields efficiently labeled
mature moDC

Throughout the 6 day culture whereby human monocytes were enriched from prostate
cancer patient elutriation samples and differentiated into immature and then mature moDC,
an aliquot of cells at each step was collected for further analysis. A cytospin onto glass
slides was performed on day 0 cells (both before and after monocyte enrichment), day 4
immature moDC and day 6 mature moDC. Morphological changes associated with
monocyte to moDC transition and immature to mature moDC can be observed in
conjunction with brightfield microscopy (Fig. 6-1). When observing the morphological
changes associated with immature to mature moDC, it is evident that moDC become
slightly larger after addition of the cytokine maturation cocktail as well as develop long
dendrites protruding outward from the central region of the moDC (Fig. 6-1, bottom right
panel), which is consistent with previous reports298, 339. Thus, the 6 day culture of moDC
appears to be sufficient in generating mature moDC; however, further experimentation is
required to confirm this observation. Lastly, fluorescence microscopy was employed to
visualize red fluorescent 19F-PFC incorporation into moDC after its addition to culture on
day 4 (Fig. 6-1, bottom left panel). Near 100% labeling of moDC was observed, with
fluorescent label incorporating throughout the cytoplasm of these cells.
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Figure 6-1. Brightfield and fluorescent images of moDC following a cytospin to assess
morphological changes. Morphological changes associated with monocyte to moDC
Figure
6-1. Brightfield
fluorescentbyimages
ofinmoDC
following
a
transition
and moDC
maturation and
are represented
increases
the amount
and length
of
cytospin
to
assess
morphological
changes.
dendrites (bottom right image). Nearly 100% of human moDC are able to incorporate red
fluorescent 19F-PFC (bottom left image). Scale bars in each image represent 25 µm.
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Flow cytometry was employed to further confirm red fluorescent 19F-PFC incorporation
into moDC prior to performing in vivo injections. In this experiment, cells were gated on
viability based on forward and side scatter location, followed by doublet discrimination.
These viable, singlet cells were then gated on CD11c+ and CD123- selection such that
moDC were selected for and CD123+ pDC were excluded (Fig. 6-2). Then, a histogram
overlay of moDC that incorporated red fluorescent 19F-PFC (black histogram) compared
to control moDC (blue histogram) from the same patient was performed. Using a shift in
mean fluorescence intensity as a result of fluorescent uptake, 95.3% of moDC incorporated
19

F-PFC cell labeling agent. Lastly, for the mature moDC that incorporated 19F-PFC, the

majority of cells appear to be uniformly labeled as illustrated by one strong peak being
observed (black histogram) rather than a broad peak extending over multiple decades.

19
19
Figure 6-2.
Human
efficiently
label with label
red fluorescent
F-PFC. Human
moDC
Figure
6-2.moDC
Human
moDC efficiently
with red fluorescent
F-PFC.
+
were gated for live, singlet cells that are CD11c and CD123 . Following an overnight
(20h) labeling with red fluorescent 19F-PFC (2.5 mg/mL), 95.3% of moDC label with
fluorescent 19F-PFC (black histogram, bottom left image) compared to unlabeled control
moDC (blue histogram).
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6.2.2

Human moDC matured with a standard maturation cytokine
cocktail are unaffected by the addition of 19F-PFC with
respect to phenotype and viability

A phenotypic analysis using flow cytometry was performed on day 6 moDC to ensure that
there is no phenotypic difference as a result of 19F-PFC incorporation when compared to
control moDC from the same patient for each of the four cytokine maturation cocktails
used. First, gating for CD11c+/CD123- was performed to identify moDC for both 19F-PFClabeled (Fig. 6-3, blue bars) and control unlabeled (Fig. 6-3, white bars) conditions. No
difference existed in the percentage of CD11c+/CD123- between

19

F-PFC-labeled and

unlabeled conditions regardless of the cytokine cocktail used to mature moDC. Costimulatory markers such as CD80 and CD86 were analyzed, along with HLA-DR to
confirm capacity to present antigen, CCR7 to verify that moDC are migration-competent
and CD40, CD54 and CD83 served as maturation and activation markers (Fig. 6-3).
Regardless of cell surface marker or cytokine maturation cocktail that was employed, no
significant differences in expression exist between

19

F-PFC-labeled moDC and control

unlabeled moDC. This suggests that 19F-PFC-labeled moDC retain the same phenotype as
control unlabeled moDC and thus, if used in an in vivo vaccine-based immunotherapy, they
would be migration-competent, be capable of presenting antigen with appropriate costimulatory markers as well as be properly activated to initiate an antigen-specific immune
response.
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Figure 6-3. Summary of human moDC phenotype cultured with or without 19F-PFC. Day
6 matured CD11c+CD123- moDC were analyzed for markers of activation (CD83, CD40,
CD54), antigen presentation (HLA-DR), migration (CCR7) and co-stimulation (CD80 and
CD86). The percentage expression of these markers is shown for 19F-PFC-labeled moDC
6-3. moDC
Summary
of bars)
human
phenotype
cultured
withderivations
or
(blue bars) Figure
and control
(white
formoDC
all cytokine
maturation
cocktail
19
without
F-PFC.
employed. Data shown as means ± SEM (two-way ANOVA, p > 0.05).
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The viability of mature moDC that are labeled with 19F-PFC as well as control unlabeled
moDC viability was assessed after moDC maturation with all four cytokines maturation
cocktails took place. Although the viability of 19F-PFC-labeled moDC (Fig. 6-4, blue bars)
is slightly lower than control moDC (Fig. 6-4, white bars), the difference is not statistically
significant. For moDC matured with a traditional cytokine cocktail or new cytokine
cocktail (defined in methods), a small, but in some cases, significant decrease in viability
was associated with

19

F-PFC labeling of moDC (Fig. 6-4). All in vivo moDC injections

doses contained moDC that were cultured with the standard cytokine maturation cocktail
as it most closely matched the moDC protocol used in the Tn-MUC1-DC vaccine
immunotherapy clinical trial123.
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Figure 6-4. Viability assessment of 19F-PFC-labeled and control unlabeled moDC on day 6
of culture using flow cytometry. For moDC matured with the traditional cytokine cocktail,
which was the maturation cocktail used for all in vivo moDC studies, no significant difference
Figure
6-4. Viability
of 19F-PFC-labeled
andviability
controlwas
unlabeled
in viability
is observed
due to 19assessment
F-PFC incorporation.
However, the
significantly
19
on day 6 of 10-13%
culture by
flowpresence
cytometry.
reducedmoDC
by approximately
in the
of F-PFC labeling for moDC matured
with a traditional cytokine cocktail + CpG as well as for moDC matured with a new cytokine
cocktail. Data shown as means ± SEM (two-way ANOVA, * p < 0.05). All abbreviations are
defined as presented in Table 6-1.
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6.2.3

Pro- and anti-inflammatory cytokine secretion by human
moDC is unaffected by 19F-PFC labeling and appears to
increase with increasing TLR agonists in culture

Day 6 moDC culture supernatants were saved from the same moDC cultures described
above and frozen until a Luminex™ cytokine multiplex analysis was performed. The
supernatants were assayed for pro-inflammatory cytokines IL-12p70 (active form)620 and
IFN-g as well as the anti-inflammatory cytokine IL-10173. IL-12p70 (Fig. 6-5A), IFN-g
(Fig. 6-5B) and IL-10 (Fig. 6-5C) were all produced and secreted in varying degrees and
appear to increase as more TLR agonists are included in the cytokine maturation cocktail.
Importantly, there was no significant difference in cytokine production in the presence or
absence of 19F-PFC regardless of which cytokine maturation cocktail was used. However,
a more in-depth analysis is required to elucidate how an immune response would be
affected by both pro- and anti-inflammatory cytokines being present.

Figure 6-5. Luminex assay assessment of
moDC cytokine secretion profiles. The
Figure 6-5.for
Luminex
assessment
supernatants
each of assay
the four
maturation
of moDC
cytokine
cytokine
cocktail
(bothsecretion
with andprofiles.
without 19FPFC in culture) for each subject moDC
preparation was measured for secretion of IL12p70 (A), IFN-γ (B) and IL-10 (C) using a
Luminex assay. Data shown as means ± SEM
(two-way ANOVA, p > 0.05).
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6.2.4

19

F-PFC-labeled moDC can be detected and quantified at
the injection site and draining popliteal lymph node using 19F
cellular MRI

In vivo migration of matured and 19F-PFC-labeled moDC from one prostate cancer patient
was then assessed using 19F cellular MRI 48h after hind footpad injections were performed.
A 9.4T small animal scanner detected 19F signal in two locations (Fig. 6-6B), which were
confirmed to be the footpad and draining popliteal lymph node (LN) upon 19F MRI signal
being overlaid onto a standard proton MRI (Fig. 6-6A) and pseudocoloured to provide
anatomical context to the in vivo signal observed (Fig. 6-6C). Quantification of in vivo 19F
signal did not take place as 19F MRI signal detection was still being optimized at this point.
Note that this 19F/1H MRI image is not processed and that there is a large artifact associated
with high 19F signal in the footpad as well as 19F signal produced by TFA standards (Fig.
6-6C).
After optimizing in vivo

19

F detection as well as improving the processing of

19

F MRI

images, moDC from a different prostate cancer patient sample were adoptively transferred
and produced much more localized 19F signal in the footpad (Fig. 6-7A/B, blue arrow) and
draining popliteal lymph node (Fig. 6-7A/B, green arrow) without 19F artifact and high 19F
background signal. Upon overlaying a pseudocoloured 19F and 1H MRI, the in vivo signal
can be quantified to be 1.1x105 ± 4x104 19F-PFC-labeled moDC (Fig. 6-7C, green arrow).
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Figure 6-6. 19F/1H MRI detection of 19F-PFC-labeled moDC migration to the
popliteal lymph node
two days post adoptive19cell transfer. (A) The 1H MR image, (B)
19 1
Figure
6-6.
F/
detection
of F-PFC-labeled
moDC
migration
19
1 MRI
F MR image and (C) H
H/19F MR
image overlays
(pseudocoloured
and
not corrected
the popliteal
node two
days arrow
post adoptive
cell panels
transfer.
for 19Ftoimage
shift arelymph
represented.
A gold
in all three
identifies the
popliteal lymph node (LN). The white arrow indicates the 19F artifact generated by
the TFA reference standard.

235

Figure 6-7. Fully processed 19F/1H MRI detection of 19F-PFC-labeled moDC migration
to the popliteal lymph node two days post adoptive cell transfer. (A) The 1H MR image,
(B) 19F MR image (after image processing) and (C) 1H/19F MR image overlays (not
19 1
19
Figure
Fullyshift)
processed
F/ H A
MRI
detection
ofthe
F-PFC-labeled
corrected
for 196-7.
F image
are illustrated.
yellow
arrow in
top panel identifies the
19
moDC
to the indicates
popliteal lymph
node twomoDC
days post
popliteal
LN. migration
The blue arrow
F-PFC-labeled
signaladoptive
retained at the
cellsite
transfer.
injection
in the footpad. The green arrow indicates the 19F signal in the popliteal
lymph node from the injected 19F-PFC-labeled moDC. A “hot iron” colour scale is used
to represent 19F signal in the bottom panel. The reference standard (R) and NMR
spectroscopy of a moDC cell pellet is required to quantify the in vivo signal, which in this
figure is calculated to be 1.1x105 ± 4x104 cells in the popliteal lymph node (bottom panel,
green arrow).
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In a parallel experiment, 48h after the footpad injection of 2x106 red fluorescent 19F-PFClabeled moDC into an immunocompromised mouse, 19F signal was detected in the draining
popliteal lymph node after overlaying a 1H MRI with a pseudocoloured 19F MRI. This in
vivo signal was quantified to be 1.25x105

19

F-PFC-labeled moDC using information

obtained from the reference tube (denoted by R in the MRI image of Fig. 6-8) and NMR
spectra (Fig. 6-8).

Figure 6-8. 19F-PFC-labeled
human moDC in vivo migration is quantifiable using 19F
19
Figure
6-8.
F-PFC-labeled
human on
moDC
in vivo
migration
is
cellular MRI. NMR spectroscopy
is performed
a cell pellet
of known
cell number
to
19
quantifiable
using
F
cellular
MRI
19
determine the average number of F atoms per cell when compared to a TFA reference
standard (top right). This information and the formula shown in the bottom right are
required to accurately quantify in vivo 19F signal.
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6.2.5

19

F in vivo lymph node signal is the result of originally
injected and intact moDC

Once the in vivo 19F detection was optimized such that a number of cells in the popliteal
lymph node could be readily calculated, we next sought to confirm that the signal detected
in the lymph node was the result of the originally-injected moDC. Here, four
immunocompromised mice were injected with 2x106 and 0.5x106 red fluorescent 19F-PFClabeled moDC into the left and right footpad, respectively. Forty-eight hours later, when
19

F MRI would be conducted, the popliteal lymph nodes were removed and processed for

cryosectioning and subsequent fluorescence microscopy. Red fluorescent 19F-PFC-labeled
cells were detected in the paracortex and cortex areas of the lymph node (Fig. 6-9A/B),
which is where moDC would migrate to in order to interact with T cells and initiate a potent
antigen-specific immune response181, 182. Digital morphometry analysis demonstrated that
migration appears to increase in a dose-dependent manner; however, this difference is not
significant between high and low injections (Fig. 6-9C). Lastly, counterstaining with DAPI
to reveal nuclei demonstrates that red fluorescent signal in the lymph node is contained
within intact cells (Fig. 6-9D).
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Figure 6-9. Red fluorescent 19F-PFC-labeled moDC migration to the popliteal lymph node
appears to increase in a dose-dependent manner. Digital morphometry was used to quantify
the degree of 19F-PFC-labeled moDC migration. Representative popliteal lymph node
cryosections reveal red fluorescent 1919F-PFC-labeled moDC for the 2x106 cell high dose
Figure
6-9. Red
fluorescent
F-PFC-labeled
moDC
migration
to (B).
the Digital
6
injection
condition
(A) and
for the 0.5x10
cell low dose
injection
condition
poplitealquantification
lymph node appears
to increase
in aphase
dose-dependent
manner.
morphometric
using an Olympus
IX50
contrast inverted
microscope is
shown in (C), which appears to occur in a dose-dependent manner (C). Counterstaining with
DAPI (blue) confirms that red fluorescent signal is the result of intact cells at 100X
magnification (D). The green box is the same area as shown in the orange box inset at 400X
magnification. White scale bars represent 200 µm at 100X magnification and yellow scale
bar represents 100 µm at 400X magnification. A Leica DM IRE2 inverted brightfield
microscope was used to capture DAPI overlay images. Image-Pro® Plus 5.1 software was
used with both microscopes to capture, process and measure images. Data is shown as
means ± SEM (t-test, p > 0.05).
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Appendix II- Murine APC-based cancer immunotherapies

7

Appendix II
7.1

7.1.1

Materials and Methods
Animals

C57Bl/6 male mice (8-10 weeks old) were purchased from Charles River Laboratories
(Wilmington, USA) and C3H/HeJ male mice (8-10 weeks old) were purchased from
Jackson Laboratories (Bar Harbor, USA). C3H/HeJ mice served as an allogeneic source of
hematopoietic cells compared to C57Bl/6 mice. All experiments were pre-approved by an
Animal Use Subcommittee at the University of Western Ontario and conducted in
accordance with an approved protocol from the University of Western Ontario’s Council
on Animal Care (Protocol #2015-046). Where necessary, mice were anaesthetized with 2%
isoflurane in oxygen unless stated otherwise.

7.1.2

Reagents

DMEM was purchased from ThermoFisher Scientific (Burlington, Canada) and completed
with 100 U/mL penicillin, 100 µg/mL streptomycin, 0.3 mg/mL L-Glutamine, minimal
essential MEM NEAA, sodium pyruvate (10 mM), HEPES and 2-mercaptoethanol (55
µM) (all from ThermoFisher Scientific). Murine GM-CSF was obtained from PeproTech
(Montreal, Canada).
To generate PBMC, HBSS, PBS and trypan blue were obtained from ThermoFisher
Scientific, while BSA and NGS were purchased from Calbiotech (Spring Valley, USA)
and Jackson Immunoresearch (West Grove, USA), respectively. Lympholyte®-M cell
separation media was obtained from Cedarlane (Burlington, Canada).
For flow cytometry, CD19-PE (6D5), CD11b-Alexa Fluor 700 (M1/70), CD3e-FITC (1452C11), CD3e-BV421 (145-2C11), CD4-Alexa Fluor 700 (GK.15), CD8a-APC (53-6.7)
were obtained from Biolegend. CellTrace™ CFSE cell proliferation kit and CD3e
monoclonal antibody (145-2C11) were obtained from ThermoFisher Scientific and

240

Vectashield® Hard Set mounting medium with DAPI was purchased from Vector
Laboratories (Burlington, Canada).
ACK lysis buffer, EasySep™ mouse CD90.1 positive selection and EasySep™ mouse T
cell isolation kits were purchased from Stemcell Technologies, Vancouver, Canada).
Lastly, Celsense, Inc. (Pittsburgh, USA) supplied both 19F-PFC cell labeling agents, CS1000 ATM and CS-1000 ATM DM Red, with the latter being the red fluorescent version
of CS-1000 ATM.

7.1.3

Murine PBMC isolation and 19F-PFC labeling

C57Bl/6 and C3H/HeJ mice were euthanized with isoflurane, peripheral blood was
collected and spleens were removed. The spleen was then pushed through a 70 µm filter
(VWR) with HBSS to create a single cell suspension. ACK lysis buffer was used to remove
red blood cells from cell pellet and the 5 minute reaction was stopped with ice cold HBSS.
Splenocytes were then resuspended in HBSS and overlaid onto Lympholyte®-M cell
separation media for gradient centrifugation (20 min, 800xg, 20°C, no brakes) to enrich for
PBMC. PBMC were enriched from peripheral blood by diluting 1:1 in room temperature
HBSS and overlaid onto Lympholyte®-M cell separation media as mentioned above.
PBMC were pooled and then resuspended in complete DMEM at 5x106 cells/mL and
supplemented with GM-CSF (20 ng/mL). Half of these cells were co-cultured with red
fluorescent

19

F-PFC (5 mg/mL) overnight at 37°C/5% CO2. The following day, PBMC

were collected for each condition and blocked on ice for 30 minutes with 5% NGS (v/v) in
HBSS+0.1% BSA. After washing, PBMC were stained for lineage markers CD11b-Alexa
Fluor 700, CD19-PE and CD3e-FITC for 25 minutes on ice. PBMC were resuspended in
HBSS+0.1% BSA and fixed with 4% PFA until acquisition on a LSRII analytical flow
cytometer (BD Biosciences) to assess fluorescent 19F-PFC uptake of PBMC compared to
control PBMC for each of the 3 main lineages of cells in PBMC.

7.1.4

Murine MLR

C3H/HeJ PBMC were enriched for from splenocyte cell suspensions as mentioned above
and CD3+ T cells were removed from suspension using EasySep™ mouse CD90.1 positive
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selection kit and manufacturer’s instructions. The remaining cells were cultured overnight
at 5x106 cells/mL in complete DMEM media supplemented with GM-CSF (20 ng/mL) and
half of these cells were also cultured with

19

F-PFC at 5 mg/mL. Following overnight

culture, cells were collected and washed in HBSS and then resuspended at 2.5x106 cells/mL
in complete DMEM media and serially diluted starting from 2.5x105 cells per well in
triplicate. Then, PBMC were isolated from C57Bl/6 splenocytes as previously described
above and CD3+ T cells were enriched using EasySep™ mouse T cell isolation kit and
manufacturer’s instructions. Isolated T cells were labeled with CFSE as mentioned above.
CFSE+ T cells were resuspended at 3x106 cells/mL in complete DMEM and 100 µL was
aliquoted to each well such that an MLR can be carried out for 4 days at 37°C/5% CO2
(positive control wells were coated overnight with anti-CD3e antibody at 2 µg/well). After
four days of incubation, wells were washed in buffer and following the same staining
procedure as listed previously, cells were stained for CD3e-BV421, CD4-Alexa Fluor 700
and CD8a-APC and CFSE dilution was used as a readout to assess allogeneic T cell
proliferation.

7.1.5

Adoptive cell transfer

Murine PBMC that were 19F-PFC-labeled as well as unlabeled control PBMC were washed
extensively with PBS and formulated into a 8x106 cell injection in 300 µL PBS.
Intraperitoneal injections were performed into 3 mice for both conditions. In a separate
experiment, murine PBMC were isolated, labeled with 19F-PFC and then immediately prior
to injection, were labeled with CellTrace™ CFSE as described previously and
intraperitoneal injection of 5x106 19F-PFC-labeled CFSE+ PBMC was administered into 3
mice.

7.1.6

MRI of murine PBMC migration

For studies that required 19F cellular MRI imaging, C57Bl/6 mice were imaged 24 hours
following footpad injection. Mouse imaging was performed with a 9.4 T Varian smallanimal MRI scanner (Santa Clara, CA, USA). A 3D-bSSFP sequence was used for both
proton and 19F MR imaging. Animals were imaged alongside a reference tube containing
a known

19

F concentration (3.33x1016

19

F/μL or 7.3x1016

19

F/μL) suspended in agarose.
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Mice were anesthetized with 2% isoflurane, with breathing rate and temperature monitored
throughout the scan. MRI was performed using a dual-tuned birdcage volume coil
(diameter 2.2 cm, length 5.1 cm), tuned to 400.2 MHz and 376.8 MHz for proton and 19F
imaging, respectively. For proton imaging the scan parameters were: TR = 5.0 ms, TE =
2.5 ms, rBW = 78 kHz, FA = 30°, PC = 4, averages = 3, resolution = 200x200x200 μm3,
and NEX = 3. For 19F imaging the parameters were: TR = 4.0 ms, TE = 1.9 ms, rBW = 25
kHz, FA = 70°, PC = 4, averages = 200, resolution = 1x1x1 mm3, and NEX = 200. To
avoid 19F present in isoflurane confounding the 19F-PFC signal, imaging was performed by
centering on the

19

F-PFC Cell Sense-specific frequency as previously described270. The

total protocol time for both proton and 19F imaging was under 90 minutes.

7.1.7

19

F-PFC loading efficiency and signal quantification

The mean intracellular 19F content of murine PBMC was determined by NMR spectroscopy
using a 400 MHz Varian vertical spectrometer. First, a known number of 19F-PFC-labeled
cells was pelleted, then lysed through repeated cycles of sonication and freeze-thaws in a
solution containing 100 µL of 5% Triton X-100. After lysing, the cells were transferred to
5 mm diameter NMR tubes (New Era Enterprises, Inc., Vineland, NJ, USA) along with
300 µL of D2O and 100 µL of 0.1% Trifluoroacetic acid (TFA, ThermoFisher). The TFA
provides a reference peak for quantifying the number of 19F spins/ cell, since NMR signal
is linearly dependent on the number of 19F atoms (spins) present. Spectroscopy parameters
were TR = 7 s, rBW = 19 kHz, NEX = 100, and spectral range from -68 ppm to -93 ppm.
The number of PBMC detected within MR images was determined with Voxel TrackerTM
software (Celsense Inc, Pittsburgh, PA)270, 308. Prior to analysis, a signal correction was
applied to the 19F datasets by subtracting the signal value of the voxel containing the lowest
signal in the dataset. Once the correction was applied, the total 19F-PFC-labeled cell signal
contained within a hand-drawn ROI was compared to the average signal produced by the
reference tube containing a known 19F concentration. This information was used alongside
the 19F spins/cell, measured by NMR, to quantify the apparent number of cells located at
the ROI.
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7.1.8

Post-MRI lymph node histology

For the intraperitoneal injections that consisted of 5x106 19F-PFC-labeled CFSE+ murine
PBMC, the mesenteric lymph nodes were removed after 19F MRI, fixed with 4% PFA and
cryopreserved successively in 10, 20 and 30% sucrose solutions. Cryosections (16 µm)
were placed on VWR Microslides Superfrost® Plus (VWR) and coverslipped with
Vectashield® Hard Set mounting medium with DAPI (Vector Laboratories) to stain nuclei.
Confocal imaging was then performed to image a 100X magnification of the whole lymph
node followed by a 630X to identify originally-injected and intact CFSE+ cells using a
Leica TCS SP8 confocal microscope (Concord, Canada).

7.1.9

Statistical analysis

All data was presented as the mean with the standard error of the mean. A two-way
ANOVA (Graph Pad Prism, Version 7, La Jolla, USA) was used with multiple comparisons
being assessed. Significance was considered if p ≤ 0.05. When written, the number of
independent experiments is denoted by (N) while the number of replicates per independent
experiment is defined by (n).

7.2
7.2.1

Results
The three main cell lineages of murine PBMC label with red
fluorescent 19F-PFC

Murine PBMC were enriched from splenocyte single cell suspensions and diluted
peripheral blood of C3H mice after undergoing gradient centrifugation. These cells were
left unlabeled or cultured overnight with the red fluorescent version of 19F-PFC (5 mg/mL).
After labeling, PBMC were collected from culture and using flow cytometry, surface
staining of both red fluorescent 19F-PFC-labeled PBMC and control PBMC was conducted
to identify the three main cell lineages found in PBMC. Also, after lineage identification,
red fluorescent

19

F-PFC incorporation for each lineage was measured and compared to

control cells of the same lineage using a shift in the mean fluorescence intensity as a result
of fluorescent label uptake (Fig. 7-1). When comparing red fluorescent

19

F-PFC-labeled

PBMC (black histograms) to control, unlabeled PBMC (blue histograms), greater than 96%
of CD19+ B cells incorporated fluorescent

19

F-PFC (Fig. 7-1A), 99.46% of CD11b+
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myeloid cells labeled with fluorescent 19F-PFC label (Fig. 7-1B) and greater than 70% of
CD3+ T cells were fluorescent as a result of 19F-PFC label incorporation (Fig. 7-1C).

19

F-

PFC labeling and phenotyping of cell lineages has been conducted using C57Bl/6 PBMC
enriched from peripheral blood and splenic cell suspensions, yielding similar results (data
not shown).

Figure 7-1. The three main cell lineages contained within murine PBMC label with red
19
fluorescent
F-PFC
to varying
degrees.
Murine
PBMCwithin
isolated
from the
spleens of
Figure 7-1.
The but
three
main cell
lineages
contained
murine
PBMC
19
C3Hlabel
micewith
using
gradient
centrifugation
were
labeled
with
red
fluorescent
F-PFC as
red fluorescent 19F-PFC but to varying +degrees.
assessed by flow cytometry. Greater than 96% of CD19 B cells (A, black histogram),
99.46% of CD11b+ myeloid cells (B, black histogram), and 72.33% of CD3+ T cells (C,
black histogram) label with red fluorescent 19F-PFC when compared with unlabeled cells
of the same lineage (A-C, blue histograms).
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7.2.2

Murine APC labeling with 19F-PFC does not affect functional
ability to induce allogeneic T cell proliferation

After verifying red fluorescent 19F-PFC incorporation into all 3 main lineages of murine
PBMC, it needed to be determined whether this labeling had a functional effect on the
PBMC when compared to control, unlabeled PBMC. To determine if functional differences
do exist between these two populations, a MLR was conducted. C3H PBMC were depleted
of CD3+ T cells using positive magnetic bead selection. Half of the remaining cells were
cultured with 19F-PFC while the other half served as control PBMC. Both conditions were
supplemented with murine GM-CSF (20 ng/mL). After overnight culture, both cell
conditions were then combined with allogeneic CFSE-labeled CD3+ T cells that were
negatively selected for from C57Bl/6 mice. After 4 days of allogeneic cell culturing was
complete, CFSE dilution was used to determine allogeneic T cell proliferation. Upon
selecting for singlet CD3+ and CD4+ or CD8+ T cells (Fig. 7-2A-D), CFSE dilution was
measured and it was determined that there was no significant difference in APC
functionality as a result of 19F-PFC labeling. Both CD4+ (Fig. 7-2E, red) and CD8+ (Fig.
7-2E, blue) allogeneic T cell proliferation was unaffected by C3H APC labeling with 19FPFC.
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Figure 7-2. 19F-PFC does not affect the functionality of C3H APC as assessed using a
MLR. C3H APC were isolated as a result of positive selection removal of CD3+ T cells.
A MLR was then conducted for 4 days with C57Bl/6 T cells that were negatively selected
for and labeled with CFSE. Allogeneic T cell proliferation was measured by flow
19
Figure
7-2.CFSE
F-PFC
does not affect
the as
functionality
C3H (A)
APCsinglet
as assessed
cytometry
using
fluorescence
dilution
a readout. of
Viable
(B) cells
usinggated
a MLR.
were then
on CD3 to identify T cells (C) and further gated to specifically examine
CD4+ and CD8+ T cells separately (D). The percentage of allogeneic T cell proliferation
was measured for each APC cell number and is summarized in (E) for CD4+ T cells (red
dashed and solid lines) and CD8+ T cells (blue dashed and solid line). Data shown as
means ± SEM (two-way ANOVA, p > 0.05).
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7.2.3
C57Bl/6

19

F-PFC-labeled murine PBMC can be detected in vivo using
F cellular MRI

19
19

F-PFC-labeled PBMC from diluted peripheral blood and splenic cell

suspensions were labeled overnight with

19

F-PFC (5 mg/mL). The next day, 8x106

19

F-

PFC-labeled PBMC were formulated into an injection dose in 300 µL PBS and were
injected intraperitoneally. Twenty-four hours after injection, C57Bl/6 mice were scanned
using a dual-tuned 1H/19F volume coil on a 9.4 T MRI that detected 19F-PFC-labeled cells
in the inguinal lymph node (green, 2x105 cells) and axillary (yellow, 0.7x105 cells) lymph
node (Fig. 7-3A). In a second mouse, 19F-PFC-labeled murine PBMC were detected at the
injection site (purple, 1x106 cells) and the sacral lymph node (orange, 1x105 cells).
Miscellaneous signal was also detected in the intraperitoneal cavity as was calculated to be
1.14x106 19F-PFC-labeled cells (Fig. 7-3B). Identical injections were performed for control
unlabeled PBMC and no

19

F signal was detected. The images are representative of two

independent experiments with n=3 for each experiment.

7.2.4

Verification of in vivo 19F signal

To confirm that the signal detected in draining lymph nodes following an intraperitoneal
injection was from originally-injected cells, 5x106 CFSE+ 19F-PFC-labeled murine PBMC
were intraperitoneal injected (N=2, n=3). Twenty-four hours later, mesenteric lymph nodes
were removed and cryopreserved. Mesenteric lymph node cryosections were
counterstained with DAPI and using confocal microscopy, CFSE+ cells were detected and
are the source of 19F signal detection in the lymph nodes (Fig. 7-3C).
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Figure 7-3. 19F-PFC-labeled murine PBMC migration to draining lymph nodes is detected
and quantified using 19F cellular MRI following intraperitoneal injection. Twenty-four
hours after intraperitoneal injection of either 5x106 or 8x106 19F-PFC-labeled PBMC,
19
C57Bl/6 mice underwent
F cellular MRI at 9.4 T using a dual/tuned 1H/19F volume coil.
19
Figure
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19
as R (A). In a separate mouse, F-PFC-labeled PBMC were detected and quantified in the
sacral lymph node (gold), the injection site (purple) and a signal in the intraperitoneal cavity
(likely the mesenteric lymph nodes) was also detected (blue) (B). Data is representative of
2 independent experiments, with 3 mice receiving an intraperitoneal injection per cell
culture condition. In one of two replicate experiments, 5x106 19F-PFC-labeled murine
PBMC were also labeled with CFSE and using confocal microscopy and counterstaining
with DAPI to reveal nuclei, originally injected murine PBMC can be detected in the
mesenteric lymph node. The mesenteric lymph node is shown at 100X magnification, with
the red box representing the location of the 630X inset image. Scale bar represents 500 µm
(white) and 50 µm (gold) for 630X inset (C).

249

Curriculum Vitae
EDUCATION
September 2012 – December 2018

Western University, London, Ontario
PhD Candidate
Department of Microbiology and Immunology

September 2008 - April 2012

Western University, London, Ontario
Honors Specialization in Biochemistry of Infection
and Immunity (BMSc)

EMPLOYMENT EXPERIENCE
June 2012 - August 2012

Summer Employee
Robarts Research Institute, London, Ontario

VOLUNTEER EXPERIENCE
July 2015

American Society for Virology Volunteer
Western University, London, Ontario

November 2013 – present

Infection and Immunity Research Forum Member
Western University, London, Ontario

July 2013 – present

Robarts Molecular Medicine Student Leader
Robarts Research Institute, London, Ontario

July 2013 – July 2017

Microbiology and Immunology Social Committee
Western University, London, Ontario

March 2013

Western University Spring Preview Day
Western University, London, Ontario

ACADEMIC AWARDS AND ACCOMPLISHMENTS
June 2018

Oral Presentation Award
Robarts Research Retreat, London, Ontario

September 2016-August 2017

Ontario Graduate Scholarship
Western University, London, Ontario

250

September 2016

First Place Poster Presentation Award
Infection and Immunity Research Forum
London, Ontario

June 2016

Top Abstract Submission Travel Award
Biotherapeutics for Cancer Treatment: Summit for
Cancer Immunotherapy
Halifax, Nova Scotia

May 2016

Summa cum laude (1 of top 165 abstracts, 5915
total applicants)
International Society of Magnetic Resonance in
Medicine
Singapore, Singapore

September 2015-August 2016

Ontario Graduate Scholarship
Western University, London, Ontario

June 2015

Top Poster Award Winner
CIHR- Strategic Training Program in Cancer
Research and Technology Transfer- Research
Education Day
London, Ontario

March 2015

First Place Poster Presentation Award
Imaging Networks Ontario- OICR SIP
London, Ontario

September 2014 – August 2015

CIHR Strategic Training Program in Cancer
Research
and Technology Transfer Scholarship
Western University, London, Ontario

June 2013

First Place Poster Presentation Award
Cell Tracking Symposium
London, Ontario

November 2013

First Place Graduate Poster Presentation Award
Infection and Immunity Research Forum
Western University, London, Ontario

September 2013 – August 2014

CIHR Strategic Training Program in Cancer
Research
and Technology Transfer Scholarship
Western University, London, Ontario

251

September 2012 – August 2017

Western Graduate Research Scholarship
Western University, London, Ontario

Fall/Winter 2008, 2009, 2010, 2011 Dean’s Honor List
Western University, London, Ontario
September 2008

Western Scholarship of Excellence
Admission Scholarship, Western University
London, Ontario

ABSTRACTS/POSTERS
May 2018

International Society for Cellular Therapy
Montreal, Quebec
“19F-perfluorocarbon-labeled human peripheral
blood mononuclear cells can be detected by clinical
MRI in a therapeutic cell setting”
Fink C, Gaudet J, Bhatt S, Viswanathan S, Smith
M, Chin J, Foster P, Dekaban G

May 2018

Cellular and Molecular Imaging Symposium
London, Ontario
“19F cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration and
distribution”
Fink C, Gaudet J, Bhatt S, Viswanathan S, Smith
M, Chin J, Foster P, Dekaban G

June 2017

Biotherapeutics for Cancer Treatment, Summit for
Cancer Immunotherapy
Gatineau, Quebec
“19F-perfluorocarbon-labeled human peripheral
blood mononuclear cells can be detected in vivo
using clinical MRI parameters in a therapeutic cell
setting”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Smith M, Chin J, Foster P, Dekaban G

May 2017

American Society of Gene and Cell Therapy
19th Annual Meeting
Washington, DC, United States of America
“19F-perfluorocarbon-labeled human peripheral
blood mononuclear cells can be detected in vivo
using clinical MRI parameters in a therapeutic cell
setting”

252

Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Smith M, Tsang J, Chin J, Foster P, Dekaban G
November 2016

Imaging Applications in Prostate Cancer
London, Ontario
“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell migration
and distribution”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Chin J, Foster P, Dekaban G

October 2016

Robarts Research Retreat
London, Ontario
“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell migration
and distribution”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Chin J, Foster P, Dekaban G

September 2016

Infection and Immunity Research Forum
London, Ontario
“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell migration
and distribution”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Chin J, Foster P, Dekaban G

March 2016

14th Annual Imaging Network Ontario Symposium
London, Ontario
“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell
migration”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Chin J, Foster P, Dekaban G

March 2016

London Health Research Day
London, Ontario
“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell
migration”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Chin J, Foster P, Dekaban G

November 2015

CIHR Team Grant & OICR Smarter Imaging
Program: Imaging Applications in Prostate Cancer
London, Ontario

253

“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell
migration”
Fink C, Gaudet J, Foster P, Dekaban G
November 2015

Infection and Immunity Research Forum
London, Ontario
“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell
migration”
Fink C, Gaudet J, Foster P, Dekaban G

June 2015

CIHR- Strategic Training Program in Cancer
Research and Technology Transfer- Research
Education Day
London, Ontario
“Labeling of human peripheral blood mononuclear
cells with a Fluorine-19 perfluorocarbon agent
permits their in vivo detection using cellular MRI
and allows for cancer vaccine formulation
comparisons”
Fink C, Gaudet J, Foster P, Dekaban G

May 2015

International Society for Magnetic Resonance in
Medicine
Toronto, Ontario
“Labeling of human peripheral blood mononuclear
cells with a Fluorine-19 perfluorocarbon agent
permits their in vivo detection using cellular MRI
and allows for cancer vaccine formulation
comparisons”
Fink C, Gaudet J, Foster P, Dekaban G

April 2015

London Health Research Day
London, Ontario
“19Fluorine cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration”
Fink C, Gaudet J, Foster P, Dekaban G

March 2015

Imaging Network Ontario Symposium
London, Ontario
“19Fluorine cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration”
Fink C, Gaudet J, Foster P, Dekaban G

254

November 2014

CIHR Team Grant & OICR Smarter Imaging
Program: Imaging Applications in Prostate Cancer
London, Ontario
“19Fluorine cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration”
Fink C, Gaudet J, Foster P, Dekaban G

November 2014

Infection and Immunity Research Forum
London, Ontario
“In vivo non-invasive tracking of human
therapeutic cells by cellular MRI”
Fink C, Gaudet J, Foster P, Dekaban G

June 2014

CIHR- Strategic Training Program in Cancer
Research and Technology Transfer- Research
Education Day
London, Ontario
“In vivo non-invasive tracking of cell-based
therapies by cellular MRI”
Fink C, Gaudet J, Foster P, Dekaban G
Cell Tracking Symposium
London, Ontario
“In vivo non-invasive tracking of cell-based
therapies by cellular MRI”
Fink C, Gaudet J, Foster P, Dekaban G

June 2014

June 2014

Robarts Research Retreat
London, Ontario
“In vivo non-invasive tracking of cell-based
therapies by cellular MRI”
Fink C, Gaudet J, Foster P, Dekaban G

May 2014

American Society of Gene and Cell Therapy
17th Annual Meeting
Washington, DC, USA
“In vivo non-invasive tracking of cell-based
therapies by cellular MRI”
Fink C, Gaudet J, Foster P, Dekaban G

March 2014

London Health Research Day 2014
London, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI using the [19F]perfluorocarbon cell labeling agent Cell Sense”
Fink C, Gaudet J, Foster P, Dekaban G

255

November 2013

CIHR Team Grant & OICR Smarter Imaging
Program: Imaging Applications in Prostate Cancer
London, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI using the 19Fperfluorocarbon contrast agent Cell Sense”
Fink C, Gaudet J, Foley R, Foster P, Dekaban G

November 2013

Infection and Immunity Research Forum
London, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI using the 19Fperfluorocarbon contrast agent Cell Sense”
Fink C, Gaudet J, Foley R, Foster P, Dekaban G

June 2013

Canadian Cancer Immunotherapy Consortium
Toronto, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI through the use of the
[19F]-fluorocarbon contrast agent Cell Sense”
Fink C, Gaudet J, Ribot E, Foley R, Foster P,
Dekaban G

June 2013

CIHR- Strategic Training Program in Cancer
Research and Technology Transfer- Research
Education Day
London, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI through the use of the
[19F]-fluorocarbon contrast agent Cell Sense”
Fink C, Gaudet J, Ribot E, Foley R, Foster P,
Dekaban G

November 2012

Infection and Immunity Research Forum
Western University, London, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI through the use of the
[19F]-fluorocarbon contrast agent Cell Sense”
Fink C, Gaudet J, Ribot E, Foley R, Foster P,
Dekaban G

256

PRESENTATIONS
June 2018

Robarts Research Retreat
London, Ontario
“19F cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration and
distribution”
Fink C, Gaudet J, Bhatt S, Viswanathan S, Smith
M, Chin J, Foster P, Dekaban G

May 2018

Cellular and Molecular Imaging Symposium
London, Ontario
“19F cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration and
distribution”
Fink C, Gaudet J, Bhatt S, Viswanathan S, Smith
M, Chin J, Foster P, Dekaban G

April 2017

International Society for Magnetic Resonance in
Medicine
Honolulu, Hawaii, USA
“19F-perfluorocarbon-labeled human peripheral
blood mononuclear cells can be detected in vivo
using clinical MRI parameters in a therapeutic cell
setting”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Smith M, Chin J, Foster P, Dekaban G

March 2017

Imaging Networks Ontario
London, Ontario
“19F-perfluorocarbon-labeled human peripheral
blood mononuclear cells can be detected in vivo
using clinical MRI parameters in a therapeutic cell
setting”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Smith M, Chin J, Foster P, Dekaban G

June 2016

Biotherapeutics for Cancer Treatment: Summit for
Cancer Immunotherapy
Halifax, Nova Scotia
“19Fluorine (19F) cellular magnetic resonance
imaging to monitor in vivo therapeutic cell migration
and distribution”
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S,
Chin J, Foster P, Dekaban G

257

May 2016

International Society for Magnetic Resonance in
Medicine
Singapore, Singapore
“Translation of high-field fluorine-19 MRI cell
tracking techniques into the clinical realm”
Gaudet JM, Fink C, Fox M, Dekaban G, Foster PJ

March 2015

Imaging Networks Ontario
London, Ontario
“19Fluorine cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration”
Fink C, Gaudet J, Foster P, Dekaban G

November 2014

CIHR Team Grant & OICR Smarter Imaging
Program
Prostate Workshop- Imaging Applications in
Prostate Cancer
London, Ontario
“19Fluorine cellular magnetic resonance imaging to
monitor in vivo therapeutic cell migration”
Fink C, Gaudet J, Foster P, Dekaban G

November 2013

CIHR Team Grant & OICR Smarter Imaging
Program Prostate Workshop- Imaging Applications
in Prostate Cancer
London, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI using the 19Fperfluorocarbon contrast agent Cell Sense”
Fink C, Gaudet J, Foley R, Foster P, Dekaban G

June 2013

Canadian Cancer Immunotherapy Consortium
Toronto, Ontario
“Tracking and quantification of dendritic cell
migration by cellular MRI through the use of the
[19F]-fluorocarbon contrast agent Cell Sense”
Fink C, Gaudet J, Ribot E, Foley R, Foster P,
Dekaban G

April 2012

Fourth Year Undergraduate Thesis Presentations
Western University, London, Ontario
“Pathogenesis of Rheumatoid Arthritis”
Fink C, Bell D, Cairns E

258

PUBLICATIONS
Fink C, Gaudet J, Fox M, Bhatt S, Viswanathan S, Smith M, Chin J, Foster P, Dekaban
G. 19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be
detected in vivo using clinical MRI parameters in a therapeutic cell setting. Sci Rep 2018,
8:590 doi: 10.1038/s41598-017-19031-0.
Scheid E, Major P, Bergeron A, Finn, OJ, Landry C, Favre D, Eady R, Dekaban GA,
Foster PJ, Fink C, Gaudet J, Mukherjee S, Hotte S, Gariepy JP, Sekaly RP, Lacombe L,
Fradet Y and Foley R. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II
Trial in Patients with Non-metastatic Castrate-Resistant Prostate Cancer. Cancer
Immunol Res 2016, 4:881-892.
Dekaban GA, Hamilton AM, Fink CA, Au B, de Chickera SN, Ribot EJ and Foster PJ.
Tracking and evaluation of dendritic cell migration by cellular magnetic resonance
imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013, 5:469-483.
PUBLICATIONS (in preparation)
Fink C, Gaudet J, Smith M, Makela A, Foster P, Dekaban G. Using 19Fluorine cellular
MRI to track in vivo 19F-PFC-labeled BMDC and anti-tumor immune response in a
mouse model of melanoma. (in preparation)
Fink C, Gaudet J, Smith, M, Rieder M, Fox M, Foster P, Dekaban G. Multimodal
cellular and molecular imaging of in vivo 19F-PFC-labeled human PBMC migration to the
lymph node in an immunocompromised mouse model. (in preparation)
CLINICAL TRIAL INVOLVEMENT
May 2018

Pre-CTA submission complete and preparation for
Module III submission January 2/2019
(NCT02921373)
Robarts Research Institute, London, Ontario
Foster PJ, Viswanathan S, Dekaban GA

ADDITIONAL PROGRAM ENROLMENTS
September 2013 – present

Graduate Collaborative Program in Molecular
Imaging
Western University, London, Ontario

259

ADDITIONAL AWARDS
May 2018

Graduate Collaborative Program in Molecular
Imaging
Travel Award ($300)
Western University, London, Ontario

June 2017

BioCanRx Highly Qualified Personnel Travel
Award ($1000)
Ottawa, Ontario

April 2017

BioCanRx Highly Qualified Personnel Travel
Award ($1000)
Ottawa, Ontario

February 2017

Graduate Collaborative Program in Molecular
Imaging Travel Award ($400)
Western University, London, Ontario

February 2017

Microbiology and Immunology Travel Award
($2000)
Department of Microbiology and Immunology
Western University, London, Ontario

June 2016

Microbiology and Immunology Travel Award
($1000)
Department of Microbiology and Immunology
Western University, London, Ontario

June 2016

Graduate Collaborative Program in Molecular
Imaging
Travel Award ($400)
Western University, London, Ontario

March 2015

Microbiology and Immunology Travel Award
($1000)
Department of Microbiology and Immunology
Western University, London, Ontario

May 2014

Microbiology and Immunology Travel Award
($1000)
Department of Microbiology and Immunology
Western University, London, Ontario

